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ABSTRACT 
 
The bacterial enzyme DapE is a hydrolase in the late stage of the mDAP/lysine 
biosynthetic pathway that catalyzes the hydrolysis of N-succinyl-L,L-diaminopimelic acid (L,L-
SDAP) to succinic acid and L,L-diaminopimelate (DAP). The product DAP is ultimately 
converted to m-DAP and then to lysine which is used in the construction of proteins, whereas for 
humans, lysine is an essential amino acid obtained through diet. DapE has been shown to be 
conserved across many strains of bacteria. The m-DAP produced through the succinylase 
pathway is used by both gram negative and gram-positive bacteria in the construction of the 
essential peptidoglycan cell wall. Because of conservation across bacterial strains and its absence 
in humans, DapE has been identified as an ideal drug target for antibiotics with a new 
mechanism of action1. Inhibitors of this enzyme may serve as broad-spectrum antibiotics with 
selective toxicity towards bacterial strains without mechanism-based toxicity in humans. 
Previously, the enzymatic activity was determined by monitoring the cleavage of the substrate’s 
amide bond at 225 nm.2 The development of a new assay which can be observed at a wavelength 
of 570 nm through detection of Ruhemann’s purple complex produced by reaction of ninhydrin 
and the hydrolyzed primary amine product of a newly synthesized L,L- SDAP substrate analog 
enables identification of new inhibitors and establishing SAR. Inhibitory data of ligands 
identified through a HTS screen and their analogs have been obtained using the new ninhydrin-
based enzymatic assay. A High-Throughput Screening (HTS) of over 33,000 compounds 
licensed from by Chembridge Corporation utilizing the enzyme coupled assay identified five 
  xvii  
 
lead ligands as inhibitors with inhibition of >20% at 12 μM of DapE. The results consist of four 
series of inhibitors: a simple amide with a β-sulfonyl moeity, a difluoromethyl sulfonamide 
ligand, two N-acyl-6-sulfonamide indolines and a chiral phenyltetrazole thioether. Inhibitory 
data of ligands identified through a HTS screen and their analogs have been obtained using the 
new ninhydrin-based enzymatic assay.  Herein, we report the synthesis, inhibitory data and SAR 
of analogs from the last three series of inhibitors as well as a novel synthesis for the formation of 
7-sulfonamide indolines as a new series of inhibitors of DapE. 
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CHAPTER ONE  
AN INTRODUCTION TO BACTERIAL INFECTIONS AND ANTIBIOTIC RESISTANCE 
Bacterial infections are a significant and growing medical problem in both the United 
States and around the world.1 It is estimated that at least 90 million new tuberculosis cases were 
reported worldwide in the 1990’s resulting in about 30 million deaths.2 These data reveal that 
tuberculosis is the leading cause of death in adults by an infectious disease, worldwide. 2 The use 
of antibiotics has substantially decreased the number of deaths due to infectious diseases.  
Antibiotics are used to treat both gram-negative and gram-positive bacterial infections. 
Both gram-negative and gram-positive bacteria include pathogenic as well as non-pathogenic 
bacteria. Most bacteria are harmless or even beneficial while only some are pathogenic, and 
pathogenic bacteria lead to infectious diseases. The term gram-negative and gram-positive comes 
from the crystal violet staining that is used to classify bacteria based on the structure of the 
peptidoglycan cell wall.3 Gram-positive bacteria, aptly named so due to the positive test result, 
have a thick cell wall that can absorb the crystal violet dye. Gram-negative bacteria do not 
absorb the violet staining and instead turn pink showing a negative result. This is due to the fact 
that  gram-negative bacteria have a thinner peptidoglycan layer and an extra outer lipid 
membrane which makes cell wall penetration more difficult.  Despite having a thicker cell wall 
than gram-negative bacteria, gram-positive bacteria are more susceptible to antibiotics because 
they lack that outer membrane.  
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As of 2004, more than 70% of pathogenic bacteria were resistant to at least one of the 
currently used antibiotics.4 Resistance stems from a spontaneous or induced genetic mutation or 
the acquisition of resistant genes from other bacteria by horizontal gene transfer.5 This enables 
bacteria to become immune to specific antibiotics and potentially to structurally-related variants 
as well.  Unfortunately, the widespread distribution and over-administration of antibiotics by 
physicians has contributed to the development of antibiotic resistance. Antibiotic resistance has 
been recognized since the advent of penicillin-resistant Staphylococcus aureus infections rapidly 
appeared.6 Nevertheless, penicillin is still widely effective against many bacteria today. MRSA 
or methicillin-resistant Staphylococcus aureus is probably the most familiar drug-resistant 
bacteria. However, the emergence of ESKAPE pathogens is the biggest threat to the successful 
treatment of infectious diseases thus far. ESKAPE pathogens are six strains of bacteria that have 
become resistant to many antibiotics on the market, and include Enterococcus faecium, 
Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas 
aeruginosa and Enterobacter species.7 At least two other strains of common bacterial species 
capable of causing life-threatening illnesses (Mycobacterium tuberculosis and Escherichia coli 
O157:H7) are already resistant to all drugs in clinicians’ current arsenal of more than 100 
antibiotics.6, 8 
 Once easily treatable infections can render a person extremely sick and can be fatal. A 
bacterial strain such as E. coli developing resistance is especially dangerous because it is 
commonly found in cases of food poisoning and urinary tract infections in otherwise healthy 
people. This new phenomenon of drug-resistant bacteria passing on resistance to other bacterial 
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strains can create a nightmare scenario. Consequently, the risk that more pathogenic bacterial 
strains will evolve resistance against new antibiotics is very high.6, 9  
Penicillin was among the first drugs to be effective against bacterial infections.  It was 
discovered in 1928 by Scottish scientist Alexander Fleming from the penicillium fungi, but was 
not used in humans until 1942.10  Penicillin is a part of the β-lactam antibiotic family which is 
comprised of many classes of β-lactams.  Penicillin resistance in bacteria developed rapidly 
within the first 4 years of use. Since the introduction of penicillin, many other antibiotics have 
been introduced including other β-lactam antibiotics such as carbapenems and cephalosporins 
which helped to combat antibiotic resistance in bacteria up until now. Most novel antibiotics that 
are developed are structural variants of a limited set of known bioactive compounds including 
those with β-lactam functionality. Many of these compounds target the same enzymatic 
pathways which include protein and cell wall synthesis.11  
There is a limited lifetime of usefulness of antibiotics from when they are first identified 
as effective against bacteria to when bacteria eventually develop resistance.  There is an urgent 
call for the introduction of new antibiotics in the R&D pipeline to help combat this problem. 
There has been a decrease in the number of antibiotics that have been introduced on the market 
over the past few decades. It takes an average of 10 years between initial discovery of a drug 
compound and when it first enters the market. This means that antibiotics launched today are 
the products of drug discovery projects initiated at least a decade ago.12  The development of 
resistance to current antibiotics makes the discovery of novel compounds towards new target 
pathways a critically important challenge.  To help overcome bacterial resistance to antibiotics, 
new enzyme targets must be identified and small molecule inhibitors developed.13  
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CHAPTER TWO 
N-SUCCINYL-L,L-2,6-DIAMINOPIMELIC ACID DESSUCINYLASE BACTERIAL 
ENZYME AS AN ANTIBIOTIC TARGET 
Introduction 
A previously unexplored target for the development of new antibiotics is the enzymatic 
pathway for the biosynthesis of lysine in bacteria. The m-DAP/lysine biosynthetic pathway in 
plants and bacteria converts L-aspartate to the amino acid lysine through its immediate precursor 
meso-diaminopimelate (m-DAP).14 In the late stage of the lysine biosynthetic pathway, m-DAP 
is synthesized by bacteria through three subset parallel pathways: the succinylase, acetylase, and 
the dehydrogenase pathways.14  The succinylase pathway is the most widely distributed in 
bacteria being utilized by all gram-positive and nearly all gram-negative bacteria.14  The dapE 
gene encoded N-succinyl-L,L-2,6-diaminopimelic acid desuccinylase (DapE) is a hydrolase 
enzyme in the late stage of the succinylase pathway that catalyzes the hydrolysis of N-succinyl-
L,L-diaminopimelic acid (L,L-SDAP) 1a to succinic acid 2 and L,L-diaminopimelate (DAP) 3a 
(Scheme 1).  DAP is then converted to meso-DAP and ultimately to lysine.14, 15 
Scheme 1. Enzymatic cleavage of L,L-SDAP (1a) by DapE to succinate (2) and DAP (3a) 
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Lysine is used by gram-negative and gram-positive bacteria in the construction of the 
peptidoglycan cell wall. Once m-DAP is synthesized, it is either incorporated into the 
peptidoglycan cell wall of bacteria or decarboxylated to lysine by LysA. It has been shown that 
the deletion of the dapE gene is lethal to H. pylori and M. smegmatis.16 Bacteria present in lysine 
substituted media with the dapE gene deletion could not grow, verifying that lysine cannot be 
effectively imported.16 This proves that lysine is essential to the proliferation of bacteria and 
strongly suggests that the m-DAP/lysine biosynthetic pathway is the only source for lysine in 
bacteria and it cannot be provided by the environment. In contrast, lysine is an essential dietary 
amino acid that humans must obtain through their diet as the lysine biosynthetic pathway is not 
present in mammals.11 In humans, lysine plays a major role in the muscle building, calcium 
absorption, injury recovery, and in the production of hormones, enzymes and antibodies. 
Humans also metabolize lysine to give acetyl-CoA used in protein synthesis. Inhibition of DapE 
therefore suggests prospects of a broad spectrum antibiotic with selective toxicity towards 
bacterial strains as free of mechanism-based toxicity in humans.9 
The lysine biosynthetic pathway enzymes, specifically DapE, are an ideal drug target for 
antibiotics in that this pathway is not present in humans. Furthermore, DapE has been shown to 
be conserved across many strains of bacteria and essential to their peptidoglycan cell wall.2 DapE 
has been identified in many drug resistant bacteria.16, 17  In summary, inhibition of the m-
DAP/lysine biosynthetic pathway could provide a new class of broad-spectrum antibiotics with a 
new mechanism of action that inhibit synthesis of the bacteria cell wall and are then lethal to 
bacteria.6, 9  The identification of new classes of inhibitors of DapE and the development of an 
enzymatic assay to determine inhibitory potency of these compounds will be described in this 
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dissertation. The two key steps to the structural insight of inhibitor binding is obtaining a crystal 
structure of the enzyme with key catalytic residues identified as well as elucidating substrate 
structural requirements for catalysis. We report new insights on the physical structure and the 
catalytic activity of DapE obtained through a combination of crystallography, molecular docking 
and enzyme inhibitory data. Understanding how the enzyme works is the most effective way of 
understanding how to inhibit its activity. The results herein advance our knowledge toward 
development of new antibiotics through inhibition of DapE. 
Results and Discussion 
DapE Crystal Structure and Important Catalytic Residues. 
DapE is a small, homodimeric enzyme (41.5 KDa/subunit) that contains one catalytic and 
one dimerization domain per monomer, and it has been shown that the dimerization domain is 
required for catalysis.18 DapE has two known conformations: an open conformation that 
resembles an old-school rotary telephone receiver, and a closed conformation.19  
Figure 1. Side-by-side comparison of [ZnZn(HiDapE)]a open and closed conformations.19 
 
[a] (A) The previously obtained apo “open” conformation of HiDapE (PDB:3IC1). (B) The “closed” conformation 
of HiDapE with products bound; succinic acid 2 in magenta and L,L-DAP 3a in yellow (PDB:5VO3).  The two 
subunits of the homodimer are colored in green and orange. 
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The DapE enzyme is conserved across various strains of bacteria. Structurally and 
experimentally we have a logical first step in inhibitor design that is understanding how the 
substrate binds to the active site.13 Two crystal structure of the open conformation of DapE with 
mono zinc center [Zn(HiDapE)] (PDB:3ISZ) and di-zinc center [ZnZn(HiDapE)] (PDB:3IC1) 
active sites with A 2.0 and 2.3Å resolution, respectively, were obtained that demonstrated that 
two Zn(II) atoms per monomer are needed for full enzymatic activity while the mono Zn(II) 
enzyme retains only ~60% activity.20  DapE can exist as different metallo-isozymes including 
physiologically relevant variants where one Zn(II) is substituted with other divalent metals 
retaining enzymatic activity. The Co(II)-substituted DapE enzyme was 25% more active than the 
Zn(II)-loaded form of the enzyme.21 Interestingly, Mn(II) can activate DapE, but the activity is 
just to ∼20% of the Zn(II)-bound enzyme.21 The order of the observed k
cat
 values are Co(II) > 
Zn(II) > Cd(II) > Mn(II) >Ni(II) ∼ Cu(II) ∼ Mg(II).21 The Zn(II) atoms sit approximately 3.30 Å 
apart with a distorted tetrahedral geometry involving one imidazole group, one carboxylate 
group and a bridged carboxylate group (Figure 2).20, 22 The Zn(II) atoms in the active site are 
coordinated to a central catalytic water molecule that is employed in the hydrolysis of the 
substrate N-succinyl-L,L-diaminopimelic acid (L,L-SDAP).20, 22  
Figure 2. Active Site of [ZnZn(HiDapE)][a] 20 
 
[a] (A) Crystal structure PDB:3IC1. (B) DapE active site with bond distances of residues to Zn 1 (blue) and Zn2 
(red). 
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The PDB:3IC1 crystal structure revealed that residues Glu134 and Thr325 of the H. 
influenzae DapE were important residues for substrate catalysis. Glu134 serves as a general 
acid/base while Thr325 hovers over the active site and plays a role in L,L-SDAP substrate 
recognition and transition state stabilization.20  Positively-charged residues likely interact with 
the negatively charged carboxylic acid groups on the substrate. More recently, a co-
crystallization attempt of [ZnZn(NmDapE)] (N. meningitidis) in the presence of inhibitors and 
5% DMSO produced crystals of DapE that diffracted at 1.30 Å. This structure was deposited in 
the RSCB Protein Data Bank with the entry 5UEJ (Figure 3).  
Figure 3. Active site of [ZnZn(NmDapE)] 1.3Å crystal structure from PDB:5UEJ [a] 
 
[a] Crystal structure obtained in the presence of 5% DMSO with a refinement R/Rfree=13/16%.   
Although the crystal structure obtained was unbound (no ligand), this is significant 
advance for two main reasons: 1) previous crystal structures of DapE were of much poorer 
resolution, the best being at 1.80 Å, and 2) this is the first time that DapE crystals were obtained 
in the presence of 5% DMSO. This is significant because DMSO can aid in the solubility of 
inhibitors but can effect crystal growth. This new, near atomic resolution of DapE allows us to 
refine the structure with a more detailed and accurate position of atoms which can translate to 
better molecular docking of inhibitors involving the active site. To further elucidate the structural 
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requirements for DapE enzymes to recognize and bind L,L-SDAP, we have determined the X-
ray crystal structure of [ZnZn(HiDapE)] bound by the products of hydrolysis: succinic acid 2 and 
L,L-DAP 3a (Figure 4).19  The atomic coordinates and structure have been deposited in the 
RCSB Protein Bata Bank as entry 5VO3. 
Figure 4. Active site of [ZnZn(HiDapE)][a] products-bound structure19 
 
[a] Electron density map of DapE enzymatic products succinic acid (cyan) and L,L-DAP (yellow) bound in the 
active site with Zinc ions shown in black.  
In Silico Modeling for Enzyme Interactions 
 In silico studies help predict the binding modes and energies of ligand-enzyme 
interactions. X-ray crystallography was used to guide our efforts in designing and synthesizing 
inhibitors of DapE. Structure-based ligand discovery uses crystal structures obtained from 
proteins and predicts the binding affinities of ligands to the enzyme through molecular docking.  
This approach identifies several ligands from a screening library that have a high affinity for the 
target. There are many different software programs available for molecular docking and virtual 
screening such as AutoDock, DOCK, SwissDOCK and FlexX.23, 24 Virtual screening can suggest 
new potential lead compounds, and this approach can also be a key tool for mechanistic studies 
in enzyme-substrate interactions. The use of molecular docking has led to the development of 
protocol termed Products-Bound Transition-State Modeling (PBTSM) developed by Cory Reidl 
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which utilizes the product-bound crystal structure of an enzyme in combination with the 
unbound crystal structure to perform in silico studies for mapping out enzyme-substrate 
mechanisms and interactions.19  A step-by-step reconstruction of the product back to the via the 
transition state aids in the identification of key residues essential for substrate binding and 
catalysis. The PBTSM protocol was first seen published in Nocek and Reidl’s work for 
determination of the critical residues responsible for the conformational change observed in 
DapE PDB:5VO3.19  
Closed Conformation of DapE.  
The products-bound structure of [ZnZn(HiDapE)] reveals previously unknown substrate-
enzyme interactions and a catalytically significant, dramatic conformational change of the 
enzyme from the known open-conformation obtained through previous crystal structures to a 
previously unobserved closed-conformation of the enzyme.19 The closed-conformation crystal 
structure reveals that residues from the dimerization domain of the B subunit come in contact 
with the active site of the A subunit.19 An overlay of the open and closed conformation shows 
that the catalytic domain rotates ~50° and moves 29 Å at the exterior and 10 Å at the interior of 
the enzyme.19  In addition, the newly formed amine of L,L-DAP is only 2.9 Å from the newly 
formed succinic acid carbon.19 There is significant movement of the enzyme which results in 
closing of the Zn(II) active site and defining two distinct binding regions:; the succinic acid 
binding region and the L,L-DAP binding region (Figure 5).19  
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Figure 5. [ZnZn(HiDapE)] products-bound active site binding region[a]19 
 
[a] Product bound structure with succinic acid (cyan) and L,L-DAP (yellow) with residues interacting with both 
products in orange and blue boxes respectively. Residues from both subunits are colored in orange and green. 
In addition, a previously unidentified residue, His194.B from subunit B, was shown to be 
critical in the formation of the closed-conformation of DapE.19 When there is no substrate in the 
active site, His194.B from the dimerization domain in the B subunit sits 10 Å away from the 
subunit A active site.19 Upon binding of the substrate, His194.B moves to a distance of 2.9 Å 
away from the succinic acid and forms an H-bond to the oxygen that binds to Zn2 forming an 
oxyanion hole.19 The closed crystal structure depicting the His194.B movement shows that this 
residue is critical in activity by activating the scissile bond  for nucleophilic attack by the active 
site H2O.
19 This stabilization possibly allows for catalysis in the absence of Zn2 by coordination 
of His194.B in this oxyanion hole.19 We proposed that the presence of the substrate induces a 
conformational change in the enzyme structure that facilitates catalytic activation within the 
active site, and without the substrate present the enzyme remains in the open, inactive 
conformation.19  In effect, the substrate acts as the glue that links the catalytic domain of subunit 
A to the dimerization/cap domain of subunit B. This is evidenced by the NmDapE mutant 
His195.B, which corresponds to His194.B in HiDapE, that provides a [ZnZn(NmDapE)] enzyme 
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that exhibits only ~3% of its WT activity.19 These data provide critical structural insights on the 
catalytic activity of DapE and the structural residues that are important for hydrolytic activity.  
Substrate Requirements for DapE Activity. 
Now that the mechanism of catalytic activity of the enzyme and the important residues 
necessary for catalytic activity, determination of the substrate requirements for hydrolysis can 
aid in the development of inhibitors of DapE. Understanding which structural components are 
necessary for DapE to recognize and bind the L,L-SDAP substrate can guide the design of 
inhibitors by competing with or complying with substrate specificity. The endogenous substrate 
L,L-SDAP is hydrolyzed by DapE, and screening substrate analogs for hydrolysis can help 
validate important structural requirements. DapE is shown to only selectively hydrolyze N-
succinyl-L,L-diaminopimelic acid (L,L-SDAP) and is inactive toward D,L-, L,D-, and D,D-
SDAP.21 Further work on substrate analogs was taken up by Holz, in addition to investigating the 
differences in activities of the zinc and cobalt metal isozymes of DapE, and it was revealed that 
the free N6-amino group of the substrate is crucial for recognition and cleavage by DapE.21 
Gelb’s and Holz’s work demonstrated that there are indeed strict structural requirements for the 
substrate in order for a substrate to be cleaved by the enzyme: The free amino group of SDAP is 
important for substrate recognition, as SDAP lacking the basic 6-amino group (at the non-
succinylated end) was hydrolyzed at only 0.036% of the rate of the natural SDAP substrate.17  
These data imply that the carboxylate of the succinyl moiety and the amine form 
important interactions with the active site of DapE as consistent with the newly obtained data 
from the closed-conformation crystal structure.19 Additional modified substrate analogs have 
been designed to explore the positive characteristic interaction of the free amine in the active 
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sight.25 These modifications include altering the substrate primary amine 1a to the N6-mono-
methyl secondary amine 1b and the N6-dimethyl tertiary amine 1c (Figure 6).25 This approach 
was first explored in silico using molecular modeling to predict substrate-enzyme interactions 
involving recognition of the amine.25 
Figure 6. L,L-SDAP, N6-methyl and N6-dimethyl substrate analogs 
 
DapE Molecular Modeling to Assess N6-Mono- vs. N6,N6-Dimethyl-SDAP Analogs. 
Ligand models of L,L-SDAP 1a, N6-methyl-L,L-SDAP 1b and N6,N6-dimethyl-L,L-SDAP 1c 
were built using the Molecular Operating Environment (MOE) computational suite’s Builder 
utility followed by minimization in the gas phase using the force field MMFF94X.  An X-ray 
crystal structure of the product-bound DapE crystal structure in the closed conformation was 
utilized (PDB:5VO3).19  Following receptor preparation, molecular docking was performed 
using ligand conformation databases. 25 Docking poses of the substrate L,L-SDAP (1a) and 
methylated analogs 1b and 1c were assessed as judged by their similarity to the product binding 
interactions seen in the original product-bound crystal structure. 25 The three ligand-enzyme 
models were then solvated in a simple water box at pH of 7.4.  The system atoms were then 
optimized with a short, localized molecular minimization process.  Molecular Dynamics 
parameters were set to globally minimize the protein, ligand and solvent atoms with a typical 
heating and cooling protocol.  Simulation results were then minimized once again before the 
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final binding poses were obtained for comparison. 25 The final solvated and minimized substrate-
bound DapE models are shown in Figure 7. 25 
Figure 7.  Molecular docking of L,L-SDAP substrate analogs[a] 
 
[a] Energy-Minimized substrate/analogs docked and modeled in the DapE active site. 25 The diaminopimelate 
moiety is depicted in yellow, and the succinate in turquoise. a) Native substrate L,L-SDAP, b) N6-methyl-L,L-
SDAP, c) N6,N6-dimethyl-LL-SDAP.  The catalytic domain of Subunit A is depicted in green, whereas the 
dimerization domain of Subunit B is shown in orange. 
The docked and modeled endogenous substrate L,L-SDAP amide carbonyl is bound to 
one of the Zn(II) atoms while the amide N-H acts as an H-bond donor to the backbone carbonyl 
of Thr325:A.  The proximal carboxylate participates in bifurcated H-bonds with the side chains 
of Arg258:A, Thr325:A, and Asn245:B. The free primary amino group acts as an H-bond donor 
to the backbone carbonyl of Ala136:A and a water molecule, which in turn participates in H-
bond donation to the backbone carbonyl of Glu135:A and to the side chain carbonyl of 
Asn245:B.  The terminal carboxylate of the pimelic acid moiety is H-bonded to the N-H of 
Asn244:B, the side chain hydroxyl of Ser181:A, and Ser290:A, and a water molecule, which in 
turn H-bond donates to the side chain hydroxyls of Thr183:A and Thr325:A. We observe by 
15 
 
comparing the enzyme-substrate interactions in the crystal-bound L,L-SDAP product(s) and the 
docked & modeled L,L-SDAP structures, that the substrate links the catalytic domain of subunit 
A to the dimerization/cap subunit of chain B. The interactions of the N6-methyl-L,L-SDAP 
analog 1b are identical to those of the endogenous substrate, except for the added methyl group 
on the primary amino group that eliminates the H-bond interaction to the backbone carbonyl of 
Ala136:A.  The presence of the N6-methyl group also leads to perturbations of the water 
interaction at the ammonium N-H. However, H-bond bridging between the backbone carbonyl of 
Glu135:A and the side chain carbonyl of Asn245:B by the ammonium N-H(s) are maintained, 
while the N-methyl forms a new hydrophobic interaction with the adjacent Ala136:A residue.  In 
contrast, the N6,N6-dimethyl-L,L-SDAP substrate 1c is quite distinct from the natural L,L-SDAP 
substrate’s binding due to the presence of the two additional methyl groups. Loss of the 
interfacial domain interaction between the backbone carbonyl of Glu135:A and the side chain 
carbonyl of Asn245:B by the ammonium N-H species, due to interference of the additional 
methyl groups, appear to be the key difference to the endogenous L,L-SDAP substrate binding 
mode.  The additional bulk of the two methyl groups also leads to the migration of the N-H bond 
from the ammonium species of the potential substrate from Glu135:A to the backbone carbonyl 
of Glu134:A.  Significantly, Glu134 (E134) is proposed to act as the general acid/base during the 
hydrolysis reaction catalyzed by DapE26 and this residue is shifted further away from the active 
site. Thus, it is concluded that the N6-methyl-L,L-SDAP substrate analog 1b retains overall 
similar binding to the endogenous L,L-SDAP 1a, while the N6,N6-dimethyl-L,L-SDAP analog 1c 
suffers loss of significant binding interactions due to the presence of the second methyl group. 
These in silico studies provide additional evidence of the binding interaction of the substrate to 
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the active site and the induced conformational change that results in the closed conformation and 
ultimate hydrolysis of the substrate. Combination of these data will aid in the development of 
inhibitors for DapE by enabling design of inhibitors that bind to the active site in lieu of the 
substrate or alternatively disrupt the closing of the enzyme to inhibit hydrolytic activity. A 
competitive inhibitor should compete with the substrate by binding at the active site. The 
important catalytic and surrounding residues at the active site which help coordinate the substrate 
for catalysis can also be important to bind the inhibitor at the active site in an ideal orientation to 
allow for binding and inhibition. 
Measuring Enzymatic Activity and Inhibition of DapE. 
 To produce an effective inhibitor of DapE, the enzymatic activity and inhibition thereof 
must be able to be monitored and quantified. The hydrolysis of the endogenous substrate L,L-
SDAP produces the two products, succinic acid and L,L-diaminopimelate, by cleavage of the 
amide bond. This allows the enzymatic activity of DapE to be observed spectrophotometrically 
by monitoring the decrease in absorbance by the cleavage of the amide bond at 225 nm. 
Similarly, the inhibition of DapE can be determined by the absorbance at 225 nm. Inhibitors of 
DapE will effectively decrease the rate of hydrolysis and the amide bond should still be detected 
at 225 nm. 
 Initial Screening for Inhibitors of DapE. High-throughput screening (HTS) is the 
dominant technique for lead-based discovery in pharmaceuticals and more recently, virtual 
screening for inhibitors has become routine. 27 To identify appropriate lead molecules for 
inhibition of DapE, initially over 30 molecules representing different structural classes and 
containing different zinc binding groups were screened against DapE using L,L-SDAP as the 
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substrate.28 These classes of compounds were selected initially because of the Zn(II) atoms at the 
active site of DapE for which at least one is essential for catalytic activity.20 Of these molecules, 
thiols, carboxylic acids, phosphates and boronic acid functional groups were demonstrated as 
inhibitors of DapE with low micromolar IC50 values including the ACE inhibitor L-captopril 
shown in Table 1.28  
Table 1.Inhibitors of DapE identified by 225nm assay28 
 
 
aIC50 values were obtained using D,D- and L,L-SDAP for which DapE selectively cleaves the L,L isoform. Activity 
was monitored by absorbance of the amide bond cleavage at 225nm at 25°C28 
 This inhibitor screen provided two key pieces of information: first, that DapE binding is 
stereoselective in both the substrate and inhibitor preferring the L- over D-enantiomer of both 
captopril and penicillamine, and second, that L-captopril is a potent and competitive inhibitor of 
DapE with a measured IC50 of 3.3 μM and a Ki of 1.82 μM. Because the enzyme has high 
specificity for L,L-SDAP functional groups and for the stereochemistry of both the L,L-SDAP 
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isomer and L-inhibitors among those tested, DapE has the potential to demonstrate high 
specificity for drug target inhibitors with high potency and selectivity.20 
Identifying Appropriate Lead Inhibitors of DapE. 
Although the clinical target use for L-captopril is not a bacterial enzyme inhibitor, it is 
the most potent DapE inhibitor identified in the literature to-date. L-captopril can thus serve as 
the control in an enzymatic assay for which synthesized inhibitors will be compared to. The next 
step in the design of inhibitors takes in account the inhibitor’s in vivo efficacy which includes the 
incorporation of functional groups for increased water solubility and oral bioavailability. 29 Oral 
bioavailability of a drug is the potential for the drug to be administered orally and enter the blood 
circulation and to have an active effect.29 The preditiction of oral bioavailability can be aided by 
Lipinski’s rule of five (RO5) which is used to determine drug likeness of a compound.29 
Lipinski’s rule states that a substance should have no more than one violation of the five rules 
which include the following: 1) no more than 5 hydrogen bond donors, 2) no more than 10 
hydrogen bond acceptors, 3) a molecular mass less than 500 Daltons and 4) an octanol-water 
partition coefficient logP less than or equal to 5. The Lipinski rule of five considerations along 
with molecular docking and inhibitory potency can be used for the assessment of structure-
activity relationship (SAR) to guide the development of potent inhibitors of DapE.   
Conclusion 
We have demonstrated that DapE is a promising inhibitory target for the development of 
inhibitors as antibiotics. X-Ray crystallography combined with computational studies have 
identified key residues necessary for substrate recognition and hydrolysis by DapE. The activity 
of DapE can be monitored by the decrease in absorbance from the cleavage of the amide bond at 
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225 nm, and a screening of inhibitors using this method has identified several low micromolar 
inhibitors. The assay measuring cleavage of the simple amide bond of the substrate at 225 nm is 
simple and reliable, but precludes the testing of inhibitors that absorb strongly in the ultraviolet 
region thus ruling out testing of many preferred medicinal chemistry leads and analogs. The 
development of a more reliable method of measuring inhibition is needed to screen and identify 
any inhibitors of DapE.  
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CHAPTER THREE 
A SPECTROPHOTOMETRIC NINHYDRIN-BASED  
ENZYMATIC INHIBITION ASSAY FOR DAPE 25 
Introduction 
Several assays have been developed for evaluating inhibitors of DapE. The original 
assay30 for DapE took advantage of the fact that the product L,L-DAP reacts somewhat faster 
with ninhydrin than with the L,L-SDAP substrate, but this assay suffered from poor 
reproducibility. Gelb then developed two new assays for DapE.  The first employed 14C-labeled 
SDAP followed by scintillation counting of liberated radioactive 14C-succinate.  The second was 
a complex, coupled-assay utilizing porcine succinate thiokinase and inositol triphosphate to 
convert liberated succinate to succinyl-CoA and inositol diphosphate.  The inositol diphosphate 
was then detected by its reaction with phosphoenolpyruvate to yield liberated pyruvate, itself 
being detected spectrophotometrically using lactate dehydrogenase.  In our own earlier work, 
inhibitors of DapE were assayed against zinc-reconstituted DapE by monitoring amide bond 
cleavage of L,L-SDAP at 225 nm utilizing L,L-SDAP as a substrate (225nm= 304 M-1 cm-1).28   
All of these assays suffered significant limitations.  The original ninhydrin assay employing 
native or racemic SDAP, as noted, had very poor reproducibility.  The 14C-labeled substrate 
assay required working with radioactivity with extra safety protocols and waste disposal issues. 
We employed Gelb’s coupled assay with some success, but found it to be technically 
troublesome and therefore difficult to reproduce. The assay involved the use of more than one
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 enzyme which meant that the inhibition measured could not be Attributed reliably as 
coming from one exclusive enzyme. Finally, the previously mentioned assay measuring cleavage 
of the simple amide bond of the substrate at 225 nm is simple and reliable, but precludes the 
testing of inhibitors that absorb strongly in the ultraviolet region, thus ruling out testing of many 
preferred medicinal chemistry leads and analogs. The desire for a robust and higher-throughput 
assay for supporting our medicinal chemistry efforts toward the discovery of DapE inhibitors as 
new antibiotics led us to consider developing a new assay. 
Ninhydrin assays have been previously employed as a tool for screening inhibitors of 
enzymes.31 Recognizing the simplicity and reliability of a ninhydrin-based assay to detect the 
release of the primary amino group upon cleavage of the succinate amide, we explored whether 
we could block the reactivity of the free amino group of the substrate to prevent interference 
caused by its reaction with ninhydrin.  We prepared both N6-acetylated (1d) and N6-methylated 
(1b) derivatives of L,L-SDAP, and deprioritized the contemplated N6,N6-dimethyl L,L-SDAP 
analog 1c based on previous in silico studies mentioned in Chapter Two (Figure 8). 
Figure 8. N6-Acetylated and N6-methylated L,L-SDAP substrate analogs 1b and 1d. 
 
Chemistry 
The N6-acetyl-L,L-SDAP substrate analog (1d) was prepared by direct acylation of L,L-
SDAP, but this analog was not cleaved by the enzyme, either due to the need for a charged 
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cationic species at that position suggestion from studies in Chapter Two, or due to unfavorable 
steric interactions.  In contrast, considering the more conservative change of adding a single 
methyl group involving minimal steric bulk and still maintaining a positively-charged 
ammonium species at physiological pH suggested preparation of the N6-methyl-L,L-SDAP acid 
(1b) analog for study (scheme 2).  Cleavage of N6-methyl-SDAP substrate 1b would yield 
succinate (2) and the N6-methyl L,L-diaminopimelic acid, a secondary amine which may be 
differentiated from primary amines in reactivity with ninhydrin.  The N6,N6-dimethyl-SDAP 
substrate 1c is inert to reaction with ninhydrin, but is more sterically encumbered at the critical 
cationic ammonium moiety.  We selected the more conservative N6-monomethyl derivative 1b, 
based on modeling described above that suggests that the tertiary N6,N6-dimethylamine substrate 
1c would be a very poor substrate. 
The N2-succinyl-N6-methyl-L,L-diaminopimelic acid substrate 1b was prepared 
enantioselectivity by Marlon Lutz as illustrated in Scheme 2 beginning with methylation of 
BOC-L-glutamic acid t-butyl ester 4, first with potassium carbonate and methyl iodide to form 
the methyl ester, then in the presence of silver oxide in the same pot to afford the α-N-
methylated ester 5.  Reduction of the methyl ester with sodium borohydride afforded the primary 
alcohol 6 which was oxidized back to the aldehyde 7 with PCC or PDC.  Horner-Wadsworth-
Emmons olefination with Cbz-α-phosphonoglycine ester gave the olefin 8a, which was 
enantioselectively hydrogenated in the presence of catalytic 1,2-bis[(2S,5S)-2,5-
diethylphospholano]benzene(1,5-cyclooctadiene)rhodium(I) trifluoromethanesulfonate to afford 
the L,L-Cbz-protected amino acid 9a in 93% yield.  Removal of the Cbz protecting group by 
hydrogenolysis followed by reaction with succinic anhydride afforded succinamide derivative 
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10a in 99% yield, which was subjected to hydrolysis with aqueous HCl to yield N6-methyl 
SDAP as the hydrochloride salt (1b.HCl) in 97% yield. 
The synthetuc route via the methyl ester intermediate was improved by proceeding with 
the benzyl ester instead.  Thus, the Wadsworth-Emmons reaction of aldehyde 7 with benzyl 2-
{[(benzyloxy)carbonyl]amino}-2-(dimethoxyphosphoryl)acetate (R = Bn) afforded olefin 8a, 
which was enantioselectively hydrogenated in the presence of catalytic 1,2-bis[(2S,5S)-2,5-
diethylphospholano]benzene(1,5-cyclooctadiene)rhodium(I) trifluoromethanesulfonate to afford 
the L,L-Cbz-protected amino acid benzyl ester 9b in 94% yield.  Hydrogenolytic removal of the 
Cbz group followed by reaction with succinic anhydride gave the succinate amide (99% for 10a, 
92-97% for 10b).  Removal of the benzyl ester with trifluoroacetic acid in methylene chloride 
gave the trifluoroacetate salt 1b.TFA in nearly quantitative yield. 
Scheme 2. Asymmetric synthesis of N6-methyl-L,L-SDAP substrate 1b[a] 
  
   
 
[a] Preparation of N6-Me-L,L-SDAP 1b as either the hydrochloride salt (1b.HCl) via the methyl ester (8a-10a 
derivatives) or trifluoroacetate salt (1b.TFA) via the benzyl ester (8b-10b derivatives);  a1) K2CO3, MeI, DMAC a2) 
Ag2O, MeI, DMAc; b) NaBH4, EtOH. 0°C to rt; c) PCC, SiO2, DCM; d) DBU, DCM; e) [Rh(I)COD(S,S)-Et-
DuPHOS][Otf], H2 (50 psi), MeOH; f1) H2 (1 atm) Pd/C, MeOH; f2) succinic anhydride, Et3N, DCM; g) TFA, 
DCM, 25°C 
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Results and Discussion 
Having synthesized the N6-methyl L,L-SDAP substrate 1b, we then demonstrated that it 
functions as a substrate by observing hydrolysis of the amide bond at 225 nm in the presence of 
DapE, with a measured kcat/Km of 3.87x 10
4 M-1S-1 compared to the endogenous L,L-SDAP  
substrate with a kcat/Km of 1.92 x 10
5 M-1 sec-1. 
Primary Amine Detection with Ninhydrin. 
Since we demonstrated that 1b can function as a substrate we set out to design a robust 
and operationally straightforward enzymatic assay that would be amenable to inhibition studies 
for drug discovery. While ninhydrin reacts with both primary and secondary amines, only 
primary amino acids can form the Schiff base known as Ruhemann's purple, which has a longer 
wavelength absorption with λ max at 570 nm and 450 nm. In contrast, ninhydrin reacts with cyclic 
secondary amino acids such as proline to form an iminium salt that is yellow-orange in color, 
with λ max at 440 and 405 nm. Other amines are known to react with ninhydrin without creating 
the Ruhemann’s purple complex.32  Initial control reactions were performed with ninhydrin in 
the absence of enzyme monitoring between 300 and 800 nm with ninhydrin to determine the 
optimal time of heating and color development. Glutamic acid was utilized as a model primary 
amino acid, while N-methylglycine (sarcosine) was selected as a model for our acyclic secondary 
amino acid substrate 1b rather than proline.  Some secondary amines are known to react with 
ninhydrin in the presence of polar aprotic solvents such as DMSO, the solvent in which the 
ninhydrin reagent is provided.33  Heating of these model primary and secondary amines with 
ninhydrin at 100°C for 15 min surprisingly provided very similar absorption spectra with 
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identical 𝜆max values of 404 and 570 nm for the products of ninhydrin with glutamic acid and 
sarcosine, respectively (Figure 9). 
Figure 9. UV Absorption spectra of primary and secondary amines with ninhydrin[a] 
 
[a] Sarcosine (Sarc) is used as a model secondary amine depicted in blue and glutamic acid (Glu) is used as a model 
primary amine depicted in orange 
It was apparent that absorption from the existing secondary amine of N6-methyl-L,L-
SDAP substrate 1b, which is a primary α-amino acid, would interfere with accurate 
determination of the primary amine from enzymatic hydrolysis of 1b, but the solution to this 
problem lay in the slower rate of reaction of the secondary amine with ninhydrin relative to the 
primary amine.  Reducing the time of incubation of the mock substrates glutamic acid and 
sarcosine with ninhydrin at 100°C to only 2 minutes (data in appendix B) provided significantly 
greater absorption at 570 nm for the primary amine than for the secondary amine, a difference 
which diminished upon continued heating of the samples to 15 minutes. These data suggested 
that a very short incubation time of ca. 2 minutes should enable a clear distinction between the 
primary and secondary amines of the N6-methyl-L,L-SDAP 3b product.  However, at two 
minutes, even the primary amine had not completely reacted, and furthermore, the practical 
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challenge of a short incubation time, combined with associated increased error precluded this 
option, but encouraged us to examine lower incubation temperatures to enable the reaction of the 
primary amine with ninhydrin while minimizing the reaction of the secondary amine.  The first 
directed approach was to monitor product absorption development over 15 minutes at varying 
temperatures in 20-degree increments. Time course plots of the reaction with glutamic acid or 
sarcosine (1.0 mM) and ninhydrin (Figure 10) show positive reactions with the primary amine at 
80°C and 60°C, whereas little or no detectable reaction is observed with the secondary amine at 
these same temperatures.  The absorbance from the primary and secondary amines at these lower 
temperatures reaches a maxima and plateaus around 15 min of development. This demonstrates 
that adding ninhydrin and heating the amine reaction mixture at 80°C for 15 minutes provides 
easily detectable absorbance of ~1 AU for the primary amine product without reacting to any 
significant extent with secondary amines. 
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Figure 10. Absorption spectra of primary and secondary amines as a function of time [a] 
 
 
 
[a]Glutamic acid (Glu) serves as a standard from primary amines depicted in orange and sarcosine (Sar) serves as a 
standard for acyclic secondary amines depicted in blue. (A) The time course plot of ninhydrin with primary and 
secondary amines at 100°C. (B) Development of ninhydrin with primary and secondary amines at 80°C. (C) 
Development of ninhydrin with primary and secondary amines at 60°C.  
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Quenching of DapE Hydrolytic Activity. 
Given the somewhat lower temperature (80°C) selected for the N6-methyl-L,L-SDAP 
(1b) hydrolyzed product development with ninhydrin upon completion of the enzymatic reaction, 
it was also essential to confirm that the enzyme activity is effectively halted at the time of 
quench.  When quenching the enzymatic reaction, ninhydrin is added as a commercially-
available 2% solution in DMSO, so both the addition of DMSO as well as the elevated reaction 
quench temperature needed to be examined independently to ensure that the enzymatic reaction 
was halted. The total final assay volume was 300 µL after the addition of 100 µL of ninhydrin 
reagent giving a final concentration of 33 vol% of DMSO. The solvent DMSO is known to 
decrease or halt enzyme activity due to denaturation in the presence of as little as 10% by 
volume.34 Therefore, control reactions of standard enzyme activity were carried out in triplicate 
as follows: to a buffered DapE solution at 30°C was added the N6-methyl-L,L-SDAP TFA salt 
1b. The reaction proceeded for 10 minutes after which a 2% ninhydrin reagent in 100% DMSO 
was added and subsequently heated to 80°C for 15 minutes. The ninhydrin reaction was 
quenched by placing the mixture in ice for 2 minutes after which the absorbance was read at 570 
nm. This control reaction was set as 100% standard enzymatic activity of DapE.  
DapE was incubated with DMSO prior to addition of N6-methyl-L,L-SDAP substrate 
under various times to show the effects of DMSO on the hydrolytic activity of DapE. The 
DMSO incubation reactions were carried out with the exchange of buffered solution with 
DMSO. The enzyme was incubated for the desired time between 0 and 10 minutes. After the 
allotted incubation time, N6-methyl-SDAP TFA salt 1b was added and the reaction proceeded for 
10 minutes. The enzymatic reaction was quenched by addition of 2% ninhydrin solution and was 
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subsequently heated to 80°C for 15 minutes. The ninhydrin reaction was quenched by placing in 
an ice bath for 2 minutes and the absorbance was measured 570 nm. Plots of normalized 100% 
enzymatic activity versus reaction rates obtained in the presence of DMSO indicate a ca. 50% 
decrease in enzymatic activity over a 10-minute time frame in the presence of ninhydrin/DMSO, 
but enzymatic activity is not quenched even after 10 minutes.  This demonstrates that the 
addition of the ninhydrin/DMSO solution does not fully quench the catalytic activity of DapE.  
Circular Dichroism Denaturation Studies.   
The effect of heating the DapE reaction mixture at 80°C was examined to determine if all 
DapE hydrolytic activity is halted as when heating to 100˚C. Denaturation upon heating was 
examined by Circular Dichroism (CD) spectroscopy as a function of temperatures up to 80°C 
(Figure 11).    
Figure 11. Circular Dichroism thermal denaturation study of DapE[a] 
 
[a] CD α-helical structure represented in red and β-sheets represented in blue. (A) percent secondary structure 
observed over the course of heating from 20-80oC, and (B) percent secondary structure remaining with continued 
heating at 80oC. 
A loss of ca. ~5% in the α-helical structure was used as an indication that DapE was 
unfolding, while ≤10% total remaining α-helical structure suggested completely denatured 
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protein.  DapE begins to denature at ~60 ˚C as evidenced by a ~15% reduction in α-helical 
secondary structure.  Upon heating to 80 ˚C, the percent observed α-helical structure decreased 
to ~10%.  Thus, complete denaturation of DapE after 2 minutes of heating at 80°C was 
confirmed.  
Pre-Heat Incubation Studies.  
To complement the CD studies, DapE was pre-heated to 80°C and to 100°C 
independently to determine the effect on enzymatic activity. The DapE enzyme was incubated at 
80oC or 100oC in increments from 0 to 10 minutes and was then cooled to room temperature 
before addition of N6-methyl-L,L-SDAP substrate 1b. Incubating DapE at 80°C for 0 to 5 
minutes before adding substrate shows the dramatic decrease of enzymatic activity over one to 
two minutes with enzyme activity completely disrupted after 2 minutes. Incubating DapE at 
100oC shows that enzymatic activity is eliminated within one minute of heating (Plot given in 
Appendix B). However, as noted, heating to 100°C also causes both primary and acyclic 
secondary amino acids to react at an appreciable rate with ninhydrin within this time. It was 
therefore concluded that heating the enzyme at 80°C both stops enzyme activity within 1-2 
minutes and enables enzyme activity to be measured accurately by allowing only the primary 
amine from the cleaved substrate to react with the ninhydrin. To minimize the associated error, 
DapE enzymatic activity is initially quenched by heating at 100oC before addition of 
ninhydrin/DMSO and subsequent development to 80oC for detection of N6-methyl-SDAP 
hydrolyzed product.  
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Enzyme Kinetics for N6-methyl-SDAP 1b. 
We determined the kcat/Km for the modified N
6-methyl-L,L-SDAP substrate 1b to 
compare with the endogenous substrate SDAP. The optimized experimental assay conditions 
enable the detection of the formation of products as well as providing proper conditions for 
quenching DapE hydrolytic activity. The saturation of DapE concentration versus product 
formation was examined by reacting the glutamic acid standard to obtain a DapE concentration 
that would produce hydrolyzed product with a normalized absorbance less than 1 AU, so as to 
not saturate the spectrophotometer. Based on the glutamic acid standards, the ideal DapE 
concentration will hydrolyze 2 mM of N6-methyl-SDAP to produce around 0.4 mM (80 nmol) of 
product in ten minutes (Figure 12).  
Figure 12. Development of primary amine standard with ninhydrin.[a] 
 
[a] Glutamic acid is used as a primary amine control in the development with ninhydrin at 80°C for 15 minutes. 
The N6-methyl SDAP (1b) concentration was increased to 2 mM to mimic the original 
L,L- SDAP concentration employed in the 225 nm enzymatic assay. The plot of Abs vs DapE 
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concentration reveals the need for a final adjusted enzyme concentration of around 8 nM to keep 
the product absorbance under 1 AU (Figure 13). 
Figure 13. Enzyme saturation curve of DapE[a] 
 
[a] Enzyme saturation curve of DapE using 2 mM of N6-Me-SDAP substrate. Optimal enzyme concentration 
selected for absorbance of primary amine product at or around 1 AU as to not saturate the spectrophotometer. 
Reaction Rate/Velocity and Characterization of DapE Activity.  
The rate of the enzymatic reaction was observed to check the linearity of the hydrolysis. 
Using an N6-methyl SDAP (1b) concentration of 2 mM with a DapE concentration of 8 nM, the 
hydrolysis was plotted with reaction time in minutes versus product formed to check for linearity 
followed by saturation along the whole curve. A reaction time of 10 minutes should lie along the 
linear line of the curve and ideally should be followed by some additional time to allow for some 
variation in quenching enzyme activity after the 10-minute reaction time period. The next step 
was to determine the velocity of the reaction to properly characterize the activity of the enzyme. 
Varying the concentration of N6-methyl SDAP and plotting product versus time enabled 
determination of the velocity of the reaction. This was performed using smaller concentrations of 
substrate with the ninhydrin-based assay to avoid associated error with increased absorbance 
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well above 1 AU as observed with higher concentrations. This analysis was also performed on 
the original 225 nm assay for comparison and in attempt to define Km through an experimentally 
obtained Vmax. It is important to note that the use of the N
6-methyl-SDAP TFA salt in a 50 mM 
HEPES buffered solution of pH 7.5 at concentrations above 9 mM lowers the pH of the solution 
making the DapE enzyme hydrolytically inactive. The actual Vmax of N
6-methyl-SDAP could not 
be experimentally determined under these conditions by use of the TFA salt.  N6-Methyl-SDAP 
TFA salt 1b was determined to have a kcat/Km of 3.87 x 10
4 M-1S-1 using the 225 nm assay vs 3.3 
x 104 M-1S-1 using the ninhydrin-based 570 nm assay. 
DapE Ninhydrin-based Enzymatic Assay and IC50 Determination. 
Combination of these data indicate that the optimal DapE assay conditions using the 
trifluoroacetate (TFA) salt of N6-methyl-L,L-SDAP 1b as the substrate and with ninhydrin  as 
the colorimetric probe are 8 nm DapE in 50 mM HEPES buffer at pH 7.5 at 30°C followed by  
the addition of 2 mM N6-methyl-SDAP.  After 10 min. the reaction is quenched by heating at 
100°C for 1 minute followed by cooling on ice.  A 2% ninhydrin solution in 100% DMSO (100 
µL) is added and the solution heated at 80°C for 15 minutes followed by cooling on ice. Once the 
sample is cooled to 30˚C the absorbance at 570 nm is determined.  
To test N6-methyl SDAP as a substrate for screening potential inhibitors of DapE, the 
potencies of several previously-identified inhibitors were examined and found to be comparable 
with results from the previous assay monitoring amide bond cleavage at 225 nm. Specifically, 
captopril was found to have an IC50 value of 3.4 ±0.2 μM which is almost identical to that 
reported using SDAP in the 225 nm assay (IC50 = 3.3 μM).28 Likewise, the IC50 values for 3-
mercaptobenzoic acid (IC50 = 21.8 ± 2.2 μM), phenylboronic acid (IC50 =316 ± 23.6 μM), and 
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thiophene boronic acid (IC50 = 111 ±16 μM) were found to be in good agreement with the 
literature values of 35 μM, 107 μM, and 92 μM, respectively.28   
Table 2. DapE inhibitor IC50 values using ninhydrin-based enzymatic assay 
 
 
[a] Inhibitor IC50 values obtained from original 225 nm assay using 4 mM racemic SDAP. [b] Inhibitor IC50 values 
obtained from ninhydrin-based enzymatic assay using 2 mM N-Me-L,L-SDAP substrate and ~10nM DapE.  
Screening Primary Amine Inhibitors Using a Ninhydrin-Based Assay 
Amines are critically important functional groups in drugs and in compound screening 
libraries.  We were therefore very concerned that primary amines might appear as false positives 
in an inhibitor library screen due to their reactivity with ninhydrin, so we screened benzylamine, 
cyclohexylamine, and aniline as potential inhibitors in the assay. At a concentration of 200 μM 
none of these amines inhibit or give the appearance of inhibiting DapE using this assay. A blank 
control of these primary amines from 100 μM up to 500 μM demonstrates that these primary 
amines are not detected at 570 nm, consistent with the fact that their reaction with ninhydrin does 
not produce the Ruhemann’s purple complex that absorbs at 570 nm, and instead produces an 
iminium salt complex which is not detected at this wavelength.  In addition, we screened 
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glutamic acid as a potential inhibitor of DapE at 200 μM, and glutamic acid does not appear to 
inhibit the DapE enzyme at this concentration, even though it is an alpha-amino acid that can 
produce Ruhemann’s purple, due to subtraction of the blank. 
Conclusion 
In summary, a new DapE spectrophotometric method is described for identification and 
optimization of DapE inhibitors as potential antimicrobial agents.  Captopril displayed modest 
antibiotic activity against Escherichia coli and Salmonella enterica9 confirming our own 
observation of antibiotic activity,28  but Udo found that captopril does not inhibit the Mn2+ 
enzyme,11 and that, surprisingly, the antibiotic activity of captopril was independent of DapE 
inhibition in bacteria.9  Ultimately, it will be imperative to screen different metalloisozymes of 
DapE, in particular the Mn2+ enzyme in addition to the Zn2+ form, as captopril was found to be a 
moderately potent inhibitor of the Zn2+ enzyme but not of the Mn2+ enzyme. Even within the 
divalent zinc enzyme, mono- and di-zinc enzymes were determined to show different activities, 
and their crystal structures have been determined with structural insights that impact rational 
design of inhibitors.20  In summary, utilizing N6-methyl L,L-SDAP 1b as the modified substrate 
enables a new ninhydrin-based assay for measuring inhibition of the bacterial enzyme DapE that 
should support both lead discovery as well as lead optimization toward the discovery of new 
antibiotics with a new mechanism of action to treat bacterial infections. 
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CHAPTER FOUR 
DESIGN, SYNTHESIS, MOLECULAR DOCKING, AND INHIBITORY  
POTENCY OF INHIBITORS OF DAPE 
Now that we have new reliable enzymatic assay available for the identification of 
inhibitors of DapE and an understanding of the active site of the enzyme with molecular docking 
to guide the development of antibiotics, our efforts are focused on synthesizing new inhibitors of 
DapE. We took another approach at identifying lead inhibitors of DapE with more novel 
structures that were not biased for Zn(II) binding groups as the enzyme has many possible 
metallo-isozymes. A High-Throughput Screening (HTS) of over 33,000 compounds licensed 
from by Chembridge Corporation utilizing the enzyme-coupled assay identified five inhibitors 
with inhibition of >20% at 12 μM of DapE. The results consist of four series of inhibitors: a 
simple amide with a β-sulfonyl compound A, the difluoromethyl sulfonamide compound B, two 
N-acyl-sulfonamide indolines compounds C and D and a chiral phenyltetrazole thioether 
compound E (Figure 14).  Interestingly, all five ligands contain two potential zinc binding 
groups within several atoms of each other which could suggest strong interactions with both 
zincs at the active site. Compound A has not been pursued as a possible inhibitor due to the 
simplicity of the ligand and the lack of novelty in the structure.  Herein, we report the synthesis, 
inhibitory data and SAR of analogs from the other three series of inhibitors as well as a screening 
of new inhibitors of DapE.
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Figure 14. HTS lead compounds identified with the DapE coupled assay 
 
Part I. 6-Sulfonamide Indolines as Inhibitors of DapE 
Introduction.  
The N-acetyl-5-bromo-6-sulfonamide indoline HTS leads C and D were of greater initial 
interest because these two compounds were identified independently of each other which was 
confirmation that this series of inhibitors was the most promising of the leads identified. Many 
substances, both natural and synthetic, with medicinal properties contain an indole structure such 
as serotonin, indole alkaloids and tryptophan (Figure 15).35 Tryptophan, an essential amino acid, 
also contains the indole moiety and is the precursor to the synthesis of serotonin and other indole 
alkaloids. Indoline is a saturated indole and derivatives of indoline are known to have inhibitory 
properties against enzymes as well as therapeutic use in the treatment of cancer.36, 37 
Figure 15. Indoline, indole, and natural indole-containing compounds 
 
 In addition, sulfonamides are also a familiar moiety in medicinal chemistry. Molecular 
docking using the open crystal structure of DapE (PDB:3IC1) was used to determine relevant 
possible binding poses of inhibitors to the enzyme. In silico studies containing the two lead 
indoline compounds suggest interaction at the zinc active site which is indicative of possible 
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competitive inhibition. Optimization of the initial indoline lead C with systematic SAR 
modifications at the 1-, 5-, and 6-positions were carried out corresponding to derivatives varying 
R1, R2, and R3, respectively, in Figure 16. 
Figure 16. HTS lead N-acetyl-6-sulfonamide indoline C [a] 
 
[a] Indoline C and points of modification through synthesis. 
Chemistry. 
  The N-acetyl-6-sulfonamide indoline HTS lead compounds have been produced 
according to the literature which makes neither the synthetic route nor the structures themselves 
novel. N-acetyl-5-bromo-6-sulfonamide indoline C was synthesized first, through acetylation of 
indoline to produce 13, followed by bromination of 13 using elemental bromine to produce the 5-
brominated indoline 14.38 Next, sulfonation of indoline 14 in a neat reaction with chlorosulfonic 
acid produced the 6-sulfonamide indoline 15. Finally, reacting the sulfonyl chloride 15 with 
isopentyl amine produced 16a (HTS compound C) shown in Scheme 3. 
Scheme 3. Synthesis of N-acetyl-5-bromo-6-sulfonamide indolines 16a and 16b[a] 
 
[a] Synthesis of the HTS lead compound C. a) Acetyl chloride, Et3N, DCM, rt to 0°C; b) Br2, AcOH, rt; c) ClSO3H, 
65°C, 3 hrs; d) isopentylamine amine for 16a or piperidine for 16b, DCM, Et3N, DMAP.  
The piperidine analog 16b was synthesized instead of the dimethyl piperidine HTS 
compound D because first, the stereocenters were not specified in the screening result and 
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second, to avoid preparing a mixture of sterioisomers during synthesis. Initial SAR modification 
was pursued with the sulfonamide at the R3-position because that is the only structural difference 
between the two leads identified. Finally, diversification by the reaction of chlorosulfonyl 
indoline 15 with simple alkyl, cyclic and aromatic primary and secondary amines in a traditional 
fashion afforded the desired R3 modified sulfonamides 16 (Scheme 4).  
Scheme 4. Synthesis of N-acetyl-5-bromo-6-sulfonamide indoline 16 derivatives[a] 
 
[a] X=primary, secondary and aromatic amines and amino acids 
Further diversification of the R3 sulfonamide substituent was achieved by conversion of 
the indoline 6-sulfonylchloride 15 to the primary sulfonamide 17 by ammonia in methanol. This 
enabled the synthesis of 7-N-acylsulfonamides 18 by reaction with acyl chlorides or the 
production of sulfonylureas 19 and sulfonyl thioureas 20 by reaction with isocyanates and 
Isothiocyanates, respectively (Scheme 5). These derivatives are in the process of being 
synthesized. 
Scheme 5. Synthesis of 6-(N-acyl) sulfonamides, sulfonylureas and sulfonyl thioureas[a] 
 
[a] Synthesis of N-acyl sulfonamides, sulfonylureas and sulfonyl thioureas. a) NH3/MeOH; b) an acyl chloride; c) an 
isocyanate or a carbamoyl chloride; d) an isothiocyanate. 
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Modification of the R2 group to develop structure activity relationships resulted in the 
conservative switch from the larger and heavier bromine atom to the smaller and lighter chlorine 
to aid in water solubility.  The 5-chloro analogs were originally synthesized by published 
methods using NCS in acetonitrile and sodium acetate as a catalyst to produce 21 (Scheme 6).39 
Since then, chlorination using NCS and DMF as a solvent in a new flow chemistry synthetic 
route employed by our lab. To date, no other substitutions at the 5-position have been tested in 
this synthesis but will be explored in time. 
Scheme 6. Synthesis of N-acetyl-5-chloro-6-sulfonamide indoline derivatives 22[a] 
 
[a] Synthesis of indoline 22 derivatives. a) NCS, MeCN, NaOAc for batch synthesis and NCS, DMF, 70°C for flow 
synthesis; b) ClSO3H, 65°C, 3 hrs; c) desired amine, Et3N, DCM, DMAP. 
Variation at the R1-position was accomplished by the hydrolysis of the acetyl group of 16 
to produce 23 with the unprotected aniline nitrogen. Subsequently, reaction of 23 with carbamoyl 
chlorides, isocyanates, or other acyl chlorides produced amides (25) and carbamate indoline 
derivatives (27 and 29) (Scheme 7).  This synthetic route was chosen for two reasons: first to 
avoid chlorosulfonation of indoline with possible labile groups present at R1 and to produce a 
single point variation at only the R1 position while keeping the R3 substituent constant.  
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Scheme 7. Synthesis of 6-sulfonamide indoline derivatives with R1 variation[a] 
 
[a] Variation at R1 R=alky, cyclic, or aryl derivatives. a) H3O+, heat ; b) acyl chloride; c) isothiocyanate; d) 
carbamoyl chlorides or isocyanates 
Results and Discussion. 
The HTS leads were first synthesized and tested for inhibitory potency to validate that 
they were identified as inhibitors of DapE. The isopentyl indoline compound 16a showed an IC50 
of over 200 μM from the ninhydrin-based assay but did confirm modest inhibition. A measured 
IC50 of 130 μM for 16b showed that this compound’s inhibition is more potent than the isopentyl 
ligand 16a. Indoline 16b was very insoluble at high concentrations and could therefore exhibit 
greater potency if modified. Considering this data, SAR was first explored by continued 
variation of the sulfonamide group R3 producing alkyl, cyclic, aromatic and amino acid 
derivatives.  
Computational Studies. Preliminary molecular docking data suggests that incorporation 
of amino acids with the free carboxylate end (16l(-)-16o(-)) would be more tightly bound to the 
active site Zn(II) atoms leading to more potent inhibitors than the various other sulfonamide 
derivatives shown in Table 3. This is evidenced by the docking pose produced in silico and the 
lower, more stable binding energies of 16l(-)-16o(-) calculated using SwissDock.40 The methyl 
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ester analogs 16l-16o of the amino acids were synthesized and tested for inhibition initially 
instead of the carboxylate counterparts. Introduction of aromatic heterocycles 16p-16s provided 
possible allosteric inhibitors that bind to the dimerization domain of DapE rather than the active 
site based on docking studies. These data suggest that these compounds will be less likely to act 
as competitive inhibitors of DapE. Considering the closed conformation of DapE and the role 
that His194 plays in the conformational change, it would be beneficial to explore this proposed 
binding at the dimerization domain of compounds 16p-16s in the near future. 
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Table 3. Molecular docking of 5-bromo-6-sulfonamide indoline 16 derivatives[a] 
 
 
Entry        R3 Δ G[b] Entry   R3 Δ G[b] 
16a 
 
-8.9 16m 
 
-8.3 
16b 
 
-8.4 16n 
 
-8.2 
16c 
 
-8.3 16o 
 
-9.4 
16d 
 
-8.7 16p 
 
-9.3 
16e 
 
-8.7 16q 
 
-8.2 
16f 
 
-8.3 16r 
 
-8.5 
16g 
 
-8.5 16s 
 
-8.6 
16h 
 
-7.4 16l(-) 
 
-13.2 
16i 
 
-8.3 16m(-) 
 
-12.5 
16j 
 
-8.6 16n(-) 
 
-14.6 
16k 
 
-8.7 16o(-) 
 
-14.5 
16l 
 
-9.5 
   
[a] Molecular docking was performed using SwissDock with the [ZnZn(HiDapE)] open crystal structure PDB:3IC1. 
[b] ΔG ligand binding energies are calculated in kcal·mol-1. 
N-Acyl sulfonamides are a biocompatible scaffold in medicinal chemistry and are often 
employed in in pharmacological uses.41 The N-acyl sulfonamide is very acidic and can resist 
hydrolysis under many conditions in biological systems. Molecular docking was performed on 
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some N-acyl sulfonamides with DapE to observe the potential binding energy and use of this 
functional group as an element of potential inhibitors given these considerations. The results of 
the in-silico studies suggest that these moieties are more tightly bound than the original HTS 
compounds containing simple alkyl, cyclic and aryl sulfonamides (Table 4). Aromatic 
substituents 18b, 19c and 20c (R3) also shows lower binding energies, however, there is no 
uniform pattern in binding energies compared to other substituents apparent from the data 
obtained.  
Table 4. Ligand binding energies of 5-bromo-6-sulfonamide indoline 18,19 and 20[a] 
 
 
Entry R3 ΔG
[b] Entry R3 ΔG
[b] 
18a 
 
-8.9 19e 
 
-8.1 
18b 
 
-10.4 19f -10.4 
18c 
 
-10.1 19g 
 
-10.6 
19a 
 
-9.7 19h 
 
-8.7 
19b 
 
-10.1 20a 
 
-8.1 
19c 
 
-10.1 20b 
 
-9.9 
19d 
 
-10.3 20c 
 
-9.3 
[a] Molecular docking of 6-sulfonamide derivatives N-acyl sulfonamide 18, sulfonylurea 19 and sulfonyl thiourea 
20 performed with SwissDock using [ZnZn(HiDapE)] open crystal structure PDB:3IC1. [b] ΔG ligand binding 
energies calculated in kcal·mol-1. 
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As previously mentioned, while attempting crystallization of DapE in the presence of 
using 6-sulfonamide indolines, it was discovered that these compounds were not very water-
soluble despite having cLogP values of 3.5 to as low as 0.17. During the co-crystallization 
attempt, the addition of 5 % DMSO was used to aid in the solubility of the inhibitors, although 
water solubility is essential for oral bioavailability of a drug candidate in vivo. 
The introduction of a 5-chloro substituent at R2, compared to the 5-bromo counterpart, 
should aid in water solubility as predicted by lower cLogP values. This halogen substitution with 
an atom of lower atomic weight also decreases the total molecular weight of the inhibitor to 
allow for additional variations at other positions while keeping the molecular weight under 500 
Daltons as per Lipinski’s RO5. Further, this bioisosteric replacement could potentially increase 
binding in the active site. In silico studies suggest that the chloro-substituent may increases and 
other times decreases the binding energies of the inhibitor-enzyme interactions as shown in 
Table 5. The chlorine analogs of the aromatic sulfonamides with heteroatoms in analogs 22p-s 
have slightly lower more favorable, binding energies than the bromine counterparts 18p-s. Most 
of the aromatic indolines have lower binding energies as well. This is indicative of more tightly 
bound ligands and potentially better inhibitors. In the cases of cyclic and acyclic sulfonamide 
indolines, the energies vary and no drastic energy difference is observed.  Inhibitory data of the 
5-chloro analogs of the original HTS ligands ultimately showed increased potency with a 
measured IC50 values of 44 μM for 22b and 54 μM 22a. 
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Table 5. Ligand binding energies of 5-chloro-6-sulfonamide indoline 22 derivatives [a] 
 
 
Entry R3 Δ G[b] Entry R3 Δ G[b] 
22a 
 
-8.8 22j 
 
-8.8 
22b 
 
-8.4 22k 
 
-8.1 
22c 
 
-8.6 22m 
 
-8.8 
22d 
 
-7.4 22n 
 
-8.4 
22e 
 
-8.4 22p 
 
-9.4 
22f 
 
-8.4 22q 
 
-8.97 
22g 
 
-8.4 22r 
 
-9.1 
22h 
 
-7.9 22s 
 
-8.4 
22i 
 
-9.0   
[a] Molecular docking of 5-chloro-6-sulfonamide indolines by SwissDock using the [ZnZn(HiDapE)] open crystal 
structure PDB:3IC1. [b] ΔG ligand binding energies are calculated in kcal·mol-1 
In these cases, analogs benefit from making the conservative change from the bromo to 
the chloro analogs for the overall decrease in molecular weight. Additionally, the aromatic 
heterocycles 22p-22s were also predicted to bind at an allosteric site at the dimerization domain 
rather than the active site of DapE similar to the 5-bromo counterparts. 
For further SAR evaluation for R1 modifications, the N-carbamate-6-sulfonamide 
indoline analogs of the N-acetyl indolines were docked with DapE to examine possible binding 
configurations at the active site. Ureas and thioureas are very good zinc binding groups and the 
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formation of these functional groups at R1 could potentially create increased binding at the active 
site. In silico studies show that the incorporation of these moieties notably improves’ the binding 
energies of these ligands (Table 6).  
Table 6. Binding energies of N-substituted-5-bromo-6-sulfonamide indolines 25, 27 and 29 [a] 
 
 
Entry R1 ΔG
[b] Entry R1 ΔG
[b] 
25a 
 
-8.9 27e 
 
-8.1 
25b 
 
-10.4 27f -10.4 
25c 
 
-10.1 27g 
 
-10.6 
27a 
 
-9.7 27h 
 
-8.7 
27b 
 
-10.1 29a 
 
-8.1 
27c 
 
-10.1 29b 
 
-9.9 
27d 
 
-10.3 29c 
 
-9.3 
[a] Molecular docking of N-substituted-5-bromo-6-sulfonamide indolines by SwissDock using the [ZnZn(HiDapE)] 
open crystal structure PDB:3IC1. [b] ΔG ligand binding energies are calculated in kcal mol-1 
The least favorable addition at the R1 N-position is by the isothiocyanate to produce the 
thioureas 29a-c where the ligand binding energy is distinctly weaker. Additionally, longer alkyl 
substituents such as a propyl group as opposed to a methyl group are more favorable as the 
methyl derivatives 25a, 27a and 29a all have higher and therefore weaker binding energies than 
the propyl derivatives 25c, 27b and 29b. Similarly, bulkier functional groups such as 5-
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membered and 6-membered cyclic substituents or aryl groups have lower calculated binding 
energies. The production of these analogs will be pursued in time and tested for inhibition 
against DapE using the ninhydrin-based enzymatic assay. 
Inhibitory Data. Inhibitory activity of N-acetyl-6-sulfonamide indolines against 
[ZnZn(HiDapE)] was measured using the new ninhydrin-based enzymatic assay. The ninhydrin-
based assay protocol was similar to the protocol reported in Chapter Two, except for the inhibitor 
dilution and incubation method. All inhibitors were diluted to 5 mM or 10 mM stock solutions in 
100 % DMSO to aid in inhibitor solubility. Serial dilutions were then made from this stock 
solution with final stock solutions containing 50 % DMSO. The addition of 20 μL of 50 % 
DMSO to 200 μL reactions provided a final concentration of 5% DMSO. Because of the addition 
of DMSO, the incubation time was cut from 10 minutes to 0-2 minutes. Inhibition was tested at 
20, 50, 100 and 200 μM and the IC50 was determined for these inhibitors where applicable and 
reported in Table 7. 
These data show that inclusion of the methyl ester amino acid derivatives did not increase 
inhibition of DapE compared to the alkyl, cyclic and aromatic sulfonamides, in fact inhibition 
was comparable to some of the other inhibitors tested, as expected.   
 
 
 
 
 
 
49 
 
Table 7. Inhibitory data (IC50) of N-acetyl-5-bromo-6-sulfonamide indolines 
 
 
Entry R2 R3 IC50 (μM)
 [a] Entry R2 R3 IC50 (μM)
 [a] 
16a Br 
 
>200 16j Br 
 
86 
16b Br 
 
130[b], 134[b] 16k Br 
 ND[c] 56% at 
200 
16e Br 
 
99 16l Br 
 
118 
16f Br 
 
>200 16o Br 
 
82 
16g Br 
 
97 16t Br 
 ND[c] 39% at 
100 
16h Br 
 
172 16u Br 
 ND[c] 26% at 
100 
 
[a] Data obtained from a set of triplicates and IC50 values were determined from a set of three or four % inhibition 
points. [b] A different batch tested separately for inhibition. [c] Not determined; solubility of the compound did not 
allow for determination of IC50 experimentally, inhibition determined for a single concentration. 
Direct comparison of inhibitory data of 5-chloro and 5-bromo analogs shows that the 
inclusion of a 5-chloro substitute increased inhibition of DapE relative to 5-bromo with the 5-
chloro isopentyl sulfonamide 22a showing an IC50 of 44 μM and the piperidine derivative 
showing and IC50 of 54 μM. Additionally, the water solubility increased for the chloro 
derivatives as expected as some 5-chloro analogs were sufficiently soluble for identification 
while the 5-bromo counterparts were insoluble at the higher concentrations (Table 8). 
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Table 8. Inhibitory data (IC50) of N-acetyl-5-chloro-6-sulfonamide indolines 22 
 
 
Entry R2 R3 IC50 (μM)
 [a] Entry R2 R3 IC50 (μM)
 [a] 
22a Cl 
 
54 22h Cl  ND[b] <200 
22b Cl 
 
44 22l Cl 
 
>200 
22c Cl 
 
88 22m Cl 
 
ND 
22e Cl 
 
ND[b] 43% at 
100 
22u Cl 
 
ND[b] >200 
22g Cl 
 
172 22v Cl 
 
ND[b] 
 
[a] Data obtained from a set of triplicates and IC50 values were determined from a set of three or four % inhibition 
points. [b] Not determined; solubility of the compound did not allow for determination of IC50 experimentally, 
inhibition reported for a single concentration. 
Conclusion. 
Several N-acetyl-5-bromo-6-sulfonamide indolines have been designed, synthesized and 
tested for inhibition of DapE.  The original HTS lead inhibitors exhibited an IC50 of over 200 μM 
and 130 μM for the isopentyl sulfonamide 16a and piperidine sulfonamide 16b, respectively, 
which were modest. However, the change from 5-bromo to 5-chloro substituents increased the 
inhibition noticeably. In-silico studies suggests favorable modifications of these compounds to 
produce more tightly-bound ligands and ultimately increased potency. The 5-chloro analogs of 
all 5-bromo ligands will be synthesized for continued SAR comparisons as well as the 
corresponding N-acylsulfonamides and sulfonylureas, in addion to This also includes the 
synthesis of N-carbamates and other acyl groups at the R1 position of indoline. Overall, inclusion 
of more water-soluble groups such as carboxylate groups, which also can bind tightly to Zn(II) 
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atoms, and tertiary amines, which will allow production of HCl salts, will be included in the 
design of future analogs. The ninhydrin-based enzymatic assay will provide inhibitory data and 
further SAR analysis to proceed with future modification of these compounds to produce more 
potent inhibitors of DapE. 
Part II. Phenyltetrazole Thioethers as Inhibitors of DapE 
Introduction. 
The phenyltetrazole thioether class of inhibitors has a more complex structure than the 
other HTS ligands, including a chiral center. There several potential Zn(II) binding groups 
located on the ligand. The pharmacophore of the HTS ligand compound E is unknown therefore 
any one of these moieties or a combination thereof could be essential to DapE binding. This 
exact ligand was synthesized in-house first to confirm inhibition and ultimately to enable 
variation at various positions. We will first perform optimization of compound E with SAR 
assessment by variations at the X, R1 and R2 positions (Figure 17). 
Figure 17. Phenyltetrazole thioether HTS compound E with plan for future analogs 
                
Molecular docking of the lead compound E with DapE performed using SwissDock 
showed that there is a significant binding energy difference between the (R)- and (S)-
enantiomers. The (R)-enantiomer was predicted to bind at an allosteric site with weaker and 
poorer binding energy than the (S)-enantiomer (Figure 18). One could assume this is indicative 
of a noncompetitive or uncompetitive inhibitor with less potency.  
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Figure 18. Molecular docking of HTS compound E[a] 
  
[a] Molecular docking performed using SwissDock and DapE open crystal structure (PDB:3IC1) and output is 
visualized using UCSF Chimera. The (S)-enantiomer is shown interacting with the Zn(II) atoms at the active site 
(picture left) with the Zn(II) atoms shown as grey spheres. The (R)-enantiomer is shown binding to an allosteric site 
(pictured right) with the Zn(II) atoms shown as purple spheres. The secondary structure is shown in grey. 
DapE has shown preference for both L-inhibitors and L-substrates. This chiral phenyl 
tetrazole compound could potentially show selective inhibition for DapE by the (S)-enantiomer 
in a similar fashion. Our goal was to confirm this series as inhibitors of DapE using the 
ninhydrin-based enzymatic assay and obtain SAR from molecular docking studies to guide the 
synthesis of novel and more potent inhibitors of DapE. 
Chemistry. 
The lead compound E was successfully synthesized with two synthetic steps: first, 
alkylation of the 5-thiol(phenyltetrazole) 30 with racemic bromopropionic acid 31 to produce the 
thioether 32.42 Next, compound 33 was produced by amide coupling of the carboxylic acid 32 
with 2-amino thiazole43 (Scheme 8).   
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Scheme 8. Synthesis of the HTS lead compound E[a] 
 
[a] Synthesis of HTS lead compound E. (a) EtOH, NaOH, reflux; b) EDCI, DMF, DMAP, 0°C-rt.  
Modification of R1 can be achieved by amide coupling of 32 with the desired primary or 
secondary amine in lieu of 2-aminothiazole. Variation of R2 comes by the same synthetic route 
with the use of the appropriate α-bromo carboxylic acid 34 for alkylation of 30. 
 Variation at X where X=N is achieved by the proposed synthesis of a thiourea 35 by 
reaction of a racemic α-amino acid 34 with phenyl isothiocyanate.44 Next, the tetrazole 36 is 
formed by reaction with Mukaiyama’s reagent (N-Methyl-2-chloro-pyridinium iodide) and 
sodium azide with 35.45 Finally, coupling of 36 with 2-aminothiazole using EDCI produces 3743 
(Scheme 9).  
Scheme 9. Synthesis of HTS lead compound E amine analog[a]  
 
[a] Synthesis of the amine derivative of compound E where X=N. a) Phenyl isothiocyanate, acetone; b) 
Mukaiyama’s reagent, NaN3; c) EDCI HCl, 2-aminothiazole. 
Results and Discussion. 
Computational Studies. Compound E (33a) was synthesized as a racemic mixture and 
tested for inhibition against DapE and exhibited an IC50 of 89 μM. This is validation that this 
HTS ligand was correctly identified as a new class of inhibitors of DapE.  Variation at R1 using 
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other aromatic heterocycles with both (R)-and (S)-enantiomers in molecular docking showed that 
there is no explicit preference for either enantiomer by DapE in this case. Both bind to DapE 
with the (R)-enantiomers having a carbonyl oxygen bridging between both Zn(II) atoms at the 
active site, like L-captopril, while the (S)-enantiomers are bis-ligated to the active site with the 
carbonyl oxygen bridging between both Zn(II)s and either a nitrogen or sulfur coordinating to 
one Zn(II). Bis-ligated compounds could be more tightly bound ligands but in these cases, it is 
not indicative of such trends with this variation of R1 (Table 9). This was evidenced by an 
increase in energy of the bridging inhibitors analogs (R)-33b and (R)-33c compared to the bis-
ligated inhibitors (S)-33b and (S)-33c. 
Table 9. Binding energies of compound E with (R)- vs (S)-enantiomers with R1 variation [a] 
 
 
R1 Entry R/S ΔG[b] Binding Mode 
 
 
 
(S)-33a S -8.2 C=O to Zn1; NH to Zn2 
 (R)-33a R -8.1 Allosteric 
 
 
 
(S)-33b S -9.8 C=O bridging; C=N close by 
 (R)-33b R -10.1 C=O bridging 
 
 
 
(S)-33c S -9.1 C=O bridging; C=N close by 
 (R)-33c R -9.4 C=O bridging 
 
 
 
(S)-33d S -9.4 C=O bridging; S is close by 
 (R)-33d R -8.8 C=O bridging 
 
[a] Molecular docking performed by SwissDock using ZnZn(HiDapE) open structure PDB:3IC1. [b] Ligand binding 
energies calculated in kcal·mol-1. 
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Structure-activity relationships are in progrees exploring variations of R2. The synthesis 
of compound E employs the use of chiral α-bromo-carboxylic acids for alkylation of the thiol 
tetrazole. Taking advantage of the fact that 2-bromopropionic acid is a direct analog of alanine, 
amino acid analogs can be synthesized by diazotization and substitution with bromine46 which 
would provide a wider variety of analogs of compound E to be tested for inhibition (Scheme 10).  
Scheme 10. Diazotization and bromination of α-amino acids to α-bromo carboxylic acids[a] 
 
[a] Diazotization and bromination of non-functionalized amino acids (top) and functionalized amino acids 
(bottom). 
This prompted molecular docking studies of α-bromo-carboxylic acid derivatives of 
natural α-amino acids. This design first included the change of methyl to the primary alcohol      
-CH2OH (38) which is corresponds to a change from alanine to serine shown in Table 10 below. 
Similarly, the incorporation of an aromatic motif along with a hydroxyl group that can serve as a 
hydrogen bond donor or acceptor prompted the docking of the phenyl alanine and tyrosine 
analogs (39 and 40). A substructure search via Scifinder Scholar shows that serine and tyrosine 
derivatives 38 and 40, respectively, are more novel than the alanine derivative 33. Combination 
of these derivatives with a variety of different heterocyclic amines at R1 can provide for a novel 
series of inhibitor. Both (R)- and (S)-enantiomers were docked with a variety of proposed 
analogs with R1 and R2. variations.  
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In silico studies were promising with the indication of the novel tyrosine-derived analogs 
40 as well as serine-derived analogs 38. The R2 variation with -CH2OH showed decreased 
binding energies for each analog docked compared to their methyl counterparts (Table 10).  
Table 10. Binding energies of compound E serine derivative 38 [a] 
 
 
R1 Entry R/S ΔG[b] Binding Mode 
 
 
 
(S)-38a S -8.9 C=O bridging  
 (R)-38a R -8.2 Allosteric 
 
 
 
(S)-38b S -10.9 C=O bridging; OH-Zn1 
 (R)-38b R -10.7 C=O bridging; OH-Zn1 
 
 
 
(S)-38c S -10.5 C=O bridging; OH-Zn1 
 (R)-38c R -9.4 C=O bridging; OH-Zn1 
 
 
 
(S)-38d S -9.5 C=O bridging; S-Zn1 
 
(R)-38d R -10.2 C=O bridging; tetrazole-Zn1 
 
[a] Molecular Docking performed using SwissDock with the [ZnZn(HiDapE)] structure PDB:3IC1. [b] Ligand 
binding energies calculated in kcal·mol-1. 
We did note that there was no distinct preference for one enantiomer over the other 
except for aminothiazole (R)-38a similar to the original HTS ligand. The active-site binding of 
these analogs was presented as bridged inhibitors with interaction of both Zn(II) atoms in a 
mono-ligated fashion. In most cases, the -OH group is positioned to coordinate with Zn1 
allowing for a bis-ligated coordination with both Zn(II) ions (Figure 19).  
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Figure 19. Phenyltetrazole (S)-38b interaction with the Zn(II)s at DapE active site[a] 
 
[a] Molecular docking of (S)-38b serine derivative was performed using SwissDock and visualized with 
UCSF Chimera. The Zn(II) atoms ate shown as grey spheres with the secondary structure in grey. 
The incorporation of the benzyl group similar in structure to phenylalanine, also showed 
decreased and more potent binding energies in most cases compared to their methyl counterparts 
(Table 11).  
Table 11. Ligand binding energies of compound E phenylalanine derivatives 39[a] 
 
 
R1 Entry R/S Δ G[b] Binding Orientation 
  
 
(S)-39a S -8.9 C=O bridging; S-Zn1 
 (R)-39a R -9.5 C=O bridging; S-Zn1 
 
 
 
(S)-39b S -9.7 C=O bridging; S-Zn1 
 (R)-39b R -10.2 C=O bridging; S-Zn1 
 
 
 
(S)-39c S -10.3 C=O bridging  
 (R)-39c R -9.4 C=O bridging  
  
 
(S)-39d S -10.4 C=O bridging; S-Zn1 
 
(R)-39d R -9.4 C=O bridging; S-Zn1 
[a] Molecular Docking performed using SwissDock with the [ZnZn(HiDapE)] structure PDB:3IC1. [b] Ligand 
binding energies calculated in kcal·mol-1. 
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Thus, docking provided evidence of potentially more tightly-bound ligands. In the 
phenylalanine derivatives, no preference for either the (R)- or (S)-enantiomer was uniformly 
observed. However, variation of R1 with other aromatic heterocycles showed that the original 2-
aminothiazole was not as favorable for binding to DapE with both (S)-39a and (R)-39a having 
higher binding energies than the other substituents tested. Inhibitor binding was observed with a 
bridging mode between both Zn(II) ions andthe sulfur coordinating to Zn1.  More insight on the 
interactions with the binding pocket of DapE will be explored in future studies.  
The biggest decrease in energy representing more tightly-bound ligands was observed 
with the tyrosine derivatives 40 of which most docked analogs showed binding in a bridging 
mode between the two Zn(II) ions by the amide carbonyl oxygen (Table 12, Figure 20). 
Figure 20. Phenyltetrazole inhibitor (R)-40b interaction with Zn(II)s at DapE active site[a] 
 
[a] Molecular docking of (R)-40b tyrosine derivative was performed using SwissDock and visualized with UCSF 
rChimera. The Zn(II) atoms are shown as grey spheres with the secondary structure of DapE in grey. 
 As seen with the alanine 33, serine 38, and phenylalanine derivatives 39, there was no 
preference for one enantiomer over the other for tyrosine derivatives 40. There is a further 
decrease in energy with the incorporation of a pyridine or pyrimidine modification at R2 (Table 
12) suggesting favorable ligand design and binding. 
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Table 12. Ligand binding energies of compound E tyrosine derivatives 40[a] 
 
 
R1 Entry R/S ΔG[b] Binding Mode 
  
 
(S)-40a S -10.2 C=O-Zn1 
 (R)-40a R -9.0 OH- bridging 
 
 (S)-40b S -11.2 C=O bridging  
 
(R)-40b R -11.0 C=O bridging  
 
 (S)-40c S -10.5 C=O bridging  
 (R)-40c R -10.99 C=O bridging  
 
[a] Molecular Docking performed using SwissDock with the [ZnZn(HiDapE)] structure PDB:3IC1. [b] Ligand 
binding energies calculated in kcal mol-1. 
One clear indication for the variation of the R1 and R2 groups is that incorporation of a 
the -OH group decreases the ligand binding energies corresponding with tighter binding as 
evidenced by the serine 38 and tyrosine derivatives 40. Also, the introduction of a 6-membered 
aromatic heterocycle also decreases the ligand binding energies as seen in analogs b and c of 
each derivative. The in-silico studies using SwissDock provide a key starting point to the design 
of future analogs. The binding modes of these inhibitors may play a key role in the inhibition of 
DapE. 
 The aza analog 37 is an alternative bioisostere to the thioether 33. The secondary amine is 
less likely to by oxidized than the sulfur making the shelf life potentially longer than the 
thioether, which is preferred in medicinal chemistry applications. Most importantly, there is an 
ease of analog synthesis as single enantiomers from natural or unnatural amino acids. Also, the 
modification to the amine adds for another point of derivation compared to the thioether. A 
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Scifinder Scholar substructure search shows that this simple modification in itself is not novel 
but the incorporation of a simple methyl addition to the amine or the use of serine or tyrosine 
derivatives at R2 provides a novel structure and perhaps may enhance the pharmacophore. The 
amine analog 37 is currently being synthesized as an alternative to be compared to the inhibitory 
data by the original HTS ligand compound E. 
Conclusion. 
The phenyltetrazole HTS ligand E was validated as a lead toward a series of potent 
inhibitors of DapE demonstrated by use of the ninhydrin-based enzymatic assay with an IC50 of 
89 μM for 33a. This is promising since this was a racemic mixture and if one enantiomer is 
completely inactive then the IC50 is cut essentially in half. If one enantiomer shows slight 
inhibition while the other is more potent, the apparent IC50 for a single enantiomer would still be 
lower than reported for the racemic. Molecular docking has guided the design of more potent 
inhibitors of this series. The novelty space on this series is easily achieved by slight variations 
such as the incorporation of serine or tyrosine derivatives and the change from a thioether to a 
secondary or tertiary amine, as shown by SciFinder Scholar. The use of MOE for more extensive 
molecular docking will be more beneficial because docking of the ligands is not computed with a 
rigid receptor as in SwissDock and will allow for the active site of the enzyme to more 
accurately accommodate the inhibitors. This will aid in the design of new inhibitors with 
increased interactions with the residues in proximity to the active site. Key interactions can be 
assessed that are not explicitly observed using SwissDock. Additionally, the MOE software suite 
can generate a library of potential inhibitors that fit in the active site that should improve the 
novelty and potency of the synthesized inhibitors. Results from the molecular docking 
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experiments using MOE are currently in progress. Analogs will be synthesized and inhibitory 
data using the newly-developed ninhydrin assay will be obtained in due course. 
Part III. Difluoromethyl Sulfonamides as Inhibitors of DapE 
Introduction. 
The difluoromethyl sulfonamide compound B identified through HTS is a simplified 
class of inhibitors with much room for variation. Difluoromethyl (-CF2H) groups are important 
structural motifs in medicinal chemistry as the group acts as a lipophilic hydrogen donor. The 
difluoromethyl group can also act as a bioisostere of thiols, anilines, amines and thiophenes but 
not of alcohols.47 Possible inhibition of DapE could come from interaction with a negative 
charge on the enzyme or between F and the Zn(II) ion itself. Take in account the proximity of the 
methoxy oxygen and the sulfonyl oxygen, these both could act as Zn(II) ion binding groups 
through bis-ligation. With these possible modes of interaction, a HTS ligand expansion was 
performed with a goal of establishing SAR and obtaining proposed binding configurations of 
Compound B through in silico studies. The original HTS compound B was resynthesized along 
with analogs and tested for inhibition against DapE using the ninhydrin-based enzymatic assay. 
Figure 21. Difluoromethyl sulfonamide HTS lead compound B with points of modification 
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Chemistry. 
The lead inhibitor compound B was synthesized through the condensation of toluene 
sulfonyl chloride and 2-methoxy aniline to yield 4148, followed by the difluoromethylation using 
potassium carbonate and chlorodifluoroacetate sodium salt49 (Scheme 11).  
Scheme 11. Synthesis of HTS lead difluoromethyl sulfonamide compound B[a] 
 
[a] a) DCM, Et3N, rt; b) MeCN, chlorodifluoroacetate sodium salt, K2CO3 [b] Synthesis of compound B, the 
synthesized ligand will be referred to synonymously as 42a. 
Variation of the R1 and R2 groups is obtained through use of substituted aniline 
derivatives in a reaction with substituted benzene sulfonyl chloride. Further variation at position 
R2 meta and para to the amine can be achieved by use of appropriate-substituted anilines. 
Modification of R3 is performed by reaction of 41 through alkylation, acylation, etc. 
Scheme 12. Synthesis of compound B analogs with modification of R3 
 
Results and Discussion. 
For HTS compound B (42a), molecular docking simulations were performed in 
SwissDock using the PDB:3IC1 crystal structure to obtain predicted binding modes. The ligand 
scaffold of compound B from the HTS is not as complex as the other inhibitors identified and the 
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presence of potential zinc binding groups guided the design of analogs. The sulfonyl oxygens 
were observed coordinating to the zinc atoms at the active site of DapE with one oxygen 
bridging between both Zn(II)s in the docking results (Figure 22). 
Figure 22. Difluoromethyl sulfonamide B interaction with the Zn(II) ions at DapE[a] 
 
[a] Molecular docking performed using SwissDock and DapE open crystal structure (PDB:3IC1) with outputs 
visualized using UCSF Chimera. Zn(II) atoms shown in purple with the inhibitor in light blue and the enzyme 
secondary structure in grey. 
Interestingly, one zinc atom appeared to coordinate to the methoxy oxygen, the 
difluoromethyl, and to both sulfonyl oxygens. The proximity of these zinc-binding groups allows 
for multiple interactions at the active site where all three groups play a distinct role in 
coordination. To initiate the SAR studies, we utilized the synthesis of compound B to vary the 
most easily altered positions pertaining to these functional moieties. This included testing the 
location of the methoxy group to the sulfonamide by synthesizing both the ortho and para 
methoxy derivatives. Finally, the difluoromethyl group on the sulfonamide was replaced with 
isosteres including a traditional methyl group. 
Computational Studies. The o-methoxy difluoromethyl sulfonamide 42a and the p-
methoxy analog 42b were docked to DapE along with the methyl derivatives 43a and 43b 
(Figure 23). The methylated derivatives of o-methoxy and p-methoxy sulfonamides serve two 
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purposes: first, to assess SAR of the difluoromethyl group acting as a methyl isostere versus its 
potential to act as a more complex moiety; and second, to determine if ortho substitution aids in 
the binding of the inhibitor as demonstrated in the molecular docking of compound B.  
Figure 23. Methyl sulfonamide analogs of compound B 
 
Initial docking studies indicated that the difluoromethyl group decreased binding to the 
active site as the methyl derivatives showed lower binding energies of -8.29 kcal·mol-1 and -8.79 
kcal·mol-1 for 43a and 43b, respectively, indicating tighter binding than the lead compound. No 
further computational studies have been performed to date on compound B, but initial results 
confirm the HTS ligand suggests active-site binding.  
Inhibitory data. The methyl analogs 43a and 43b have also been synthesized alongside 
the original compound 42a. Inhibitory data showed that both methylated structures 43a and 43b 
have increased potency compared to the difluoro 42a which only inhibited 31 % at 100 μM. The 
methylated derivative 43a showed 60 % inhibition at 100 μM and 43b showed an IC50 of 151 
μM. Interestingly, the non-functionalized sulfonamide 43c showed no measurable inhibition at 
100 μM (Table 13). 
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Table 13. Inhibitory data of HTS compounds B  
Entry Structure IC50 μM[a] Entry Structure IC50 μM[a] 
42a 
 
ND[b] 31% at 100 43b 
 
151 
43a 
 
ND, 60% at 100 43c 
 
ND, 0% at 100 
[a] Data obtained from a set of triplicates and IC50 values were determined from a set of three or four % inhibition 
points. [b] Not determined, low solubility at higher concentrations, inhibition reported by a single concentration 
Conclusion.  
The difluoromethyl sulfonamide series was confirmed as inhibitors of DapE with 
compound E showing a 31 % inhibition at 100 μM using the ninhydrin-based enzymatic assay. 
Although the inhibition of DapE by 42a was less than that of the methylated analogs 43a and 
43b, expansion of the series by has already been proven to be beneficial. Further, molecular 
dockings studies are needed to further guide the design of future analogs of this series. In silico 
inhibitory screening of additional analogs to increase potency of this motif should prove 
advantageous. We will continue to focus on building a library of compounds to be synthesized in 
due course. 
Part IV. Inhibitory Data of Miscellaneous Compounds 
The spectrophotometric ninhydrin-based enzymatic assay was used to determine the 
inhibitory activity of the HTS compounds and analogs. Inhibition was screened at 20 and 200 
uM and the IC50 values were not yet determined for these inhibitors. The ninhydrin-based assay 
protocol was similar to the protocol for screening described in Chapter Two. The exception is 
that the inhibitor dilution and incubation methods were modified, in that all inhibitors were 
diluted to 5 mM or 10 mM stock solutions in 100 % DMSO to aid in inhibitor solubility. Serial 
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dilutions were then made from this stock solution with final stock solutions containing 50 % 
DMSO. The addition of 20 μL of 50 % DMSO to 200 μL reactions provide a final concentration 
of 5 % DMSO. Because of the addition of DMSO, the incubation time was cut in half from 10 
minutes to 5 minutes and reactions were incubated on ice. Inhibitory data is reported as percent 
inhibition. 
Inhibitory Data. 
Table 14 shows the inhibition of DapE by compounds prepared by our research group outside 
those identified in HTS. 
Table 14. Inhibitory data of miscellaneous compounds using ninhydrin-based assay 
 
Entry Structure 
% Inhibition at 
200 μM[a] 
% Inhibition 
at 20 μM[a] 
44 
 
43 21 
45 
 
94 15 
46 
 
92 37 
47a 
 
86 32 
47b 
 
25 12 
48a 
 
79 22 
48b 
 
27 25 
[a] Data obtained from a set of triplicates; Inhibitors were allowed to incubate with HiDapE at 30°C for 10 minutes 
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CHAPTER FIVE  
7-SULFONAMIDE INDOLINES AS INHIBITORS OF DAPE 
Introduction 
The identification of 7-sulfonamide indolines as a class of possible inhibitors of DapE 
arose curiously from the mislabeling of the structures of the 6-sulfonamide indolines identified 
through the HTS performed on compounds licensed from Chembridge Corp.  The actual 6-
sulfonamide indoline structure was incorrectly labeled by Dorogov and others as the 7-
sulfonamide indoline regioisomer produced from the sulfonylation of N-acetyl-5-bromo-indoline 
using chlorosulfonic acid in an electrophilic aromatic substitution reaction.50  Subsequently, 
Borror and colleagues confirmed through X-ray analysis and NMR spectral analysis that this 
chlorosulfonic reaction actually produces the sole 6-chlorosulfonated regioisomer.51 This may be 
due to the rotamer of the amide bond of N-acetyl indoline favoring an endo vs an exo position. 
The endo conformer is favored when the carbonyl oxygen is in close proximity to the 7-H on the 
aromatic ring due to the partial positive and partial negative charge the two atoms carry from 
hydrogen bonding (Figure 24). This endo conformation may block substitution at the 7-position 
on indoline leaving the 6-position open for substitution. This conformation also explains why 
halogenation of N-acetyl indoline occurs only para to the amide bond at the 5-position with 
exclusive formation of the 5-halo regioisomer. 52 
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Figure 24. Conformation of N-acetyl-5-bromoindoline rotamers 
 
The 7-sulfonamide indolines rose in interest due to molecular docking that was initially 
performed based on the incorrect HTS structure docking suggested that the proximity of the 
amide oxygen and a sulfonamide oxygen in these 7-sulfonamide indoline regioisomers could 
allow for a bis-ligated interaction to the Zn(II) ions at the active site of DapE. Furthermore, 
lower binding energies were observed for the 7-sulfonamide indolines compared to the 6-
sulfonamide indolines which could be a direct correlation of suggested interaction at the active 
site. More tightly bound ligands should be more potent inhibitors of DapE, which led us to 
explore these structures. Correspondingly, we hypothesized that 7-sulfonamide indolines would 
function as potent inhibitors of DapE and herein report molecular docking data that predicts the 
increased potency over the 6-sulfonamide regioisomers. To date, the only published methods on 
a synthetic route to 7-sulfonamide indolines is by Borror et. al. using a tricyclic indoline system 
containing a cyclic sulfonyl urea moiety as an intermediate.51 Our attempts to repeat this method 
revealed severe limitations on both the yield and the variety of analogs that could be produced. 
Herein, we report an improved method for the formation of 7-sulfonamide indolines via the 
tricyclic sulfonylurea indoline, in addition to a novel synthetic approach to the direct 7-
sulfonation of indolines. The inhibitory data of the 7-sulfonamide indolines have validated our 
hypothesis that 7-sulfonamide indolines should be more potent inhibitors of DapE than the 6-
sulfonamide indolines. 
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Computational Studies 
 Based on the presence of two zinc binding groups on the indoline compounds it is 
suggestive of bis-ligation involving both the N-acetyl and the sulfonamide groups on the indoline 
with both Zn(II) ions at the DapE active site.  The 7-sulfonamide indolines provide just the right 
distance for this ligand-zinc interaction to take place where the 6-sulfonamide groups are 
positioned farther apart in indoline making bis-ligation less possible. Molecular docking of the 7-
sulfonamide indolines with [Zn2(HiDapE)] crystal structure 3IC1 performed with SwissDock 
showed six different possible modes of interaction with DapE. Upon completion of the 
calculations, the ligand conformations satisfying the di-zinc metal ion coordination with the 
lowest binding energies around the target active site were used to identify potential inhibitors and 
are represented in Figure 25.  
In the docked structure, the 7-sulfonamide indolines were observed interacting with both 
zincs at the active site in a bis-ligated mode as hypothesized. Additionally, the 7-sulfonamide 
indolines were also observed binding in a bridging manner with either the acetyl or a sulfonyl 
oxygen coordinated to both Zn(II) ions. In some cases, one oxygen was shown coordinating to 
just one zinc while the other oxygen was bridged between both. And, like the 6-sulfonamide 
indolines, some inhibitors were observed bound to DapE at an allosteric site.  
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Figure 25. Molecular docking interaction of 7-sulfonamide indolines with DapE[a] 
 
[a] Molecular docking of 7-sulfonamide indolines bound to DapE performed by SwissDock and visualized with 
UCSF Chimera with the Zn(II) ions shown as purple spheres, the inhibitors are shown in blue with the sulfonyl 
group in yellow and the secondary structure of DapE shown in grey. A) Bis-ligated pose. B) Sulfone oxygen 
bridging Zn(II) ions. C) Acetyl oxygen bridging the Zn(II)s with the sulfonyl oxygen coordinating to only one Zn(II) 
ion. D) Both sulfonyl and acetyl oxygens coordinating to one Zn(II). E) Allosteric binding. F) carboxylate 
coordinating to active site.  
 
The overall binding energies of the 5-brominated-7-sulfonamide indolines versus the 6-
sulfonamide indoline regioisomers were markedly lower representing superior predicted binding 
(Table 15). The arithmetic differences in the 7-sulfonamides compared to the 6-sulfonamides 
that result in a negative number indicate more tightly-bound ligands favoring the 7-sulfonamide 
regioisomer. The 7-sulfonamide indolines could act as more tightly-bound ligands to the active 
sites based on lower calculated energies and the suggestive binding configurations obtained from 
the molecular docking. Some of the trends between the direct analogs of the regioisomers were 
similar such as for the nitrogen-containing aromatic sulfonamide derivatives which are predicted 
to act as allosteric inhibitors. 
A B
C
D E F
71 
 
   
 
Table 15. Molecular docking energies of brominated 7- vs. 6-sulfonamide indolines [a] 
 
 
Entry Entry R2 R3 Δ G for 49 ΔG for 16 Difference 
49a 16a  -Br 
 
-9.7 -8.9 -0.8 
49b 16b  -Br 
 
-9.1 -8.4 -0.5 
49c 16c  -Br 
 
-7.9 -8.3 0.5[b] 
49d 16g  -Br 
 
-9.5 -8.5 -1.0 
49e 16h  -Br 
 
-9.8 -7.4 -2.4 
49f 16i  -Br 
 
-9.0 -8.3 -0.7 
49g 16j  -Br 
 
-9.6 -8.6 -1.0 
49h 16k  -Br 
 
-9.9 -8.7 -1.1 
49i 16l  -Br 
 
-10.4 -9.5 -0.9 
49j 16m  -Br 
 
-9.9 -8.3 -1.6 
49k 16n  -Br 
 
-8.7 -8.2 -0.5 
49l 16o  -Br 
 
-9.7 -9.4 -0.3 
49m 16p  -Br 
 
-9.7 -9.3 -0.4 
49n 16q  -Br 
 
-8.7 -8.2 -0.5 
49o 16r  -Br 
 
-8.2 -8.5 0.3[b] 
49p 16s  -Br 
 
-9.2 -8.3 -0.9 
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Entry Entry R2 R3 Δ G for 49 ΔG for 16 Difference 
49i* 16l*  -Br 
 
-13.8 -13.2 -0.6 
49j* 16m*  -Br 
 
-13.5 -12.5 -1.0 
49k* 16n*  -Br 
 
-13.9 -14.6 0.8[b] 
49l* 16o*  -Br 
 
-14.0 -14.5 0.5[b] 
[a] Molecular docking performed with SwissDock using PDB:3IC1. [b] Only four of the twenty indoline 6-
sulfonamides were predicted to be better than the corresponding 7-sulfonamides. 
Part I. N-Acetyl-7-Sulfonamide Indoline Syntheses 
Borror Synthetic Route to 7-Sulfonamide Indolines. 
The 7-sulfonamide indolines were synthesized using a unique tricyclic indoline system 
containing a cyclic sulfonyl urea moiety as an intermediate. The key step in this synthesis is 
using the indoline nitrogen as an anchor to deliver the sulfonyl group for formation of the 7-
sulfonamide indoline.  The 7-sulfonamide indolines are synthesized by the condensation of 
indoline and chlorosulfonyl isocyanate (51) followed by thermally-induced intramolecular 
cyclization. This produces the unique tricyclic indoline system with a cyclic sulfonyl urea 52. 
Alkylation of this cyclic sulfonylurea 52 using a haloalkane and K2CO3 produced 53 and was 
followed by a base-catalyzed hydrolysis using KOH afforded 7-sulfonamide indoline 54. Finally, 
acetylation using acetyl chloride produces the desired N-acetyl-5-bromo-7-sulfonamide indoline 
49 (Scheme 13).51 
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Scheme 13. Borror’s synthesis of N-acetyl-7-sulfonamide indolines[a] 
 
[a]Only published synthesis of 7-sulfonamide indolines.51 R= alkyl halide. (a) ClSO2NCO, MeCN, 0 °C; b) toluene, 
116 °C, 4 hrs; (c) K2CO3, DMF, R-X, rt, 72 hrs; (d) KOH, MeOH, rt, 24 hrs; (e) acetyl chloride, DCM, Et3N, 1 hr. 
The literature procedure provided the desired indoline 51, however, the isolated product 
was not stable over time. Additionally, the heat-mediated cyclization produced an even lower 
yield of 52 over two steps. By the time we synthesized derivatives of 53, the overall yield was 
barely enough to characterize the products, let alone enough to take into the next step. 
Improved Borror Synthetic Route.  
Synthesis of 7-sulfonamide indolines proved difficult through this method of 
intramolecular cyclization, alkylation, and hydrolysis, which led us to pursue modifications of 
the synthesis described by Borror. The first modification came by performing an intramolecular 
cyclization under Friedel-Crafts conditions53 in a one-pot synthesis to create the tricyclic 
sulfonylurea indoline 56. After alkylation and halogenation of the tricyclic indoline 56 to 
produce 53, hydrolysis was performed with 50% sulfuric acid heated to 135 ˚C rather than using 
KOH. We observed that the viscous nature of the sulfuric acid aided in solubility (Scheme 14).53  
74 
 
   
 
Scheme 14. Improved synthesis of N-acetyl-7-sulfonamide indolines[a] 
 
 [a] Improved Borror synthesis. R= alkyl (1a) One-pot synthesis employing ClSO2NCO, nitroethane, -42°C; 
followed by (2a) AlCl3, rt-110°C, 2 hrs; (b) alkyl halide, NaH, DMF, 60°C; (c) Br2, AcOH or NBS in MeCN; (d) 1) 
50% H2SO4, 135°C, 2 hrs; 1) 50% H2SO4, 135°C, 2 hrs (e) acetyl chloride, Et3N, DCM, DMAP. 
The improved Borror synthetic route allowed for the synthesis of three N-acetyl-5-
bromo-7-sulfonamide indolines: the isopentyl sulfonamide 49a, the propyl sulfonamide 49b and 
the benzyl sulfonamide 49c shown in Figure 26. 
Figure 26. 7-Sulfonamide indolines synthesized by the improved Borror method 
 
Although three N-acetyl-7-sulfonamide indolines were successfully synthesized through 
these methods, this synthetic route has severe synthetic limitations. First the alkylation step is 
limited to the synthesis of secondary sulfonamides from the SN2 of available primary and 
unhindered haloalkanes. This precludes the synthesis of any cyclic sulfonamides through this 
method including the reproduction of the piperidine sulfonamide HTS inhibitor compound D. 
1a 2a
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Second, the harsh hydrolysis conditions brought about by the use of 50 % sulfuric acid heated to 
135˚C for two hours narrows the use of many substituents unable to tolerate these sever 
conditions including alcohols, alkenes, and other easily-hydrolyzed and other labile functional 
groups. Therefore, a more practical method for synthesizing 7-sulfonamide indoline analogs for 
evaluation as inhibitors of DapE, in addition to other potential application of indoline-7-
sulfonamides is needed.  
Modified Synthesis of 7-Sulfonamide Indolines. 
To reliably evaluate inhibition against DapE and to develop structure-activity 
relationships between the 6-sulfonamide indolines versus the 7-sulfonamide indoline 
regioisomers, is to synthesize direct analogs of each one though a similar method. Ideally, it 
would be conducive to the efficient synthesis of both in parallel with the production of the 
indoline 7-sulfonyl chloride 60 could react with primary and secondary amines with varying 
functional groups should be analogous to the synthesis of the 6-sulfonamide indolines.  This 
could be achieved by a practical alternative synthesis of 7-sulfonamide indolines using the 
existing tricyclic sulfonyl urea indoline 56 from the previously described modified method 
(Scheme 15)51. Upon hydrolysis of the non-alkylated cyclic sulfonylurea 56 the primary 7-
sulfonamide indoline 58 is produced. Acylation on the aniline nitrogen to produce 59 allows the 
primary sulfonamide to be free for conversion to the sulfonyl chloride 60 which is ultimately 
reacted with amines to provide the desired 7-sulfonamide indoline. 
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Scheme 15. Proposed synthesis of 7-sulfonyl chloride indoline 60[a] 
 
[a] Proposed synthetic route of sulfonyl chloride 61 (a) 1) 50% H2SO4 at 135 °C, 2 hrs; 2) 10N NaOH to pH 7; (b) 
acetylation; (c) deaminative chlorination 
Initially, acetylation of sulfonamide 58 using both acetyl chloride and the milder reagent 
acetic anhydride to obtain the N-acetyl-7-sulfonamide indoline 59 produced a mixture of N-
acylated products. This included the di-acetylated product 62 as the major product with the 
desired N-acetyl 7-sulfonamide indoline 59 as well as the 7-(N-acetyl)sulfonamide indoline 63 
and unreacted starting material 58 as shown in Scheme 16, demonstrating that, both the aniline 
nitrogen of indoline and the primary sulfonamide had similar reactivity towards acetylation.  
Scheme 16. Acetylation of primary sulfonamide 58 using acetyl chloride 
 
Instead, a selective carboxybenzyl (Cbz) protection of the aniline nitrogen of the indoline 
ring was achieved by use of a Cbz protecting group (64) as supported by NMR. This selective 
amine protection allows for the primary sulfonamide to be converted to the sulfonyl chloride 65 
(Scheme 17). 
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Scheme 17. Selective aniline protection using carboxybenzyl (Cbz) group. 
 
Deaminative chlorination of 7-sulfonamide indolines. The deaminative chlorination of 
the primary sulfonamide 64 to produce the 7-chlorosulfonyl indoline 65 was explored.  An 
attempt to change the primary sulfonamide directly to a sulfonyl chloride using thionyl chloride 
and dioxane at reflux as per Park’s54 procedure yielded <20% desired product with unreacted 
starting material. 1,4-Dioxane and thionyl chloride proved troublesome to remove and the low 
product yield compared to the expected yield of 55% proved this route may not be practical. The 
use of chlorosulfonic acid followed by thionyl chloride would not be applicable due to reaction 
of the strong electrophilic with the more sensitive Cbz group55 (Scheme 18). 
Scheme 18. Unsuccessful attempts at deaminative chlorination  
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Due to a lack of other literature procedures for the direct deaminative chlorination of aryl 
sulfonamides, a more productive synthetic route to synthesize the sulfonyl chloride through a 
sulfonic acid intermediate was pursed since there are many known literature procedures for the 
synthesis of sulfonyl chlorides from sulfonic acids. Conversion of the N-Cbz-7-sulfonamide 
indoline 64 has been achieved using isoamyl nitrite suing to produce56 the 7-sulfonic acid 
indoline 67, which can then be more efficiently converted to the sulfonyl chloride 65 (Scheme 
19).  
Scheme 19. Proposed synthesis of 7-sulfonic acid 67 from the primary 7-sulfonamide indoline 64 
 
A neat reaction with thionyl chloride (SOCl2) and the N-Cbz-7-sulfonic acid indoline 67 
produced a complex mixture of products. This could be due to the proximity of the Cbz group to 
the 7-sulfonyl chloride. The proximity of these groups could allow for intramolecular reactions 
between these two groups due to a 6-membered ring that could be formed. In addition, this could 
have been the result of thionyl chloride reacting directly with the Cbz group despite reports that 
the Cbz protecting group is stable to thionyl chloride.  This is hypothesized because of the 
presence of 7-sulfonamide indoline 58 was detected as one of the products produced. The two 
variables of this reaction are the reagents used and the Cbz protecting group and the most logical 
remedy to this problem is to use a milder reagent. We decided to preserve starting materials by 
substitution of toluene sulfonic acid (TsOH) as a model aryl sulfonic acid to optimize the 
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reaction conditions for converting an aryl sulfonic acid to a sulfonyl chloride and ultimately to a 
sulfonamide.   
Toluene sulfonic acid as a model aryl sulfonic acid. We decided to address the two 
concerns of the Cbz group and the thionyl chloride as two separate problems. First, we looked at 
the use of milder reagents and/or reaction conditions for the chlorination of sulfonic acid. 
Cyanuric trichloride (CTC) is often employed for the conversion of alcohols and carboxylic 
acids to alkyl chlorides and acyl chlorides, respectively, CTC can convert aryl sulfonic acids to 
sulfonyl chlorides in different applications. A solvent-free reaction of TsOH, CTC and KCl 
ground in a mortar and pestle for 5 minutes with the addition of a drop water followed by a 
workup with EtOAc showed mainly unreacted CTC in the organic layer by HPLC and the 
toluene sulfonic acid remained in the aqueous layer unreacted.57 A more direct approach 
employing TsOH, CTC, Et3N in acetone at reflux showed full and clean conversion to toluene 
sulfonyl chloride (TsCl)58. The HPLC retention times and the NMR reference peaks matched 
those of commercially available TsCl.  
Second, we addressed the possibility of the sulfonyl chloride 65 being successfully 
synthesized and soon after reacting intramolecularly or intermolecularly with the Cbz group. To 
avoid this potential problem, we considered synthesizing 65 as an intermediate without isolation, 
or technically in a one-pot reaction to produce the desired sulfonamide. When reacted with DMF, 
CTC forms a complex known as Gold’s reagent, where it subsequently reacts with sulfonic acid 
and “alkylates” the added amine to form a sulfonamide.59 Although we could form Gold’s 
reagent, we were not able to get the TsOH to react and therefore no product was observed. We 
are currently pursuing a straightforward in situ attempt by synthesizing the TsCl using CTC and 
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acetone, as described above, while closely monitoring the reaction followed by addition of the 
desired amine to form the sulfonamide in a one-pot reaction. In addition, there are a few other 
one-pot reactions involving CTC and the addition of an amine to form the sulfonamide.60 
Aryl sulfonamide formation using triphenylphosphine. More recently, we have 
focused on coupling the indoline 7-sulfonic acid 67 with primary and secondary amines using 
triphenylphosphine (Ph3P). In this case, we used benzene sodium sulfonate 69 as a model aryl 
sulfonic acid. The use of a halogenating agent, Br2 
61 or trichloroacetonitrile,62 converts the Ph3P 
to Ph3PX2 (X=Br or Cl). From there, reaction with the sulfonic acid generates the sulfonyl halide 
which can react with the amine in situ to yield the desired 7-sulfonamide indoline. Ph3PBr2 68 
was generated by the addition of Br2 to Ph3P in acetonitrile. Next, benzene sodium sulfonate 69 
was added to generate the sulfonyl bromide 70 in situ which then reacted with aniline to afford 
the desired sulfonamide 71 (Scheme 20).  
Scheme 20. Use of Ph3P to couple aryl sulfonic acids to form sulfonamides 
 
The reaction was complete as determined by HPLC with full conversion of the starting 
material. However, the separation of the triphenylphosphine oxide byproduct (Ph3PO) 72 proved 
difficult based on the similar properties of benzene sodium sulfonate and the Ph3PO byproduct. 
Also, use of aniline produced a product containing only aromatic hydrogens and the presence of 
the unreacted Ph3PBr2 and Ph3PO makes confirmation of the product more difficult. By using a 
81 
 
   
 
polymer-bound Ph3P reagent, the removal of the Ph3PO was possible by filtration. Also, the 
switch from aniline to cyclohexyl amine should allow the detection of protons outside of the 
aromatic region via NMR (Scheme 21).  
Scheme 21. Use of polymer-bound Ph3P for coupling aryl sulfonic acids 
 
While monitoring the reaction by TLC and HPLC, no aromatic products were detected 
which led us to conclude that the TsOH was attached to the polymer-bound Ph3P. We decided to 
return our focus to the unbound Ph3P for these reactions as we wanted to confirm the actual 
products of the reaction as a priority in determining how to isolate the product if possible. The 
reaction was scaled up 10-fold from 20 mg to 200 mg of TsOH and the product formed was 
detected as well as the observed disappearance of most of the starting material. The sulfonamide 
71b was synthesized in a separate reaction by a known procedure using cyclohexyl amine and 
commercially available TsCl for use as a standard. Unfortunately, neither the HPLC retention 
times nor the TLC rf values matched as they were distinctly different. Co-chromatography of the 
Ph3P reaction and the sulfonamide 71b showed two different retention times instead of the 
increase in the concentration of the product as expected. Lastly, we attempted to synthesize the 
sulfonyl chloride in situ by use of trichloroacetonitrile as described by Chantarasriwong62 but 
this proved unsuccessful as very little TsOH was converted to the TsCl.   
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A Successful Selective Acetylation of 7-Sulfonamide Indoline 58.                                                   
……. .We have concluded that the Cbz group is unsuitable for further use in the synthesis of N-
acyl-7-sulfonamide indolines through the formation of the sulfonyl chloride 65 due to the labile 
nature of this protecting group in proximity to the electrophilic sulfonyl species on the 7-position 
of the indoline. We decided to revisit the selective amine protection of 7-sulfonamide indoline 58 
by acetylation. The use of Et3N led to the di-acetylation of 7-sulfonamide indoline 58. Borror 
used K2CO3 as a base for the alkylation of the 5-bromo cyclic sulfonamide indoline 51,
51 
however this was not successful when attempted with the cyclic indoline 56. We attempted 
acetylation of 58 using either K2CO3 or the weaker base NaHCO3. We observed the formation of 
one main product and two smaller byproducts with K2CO3 and one main product and a small 
byproduct with the use of NaHCO3 as a base. Acetylation of 58 in THF with 3 equivalents of 
solid NaHCO3 cooled to 0 °C and 1.05 equivalents of acetyl chloride dissolved in THF was 
added slowly. The temperature was kept below room temperature (15-18°C), and the formation 
of the deisred mono-acetylated indoline 59 product (Scheme 22) was suggested by the 
disappearance of the aniline nitrogen and the retention of the correctly integrated sulfonamide 
hydrogens on 1H NMR. 
Scheme 22. Selective acetylation of 7-sulfonamide indoline 58. 
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 The successful synthesis of the N-acetyl-7-sulfonamide indoline 59, demonstrates that we 
have designed a new modified synthetic route of N-acetyl-7-sulfonamide indolines through a 
sulfonyl chloride. With the robust acetyl functional group in contrast to Cbz, the synthesis of the 
sulfonyl chloride is synthesized with greater ease. The hydrolysis of the cyclis sulfonyl urea 
indoline 56 to produce the 7-sulfonamide indoline 58 allows for the acetylation of the indoline 
nitrogen to produce 59. The primary sulfonamide 59 is available for conversion to the sulfonic 
acid 73 by isoamyl nitrite. From here, the sulfonamide can be synthesized by formation of the 
sulfonyl chloride 74 and either isolated or generated in situ and reacted with the desired amine to 
produce the sulfonamide 75 (Scheme 23). 
Scheme 23. Modified Synthesis of N-acetyl-7-sulfonamide indolines[a] 
 
[a] R= alkyl, cyclic, aromatic amines.  (a) One-pot synthesis of cyclic sulfonylurea 1) ClSO2NCO, nitroethane, -
42°C; 2) AlCl3, rt-110°C, 2 hrs; (b) 1) 50% H2SO4, 135°C, 2 hrs; 2) 10°C, 10 N NaOH, pH 7; (c) 1.05 eq of acetyl 
chloride, 3 eq NaHCO3, THF 0°C to 15°C; (d) isoamyl nitrite, dioxane, reflux; (e) Cyanuric trichloride, acetone; (f) 
amine; (g) optional one-pot reaction of e) and f) without isolation of indoline 74.  
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Substituted N-Cbz-7-Sulfonamide Indoline Derivatives. 
 We used the N-Cbz-7-sulfonamide indoline 64 intermediate to synthesize derivatives of 
the primary sulfonamide at R3. Similar to the derivatives designed for the 6- sulfonamide 
indolines, we aimed to synthesize N-acyl sulfonamides 76 by reaction of acyl chlorides or 
carboxylic acids. In addition, thioureas 77 can be synthesized by the reaction of the primary 
sulfonamide with isothiocyanates, and sulfonylureas 78 can be synthesized by reaction with 
isocyanates or carbamoyl chlorides (Scheme 24).  
Scheme 24. Variation of N-Cbz-7-sulfonamide indoline 64 at R3[a]  
 
 [a] R2= H, Br or Cl; R3=alkyl or aryl 
 The N-acyl sulfonamides were explored in Chapter Four as precursors to the compounds 
in the 6-sulfonamide indoline series. As previously mentioned, our aim is to have direct head-to-
head comparisons of 6- and 7-sulfonamide regioisomers. The Cbz at the R1-position of the 
indoline is intended as a protecting group that can be replaced with various acyl groups. To 
assess SAR of the N-acylsulfonamides, molecular docking was performed on N-acyl-7-(N-
acyl)sulfonamides and [ZnZn(HiDapE)] utilizing SwissDock. N-Acyl sulfonamides are 
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moderately acidic with a pKa of 5-6 which is similar to a carboxylic acid. In aqueous solutions, 
this functional group exists predominantly as an anion. Both the neutral acylsulfonamides and 
their anions were docked, along with 5-bromo and 5-chloro analogs. 
 Computational Studies of 7-(N-acyl)sulfonamides and DapE Binding.                              
………Initial molecular docking showed that 1-N-acetyl-5-bromo-7-(N-acetyl)sulfonamide 
indoline 79a (X=Br) as the neutral compound has a ∆G of -8.5 kcal·mol-1 which is not 
significantly different from the original piperidine sulfonamide 16b (-8.93 kcal·mol-1) but is 
predicted to be significant more stable than the isopentyl sulfonamide 16a (-9.67 kcal·mol-1). 
Docking was then performed on the 5-chloro analog 79a (X=Cl) for SAR comparison showing a 
very significant decrease in energy to -10.24 kcal·mol-1 (Table 16). Using this proposed synthetic 
route, the halogenation can be performed early in the synthesis  directly after hydrolysis.  
Because of the favorable difference in binding energies, the non-halogenated 79a was docked for 
comparison. The data showed that the non-halogenated 79a (X=H) ligand has a binding energy 
comparable to the 5-chloro analog (-10.13 kcal·mol-1). Docking with a longer acyl group and a 
bulkier acyl group with 5-bromo, 5-chloro and 5-hydro substituents was performed (Table 16) as 
comparison. The butanamide derivative 79b and benzamide derivative 79c were used as 
reference.  Docking results show the opposite effect for butanamide 79b with 5-bromo (X=Br) 
and 5-hydro (X=H) substituents having comparable energies and the 5-chloro (X=Cl) analog has 
a significantly higher energy and weaker binding, whereas the benzamide 79c substituent 
showed the same trend as the acetyl groups with less of a numerical difference between either 
substituent but with 5-chloro analog 79c (X=Cl) having the lowest binding energy. The acyl 
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sulfonamide amino anions were later docked as well for a more physiological relevant 
comparison of the potential binding for the ligands shown in Table 16.  
Table 16. Ligand binding energies of the 1-acyl-7-N-acylsulfonamide indolines [a]  
                                     
Entry R 
∆G kcal·mol-1         
X=H 
∆G kcal·mol-1                 
X=Br 
∆G kcal·mol-1                 
X=Cl 
79a 
 
-10.1 -8.7 -10.3 
79b 
 
-11.1 -11.1 -9.3 
79c 
 
-10.3 -10.3 -10.8 
79a(-) 
 
-12.7 -12.3 -12.1 
79b(-) 
 
-13.7 -13.9 -12.9 
79c(-) 
 
-12.5 -13.4 -13.6 
 [a] Molecular docking performed with SwissDock and visualized with UCSF Chimera.    
 
                The deprotonated form of the acylsulfonamide anions 79a(-), 79b(-), and 79c(-) showed 
much lower binding energies, as low as -13.88 kcal·mol-1 as expected. These very low binding 
energies were similar to the carboxylate anions for both the 6- and 7-sulfonamide indolines 
which is important because those energies were reflective of the carboxylate moiety interacting 
with the Zn(II) ions. Another important take-away from the in-silico data is that substitution at 
the 5-position with chlorine supports our decision to abandon the 5-bromo substituent. Although 
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initial inhibitory data and inhibitor development with SAR can be performed without 5-
substitution, this position maybe prone to metabolism in vivo application so the 5-chloro analogs 
should continue to be analyzed. Figure 27 shows the binding of the 5-substituted-7-N-
acylsulfonamide indoline inhibitors to the active site with the anions in A-C and the protonated 
counterparts in D-F. Docking shows the weakest interactions with the neutral 5-bromo-7-
acylsulfonamide 79a. The orientation of the possible interactions with zinc the binding groups is 
different in the representations, in addition, the anions show a distinct interaction with the 
dimerization domain of DapE which will be further explored at a later date. 
 Figure 27. Ligand-enzyme interaction of N-acetyl-7-(N-acetyl)sulfonamide indolines 79a [a] 
[a] Molecular docking of 79a performed with SwissDock and visualized with UCSF Chimera with the ligand shown 
in blue, the Zn(II)s shown as purple spheres and the secondary structure of the enzyme shown in grey. Yellow lines 
from the ligand-enzyme interactions are visualization outputs that show direct coordination between atoms. Top row 
is 79a(-) in its ionic form where (A) X=H; (B) X=Br; (C) X=Cl; and the bottom row is the 79a in its neutral form 
where (D) X=H; (E) X=Br; (F) X=Cl 
88 
 
   
 
Three 1-Cbz-7-(N-acyl)sulfonamide indoline derivatives were successfully synthesized 
by reaction of the primary sulfonamide 64 with acetyl chloride to produce 76a, reaction with 
benzoic anhydride produced 76b, and reaction with p-anisoyl chloride produced 76c shown in 
Figure 28. Two heterocyclic acylsulfonamides 76d and 76e were formed by the reaction of 
thiazole carbonyl chloride and isoxazole carbonyl chloride respectively. 
Figure 28. Synthesis of 1-Cbz-7-&N-acyl)sulfonamide indolines 76 
 
Three cyclic 7-sulfonylurea indolines have been synthesized from 67 and are shown 
below (Figure 29). Ideally, inhibitors tested should be at least 95 % in purity, however an initial 
screening at slightly lower purity is practical. 
Figure 29. Synthesis of indoline 7-sulfonylureas 78 from Cbz-7-sulfonamide indoline 64 
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Next, modification of R1 was achieved by removal of the Cbz group from 76 through 
hydrogenolysis with H2 and Pd/carbon. From here, several acyl groups can be added on the 
aniline nitrogen to produce analogs of 75 for SAR comparison. Several derivatives of 75 are 
currently in progress (Scheme 25). 
Scheme 25. Hydrogenolysis to produce N-acyl-7-(N-acetyl)sulfonamide indolines 79 
 
Synthesis of 7-sulfonylureas 78 and thioureas 77 using isocyanates and isothiocyanates as 
reagents proved unsuccessful as the degradation of material was observed under a variety of 
conditions. Analysis by HPLC showed many products while 1H NMR confirmed the 
disappearance of the methylene hydrogens from the Cbz group. This was further evidence that 
the Cbz group is indeed too labile and therefore unsuitable for further use in the synthetic route 
as it limited most of the chemistry necessary for functionalization of the compounds we 
designed. 
Inhibitory Data of 7-Sulfonamide Indolines. 
N-Cbz-7-(N-acyl)sulfonamide indolines 74a and 74c have been submitted and tested for 
inhibition of [ZnZn(HiDapE)]. These indolines showed more potent inhibition of DapE having 
IC50s of 32 μM for the N-acetylsulfonamide 74a and 57 μM for the anisoyl sulfonamide 
derivative 74c. This is very promising considering that the Cbz was intended only as a protecting 
group that was essential for the functionalization of the primary 7-sulfonamide group (Table 17). 
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Table 17. Inhibition data of 7-sulfonamide indolines[a] 
Entry Structure IC50 μM 
76a 
 
32 
76c 
 
57 
[a] Data obtained from a set of triplicates and IC50 values were determined from a set of three or four % inhibition 
points 
Conclusion. 
 The N-Cbz-7-N-acetylsulfonamide indoline 76a is the most potent inhibitor synthesized 
and tested from any series of the HTS inhibitors identified. The anisole analog 76c also showed 
increased potency as well which is further confirmation that this new series should be prioritized 
for the development of a ligand library for DapE inhibition. The focus on further development of 
the synthetic route to produce 7-sulfonamide indolines is supported by both in silico data and the 
inhibitory data obtained.  
Part III. Ortho-Directed Synthesis of 7-Sulfonamide Indolines 
Synthesis of 7-Substituted Indolines in Literature. 
Synthesis of 7-substituted indolines in general has proven to be especially troubling. Our 
goal is to develop a novel synthesis of N-protected 7-sulfonamide indolines with direct 
introduction of the sulfonyl group. A number of reactions in which Rh, Ru and Ir catalysts were 
used to introduce alkenes, amines and other functionalities directly onto the 7- position of 
indoline were identified.63, 64 However, no catalytic introduction of a sulfonyl group to the 7-
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position of indoline or a position ortho to an aniline by metallation was found. We then focused 
on identifying procedures with the direct addition of any SO2 to the 7-position of indoline by any 
means. A literature procedure where PPA (polyphosphoric acid) activates the rearrangement of 
an N-sulfonamide moiety (80) to the 7-position65 as a sulfone (81) in addition to a Photo-Fries 
rearrangement were identified but these reactions gave a low yield with a mixture of products 
(Scheme 26).66 
Scheme 26. Sulfonamide rearrangement reactions 65, 66 
 
Ortho-Directed Lithiation Towards Synthesis of 7-Sulfonyl Indolines. 
The Iwao group, which is well known for developing indole, indene and indoline 
substitution chemistry, has used ortho-directed lithiation of Boc-protected indoline to produce 7-
substituted indolines.67 These include reactions with aldehydes and a range of electrophiles (I, 
Cl, Me, Me3Si).
67 Smith synthesized aryl and alky sulfonic acids by insertion of sulfur trioxide 
via STTAC into a carbon-lithium bond of alkyl and aryl organolithium reagents.68 With the 
combination of these two organic processes, we have designed a novel and promising synthesis 
of 7-sulfonamide indolines. Boc-protected indoline 85 undergoes ortho-directed lithiation using 
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n-BuLi. The carbamate acts as a stabilizer for lithium at the 7-position by coordination to the 
carbonyl oxygen (86). The 7-sulfonic acid indoline 87 is then obtained by mild insertion of sulfur 
trioxide by STTAC (sulfur trioxide trimethyl amine complex) into the carbon-lithium bond 
followed by acidification. The sulfonic acid 87 should then react with CTC in acetone to produce 
the sulfonyl chloride 88. The Boc group should be robust enough to remain intact under these 
conditions, unlike the Cbz from the modified synthesis in the previous section. The sulfonyl 
chloride 88 can then be reacted with a variety of amines to produce the desired 7-sulfonamide 
indolines 89. The Boc deprotection and replacement with similar moieties at the 1-position for 
SAR can be achieved (75) (Scheme 27). 
Scheme 27. Lithiation-mediated synthesis of 7-sulfonamide indolines 
 
Reaction of Boc-indoline 85 produced the sulfonic acid 86 with 45% conversion of 
starting material as determined by HPLC, however, after workup only 35% of product was 
detected via NMR. The humidity present in the lab and/or the degradation of both n-BuLi and 
STTAC may have been contributing factors. The lithiation step is performed at -78 ˚C and then 
warmed to room temperature before cooling back to -78 ˚C for the duration of the reaction before 
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addition of STTAC. Variation in number of equivalents of n-BuLi, the reaction temperature, and 
variation in reaction time could result in a higher conversion of starting material. There is enough 
evidence to support pursuing this synthesis as an applicable route for 7-sulfonic acid indolines 
87. Optimization of reaction methods for the synthesis of 7-sulfonic acid indoline 87 through 
ortho-directed lithiation is currently in progress. 
Ortho-Directed Lithiation by CO2. 
The use of carbon dioxide as an ortho-directing group for sulfonylation has also been 
pursued. Following a similar procedure, n-BuLi was introduced to a solution of indoline 12 in 
hexane and the lithium carbamate 90 was generated by introduction of CO2 from the sublimation 
of dry ice.69  The lithium carbamate 90 was exposed to another equivalent of n-BuLi followed by 
TMEDA and STTAC to produce 7-sulfonic acid indoline 91 (Scheme 28).  
Scheme 28. Ortho-directed lithiation using CO2 
[a] 
 
[a] Ortho-directed sulfonylation of indoline (a) 1) n-BuLi, hexane, rt; 2) CO2, n-BuLi, -78°C; b) STTAC, TMEDA, 
THF, -78 °C 
HPLC showed full conversion of starting material before isolation. During an aqueous 
workup, there was an observed effervescence, probably CO2, and a final HPLC showed a 
different retention time, but the product that was isolated appeared to resemble starting material. 
A proton NMR confirmed the isolated product was indeed starting material. A second attempt of 
ortho-directed lithiation by CO2 involved the use of CO2 generated from the addition of 12M 
HCl to Na2CO3 which was pumped through a drying tube and delivered to the reaction flask just 
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below the surface of the solvent. The HPLC showed full conversion of starting material with 
retention times that did not match the previous attempt. A proton NMR of the product was 
noticeably different from the indoline starting material. The aromatic region did however show 4 
unique aromatic protons suggesting that the 7-sulfonic acid indoline 91 was not produced but 
instead indoline-1-sulfonic acid 92. This suggests that the 7-position of indoline had not been 
lithiated under these conditions (Scheme 29).  
Scheme 29. Synthesis of indoline sulfonic acid[a] 
 
[a] Ortho-directed sulfonylation of indoline (a) 1) n-BuLi, hexane, rt; 2) CO2, n-BuLi, -78°C; b) STTAC, TMEDA, 
THF, -78 °C 
Conclusion. 
A new practical synthetic route for the production of 7-sulfonamide indolines has been 
developed by formation of a tricyclic sulfonylurea indoline extended from a published synthesis 
by Borror and colleagues.51 By hydrolysis of the cyclic sulfonylurea to produce the primary 
sulfonamide, the formation of the sulfonyl chloride by way of the sulfonic acid allows for 
production of a wider variety of analogs compared to the current literature procedure. Inhibitory 
data supports the use of N-acyl-7-sulfonamide indolines as inhibitors of DapE with data from 
two inhibitors, with IC50s of 32 μM for the N-acetylsulfonamide 76a and 57 μM for the anisoyl 
sulfonamide derivative 76c. Molecular docking studies also supports the application of 7-(N-
95 
 
   
 
acyl)sulfonamide indolines as inhibitors of DapE as evidenced by the favorable low binding 
energies and observed positive interactions at the active site with both Zn(II) atoms. Progress 
toward novel synthesis of lithium-mediated sulfonylation of N-Boc indoline as a route to 
produce 7-sulfonamide indolines is very promising. The optimization of the method will be 
addressed in due course. Some 7-sulfonamide indolines are awaiting inhibitory data and the 
development of new analogs from the improved methods are currently in progress.  
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DapE molecular modeling protocol.  
Models of L,L-SDAP (1a), N6-methyl- L,L-SDAP (1b), and N6-acetyl-L,L-SDAP (1c) 
bound to HiDapE were developed using the Molecular Operating Environment (MOE)3 
computational suite’s Builder utility followed by minimization in the gas phase using the force 
field MMFF94X.  The minimized ligands were then subjected to the Conformational Search 
protocol to generate structural-conformation data bases populated with as many as 10,000 
individual conformations.  Conformational data bases were generated for all three ligands of 
interest for use in the following docking experiments 
 
The previously-reported X-ray crystal structure of the product-bound form of HiDapE in 
a closed conformation (PDB: 5VO3)4 and the molecular system were uploaded into MOE.  
Following receptor preparation, molecular docking was performed using the previously-
generated ligand conformation data bases.  Substrate analog docking was carried out in the 
prepared HiDapE enzyme model with the products and solvent atoms inactivated and the 
docking site specified at the catalytic Zn(II) atoms.  Substrate analog placement employed the 
Proxy Triangle method with London dG scoring generating 50 data points that were further 
refined using the induced fit method with GBVI/WSA dG scoring to obtain the top 30 docking 
results.  The docking protocol was repeated for all three substrates and analyzed for selection of 
best docking pose.  Docking poses of the substrate 1a and analogs 1b and 1c were assessed as 
judged by their similarity to the product binding interactions seen in the original product-bound 
X-ray crystal structure.  A single substrate analog docking pose was selected for each of the three 
substrates providing initial substrate-bound enzyme models.   
 
The three substrate/enzyme models were then solvated in a simple water box at pH of 7.4 
that was treated with NaCl counterions to balance the charge.  Periodic boundary conditions 
were enabled, and the hydrogen bonding network of the model was optimized by automaticlly 
sampling different tautomer/protomer states using Protonate3D,1 which calculates optimal 
protonation states, including titration, rotamer, and “flips” using a large-scale combinatorial 
search.2  The system atoms were then optimized with a short, localized molecular minimization 
process with atoms further then 8 Å from the substrate fixed.  System refinement continued until 
an RMS Gradient of 0.1 kcal/mol/Å was attained.  Molecular Dynamics parameters were set to 
globally minimize the protein, substrate, and solvent atoms in the system using an NPA 
algorithm with an Amber12:EHT force field, with a typical heating and cooling protocol.  
Simulation results were then minimized once again before the final binding poses were obtained 
for comparison.  
 
Modified L,L-SDAP as potential substrates. 
The hydrolytic activity of HiDapE towards 1b and 1d was monitored by the decrease in 
absorbance at 225 nm using a Shimadzu UV-2450 UV/Visible Spectrophotometer.  All reaction 
volumes were 1 mL with 8 nM HiDapE, 5 mM 1b or 5 mM 1d in 50 mM HEPES buffer, pH 7.5.  
Spectra were recorded over 35 min with one scan per minute.  Enzyme dilutions were made 
directly before each trial from a concentrated stock solution that was stored at -80°C. 
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General Experimental Methods 
All solvents were distilled prior to use, and all reagents were used without further purification 
unless otherwise noted.  Ninhydrin solution was purchased as a 2% solution in 100% DMSO 
with a lithium acetate buffer at pH 5.2 from Santa Cruz. All synthetic reactions were conducted 
under a nitrogen atmosphere.  Silica gel 60A, 40−75 μm (200 × 400 mesh), was used for column 
chromatography.  Aluminum-backed silica gel 200 μm plates were used for TLC. 1H NMR 
spectra were obtained using either a 300 MHz spectrometer or a 500 MHz spectrometer with 
trimethylsilane (TMS) as the internal standard. 13C NMR spectra were obtained using a 75 MHz 
spectrometer or a 125 MHz spectrometer. The purity of all compounds was determined to be 
≥95% unless otherwise noted by high performance liquid chromatography (HPLC) employing 
Mobile phase A = 0.1% TFA in water, Mobile phase B= 0.1% TFA in acetonitrile, with a 
gradient of 60% B increasing to 95% over 10 min, holding at 95% B for 5 min, then returning to 
60% B and holding for 5 min.  HRMS spectra were measured on a TOF instrument by 
electrospray ionization (ESI). HRMS spectra were collected using a Waters Acquity I class 
UPLC and Xevo G2-XS QTof mass spectrometer with Waters Acquity BEH C18 column (1.7 
µm, 2.1x50 mm).  Mobile phase A was 0.05% formic acid in water and mobile phase B was 
0.05% formic acid in acetonitrile.  A gradient of 5% to 90% B in 5 minutes was applied.  
Enzyme activity curves were fitted with a program that uses a non-linear least squares regression 
of the Gauss-Newton algorithm with optional damping using an ad hoc program.5, 6 
 
Synthesized Compounds from Chapter Three 
All methods can be found in the published article referenced. 
 
Protein Purification and Expression 
Recombinant DapE from H. influenzae was expressed and purified according to a 
published protocol.10  Briefly, several grams of cell paste were thawed at room temperature. 
Cells were lysed by sonication in 2 second pulses with 5 seconds rest, repeatedly, and the cell 
debris was removed by centrifugation at 4 ˚C for 40 min at 12,000 g. The supernatant was 
applied to a column packed with 10 mL of HisTrap HP resin (GE Healthcare), connected to 
VacMan (Promega) and the chromatographic process was accelerated with a vacuum pump. The 
column was washed with 20 bed volumes of lysis buffer and the His6-tagged DapE were eluted 
with 25 mL of elution buffer (50 mM HEPES pH 8.0, 500 mM NaCl; 500 mM imidazole; 2 mM 
DTT). The His6-tag was cleaved with TEV protease (2 mg of a His6-tagged form) overnight at 
4°C and dialysis to remove the excess of imidazole was carried out simultaneously. The resulting 
solution was mixed with His-Trap HP resin to capture the cleaved His6-tag and the His6-tagg 
TEV protease and the flow through containing DapE was collected and concentrated. A SEC 
column was run and the eluent was concentrated using an Amicon YM-10 membrane to a 
concentration 20mg x ml-1 then the reducing agent TCEP (1mM) was added. Purified DapE from 
H. influenzae exhibited a single band on SDS-PAGE indicating a molecular weight of 41,500 
Da. Protein concentrations were determined from the absorbance at 280 nm using molar 
absorptivity calculated using the method developed by Gill and Hippel.11 The protein 
concentration determined using this molar absorptivity was in close agreement to that obtained 
using a Bradford assay. Individual aliquots of purified DapE were stored in liquid nitrogen until 
needed.  
 
Enzyme Zinc Metal Installation. 
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Apo-DapE was prepared by extensive dialysis for 3 to 4 days against 10 mM EDTA in 50 
mM HEPES buffer, pH 7.5.  The enzyme was then exhaustively dialyzed against metal-free 
(chelexed) 50 mM HEPES buffer, pH 7.5.  Apo-DapE samples were incubated with 1.7 
equivalents of ZnCl2 (97%; Sigma-Aldrich) in 50 mM HEPES buffer for 30 min.    
 
Modified SDAP as Potential Substrates 
 
The hydrolytic activity of DapE with modified SDAP analogs was monitored by the 
decrease in absorbance at 225 nm via Shimadzu UV-2450 UV/Visible Spectrophotometer.  All 
reaction volumes were 1mL with 8 nM DapE and 5 mM of N-Methyl-SDAP 1b or 5 mM N-Ac-
SDAP 1d in 50 mM HEPES buffer pH 7.5. Spectra were recorded over 35 minutes with one scan 
per minute. Enzyme dilutions were made directly before each trial from the concentrated stock 
solution at -80°C.  
 
DapE Assay Protocol 
 
All reaction volumes are 200 μL with 25 nM DapE and 1 mM of N-methyl-SDAP 1b 
unless otherwise stated.  Enzyme assay absorbance values were read on a BioTek Syngen 
microplate reader. Initial assay conditions to measure the activity of DapE were carried out in 
triplicate as follows: to a 50 mM HEPES buffered DapE solution at pH 7.5 at room temperature 
(18-22˚C) was added N-methyl SDAP 1b TFA salt. The reaction proceed for 10 minutes after 
which 100 μL of the 2% ninhydrin solution was added, the reaction vortexed and heated to 
100°C for 15 minutes to quench enzymatic activity and to promote the primary amine with 
ninhydrin. The ninhydrin reaction was then halted by placing the tube in ice for 2 minutes, and 
the absorbance of 80 µL was then recorded at 570 nm.  
 
Control Ninhydrin Reactions with Glutamic Acid and Sarcosine.  
 
Control reactions were carried out using glutamic acid as a primary amine model and 
sarcosine as a model secondary amine. UV/Vis absorbances between 300 and 800 nm were 
recorded on Shimadzu UV-2450 UV/Visible Spectrophotometer, and the assay was followed by 
reading the absorbance at 570 nm using a BioTek Syngen microplate reader.  Control reactions 
for the detection of primary amine were carried out in triplicate as follows: to a 50 mM HEPES 
pH 7.5 buffered solution at 30 ˚C was added glutamic acid (0-1.2 mM) and 100 μL of the 2% 
ninhydrin solution. The reaction mixture was heated to 100 ˚C (2 min vs 15 min), cooled on ice 
and the absorbance spectra was examined via UV/Vis spectroscopy. Control reactions for the 
detection of secondary amine were carried out in triplicate in the same manner using the 
secondary amine sarcosine. The final concentration of the UV-Vis spectroscopy samples were 1 
mL 0.04 mM dilutions made from 0.2 mM samples. 
Entire time course plots of glutamic acid or sarcosine and ninhydrin development were 
carried out in triplicate as follows: To a 50 mM HEPES buffered solution pH 7.5 was added 1 
mM amine at 30 ˚C. After a 5-minute incubation time the 2% ninhydrin solution was added, the 
reaction vortexed and heated at 100 ˚C with time intervals of 0, 2, 3, 5, 10, 15 and 20 minutes 
independently. The mixtures were cooled on ice for 2 minutes and 80µL of each reaction was 
examined via microplate reader at 570 nm. These experiments were repeated at 80 ˚C and 60 ˚C. 
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Incubation of DapE by DMSO.   
 
All reaction volumes were 200 μL with 25 nM of DapE and 1 mM N6-methyl-SDAP 
TFA salt substrate 1b, and the standard ninhydrin solution in DMSO.  UV/Vis spectra were 
recorded on 80 μL aliquots of ninhydrin-developed reactions unless otherwise stated, and spectra 
were measure on a BioTek Syngen microplate reader. Control reactions of enzymatic activity 
were carried out in triplicate as follows: to a 50 mM HEPES pH 7.5 buffered DapE at 30°C was 
added N6-methyl SDAP 1b. The reaction proceeded for 10 minutes after which 100 μL of the 2% 
ninhydrin solution was added and subsequently heated to 80°C for 15 minutes. This reaction was 
quenched by placing in ice, cooled to 30 ˚C and the absorbance was recorded at 570 nm. These 
control reactions were set as 100% standard enzymatic activity of DapE.  
The DMSO incubation reactions were carried out in triplicate as follows: to a 50 mM 
HEPES pH 7.5 buffered DapE solution at 30°C was added DMSO (75% v/v). DapE was allowed 
to incubate between 0 and 10 min after which time N6-methyl-SDAP 1b was added and the 
reaction was allowed to proceed for 10 minutes. The enzymatic reaction was then quenched by 
addition of the 2% ninhydrin solution, the reaction vortexed and heated to 80°C for 15 minutes. 
The ninhydrin reaction was the quenched by placing the tube in ice and cooling to 30oC, and the 
absorbance was then read at 570nm.  
 
Monitoring the Thermal Denaturation of DapE using Circular Dichroism (CD).  
 
Denaturation of DapE was measured using an Olis DSM 20 circular dichroism 
spectrophotometer. Samples were measured in a cylindrical quartz cuvette with a 1 mm path 
length, and contained 10 mM phosphate, pH 8.0, and 0.4 μM of DapE.  Data was collected every 
1 nm with a wavelength range of 190 – 260 nm.  The temperature was increased from 20°C to 
80°C using 10°C increments and incubation time of 2 min at each temperature (available in 
Appendix C). Once 80°C was attained, this temperature was held constant until complete 
denaturation was observed. OlisGlobalworks software v1.3 was used to deconvolute the spectra 
and calculate the percent of secondary structure. The secondary structure was discerned by 
measuring at the percent alpha helices and beta sheets.  
 
Pre-Heat Incubation Control Reactions.  
 
All reaction volumes were 200 μL with 25 nM of DapE and 1 mM N6-methyl SDAP TFA 
salt substrate, and the standard ninhydrin solution.  UV/Vis spectra were examined on 80 μL of 
ninhydrin-developed reactions unless otherwise stated. UV/Vis Spectroscopy was observed via 
BioTek Syngen microplate reader. The control reactions were carried out in triplicate under the 
previous for 100% standard enzymatic activity of DapE. A second set of control reactions were 
used to show no enzymatic activity. These were carried out using denatured DapE with heating 
to 100oC for 3 min prior to use and with all other standard conditions stated above.  
The measurement of the decrease in activity of DapE due to incubation at 100°C was 
carried out as follows:  a 50 mM HEPES pH 7.5 buffered DapE solution was heated at 100°C 
with an incubation time from one to 5 min independently followed by cooling in ice to 30oC. To 
this solution was added N6-methyl SDAP 1b and the reaction was allowed to proceed for 10 
minutes after which the 2% ninhydrin solution was added, the reaction vortexed and heated at 80 
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°C for 15 minutes. The ninhydrin reaction was quenched by placing in ice and the absorbance 
was examined at 570 nm. This experiment was carried out in triplicate under the same conditions 
for pre-heating at 80°C. 
 Enzyme concentration reactions were carried out as follows: To a solution of 50mM 
HEPES pH 7.5 buffer was added the desired concentration of enzyme at 30°C followed by the 
addition of 20 µL of N6-methyl- L,L-SDAP 1b TFA salt (final concentration of 1 mM SDAP, 
200 µL total volume). The reaction proceeded for 10 minutes after which it was heated at 100°C 
for 1 minute then cooled on ice for an additional 1 minute. Next, 100 µL of 2% ninhydrin 
reagent was added to a final concentration of 300 µL. The reactions were then heated to 80°C for 
15 minutes then cooled on ice for an additional 2 minutes and to which absorbance of 80 µL was 
read via a microplate reader at 570 nm.  
 
Ninhydrin-based Assay for DapE Enzymatic Activity 
 
 The enzymatic activity of DapE is measured in triplicate as follows:  To 50 mM HEPES 
at pH 7.5 buffered solution with 8 nM DapE at 30°C was added 2 mM N6-methyl SDAP 1b 
(final volume 200 μL). The reaction was allowed to proceed for 10 minutes and quenched by 
heating at 100°C for 1 minute and subsequent cooling on ice for 1 minute. To the cooled reaction 
was added the 2% ninhydrin solution, and the reaction vortexed and subsequently heated at 80°C 
for 15 minutes for the ninhydrin reaction. This reaction was quenched by placing in ice 2 
minutes and the absorbance of 80 µL was read at 570 nm. These reactions were set as 100% 
standard enzymatic activity of DapE. Glutamic acid concentrations of 0 mM, 0.1 mM, 0.2 mM, 
0.3 mM, 0.4 M, and 0.5 mM were used as a standard control of the measurement of primary 
amine.  
 
 
 
IC50 Determinations.  
IC50 values and enzyme activity curves were fitted with a program that uses a non-linear 
least squares regression of the Gauss-Newton algorithm with optional damping using an ad hoc 
program.5, 6 All inhibition assays were conducted with a reaction volume of 200 μL, 2 mM N6-
methyl SDAP 1b and 8 nM DapE unless otherwise stated. Glutamic acid standards of 0 to 0.5 
mM were used in every trial. To a 50 mM HEPES pH 7.5 buffered solution was added desired 
inhibitor concentration at 30oC followed by DapE and allowed to incubate for 10 min. N6-methyl 
SDAP 1b was added and allowed to react for an additional 10 min and quenched by heating at 
100oC for 1 minute and cooled on ice to 30oC. The 2% ninhydrin solution (100 μL) was added, 
the reaction vortexed and heated at 80oC for 15 min. after which the reaction was quenched by 
cooling on ice to 30oC and the absorbance was examined at 570 nm.   
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Circular Dichroism UV/Vis spectra of thermal denaturation of DapE observing the α-helical 
secondary structure. 
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DapE enzymatic activity after pre-heat incubation reactions at 0° C, 80°C and 100° C. 
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UV-Vis spectral overlay of primary amine standard (glutamic acid) development with ninhydrin 
from 2- 20 minutes at 100°C. 
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UV-Vis spectral overlay of secondary amine standard (sarcosine) ninhydrin development from 2-
20 minutes at 100°C.  
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Plot of DapE enzymatic activity after DMSO incubation reactions: 
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Inhibition plot for 3- Mercaptobenzoic Acid against DapE. 
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Inhibition plot of phenylboronic acid against DapE.
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Inhibition plot of 2-thiopheneboronic acid against DapE.
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Inhibition plot of L-captopril against DapE. 
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General Experimental Details 
All solvents were distilled prior to use unless purchased as anhydrous or as 98%+ purity. 
All reagents were used without further purification unless otherwise specified. 1H 13C NMR 
spectra were obtained on 500 MHz spectrometer or 300 MHz spectrometer and 13C NMR spectra 
were obtained at 125 MHz or 75 mHz, respectively on these instruments and processed manually 
or using MestreNova software. Percent yields were reported as single yields for final inhibitors 
and average of yields for intermediate materials. Reactions were run in round bottom flasks for 
large scale reactions and in vials for final small-scale reactions. Purities were obtained on 
Agilent 1050 and 1100 UV-Vis HPLC with a Mobile phase A: 5% Acetonitrile in water with 
0.1% TFA and Mobile phase B: Acetonitrile with 0.1% TFA. 
Synthesis of Compounds from Chapter Four 
 
1-Acetyl-indoline (13): To a solution of indoline 12 (20.0 g, 0.168 mol) in triethylamine (81.6 
mL) was added dichloromethane (193 mL) via pouring with stirring in air for 10 min at room 
temperature.   Another solution of acetyl chloride (17.4 g, 0.222 mol) in dichloromethane (129 
mL) was added to the first solution via pressure equalizing funnel slowly and the temperature 
maintained at 0-5o C for 15 minutes.  The resulting solution was stirred at room temperature 
under air overnight and checked for completion by TLC with a mobile phase of 50% EA/Pet 
ether.  The reaction was quenched with water and extracted with DCM three times.  The organic 
portion was washed once with deionized water, once with 1N HCl, and once with brine and dried 
over Na2SO4.  After drying, the solution was concentrated by rotary evaporation to yield the 
desired N-acetyl indoline 13 (25.2 g, 93.2%). 1H NMR (500 MHz CDCl3): δ 8.22 (d, 1 H), 7.19 
(t, 2 H), 7.02(d, 1 H), 4.06 (t, 2 H), 3.20 (t, 2 H), 2.23 (s, 1H). 
 
 
 
 
1-Acetyl-5-bromoindoline (14): To a solution of 13 (2.00 g, 12.4 mmol) in glacial acetic acid (13 
mL) at room temperature was added Br2 (0.61 mL) dropwise with stirring. The solution turned 
from dark brown to orange/yellow upon stirring. Upon completion, the reaction was quenched by 
pouring into water with rapid stirring and a gold solid remained. Sodium thiosulfate solution was 
added to quench excess bromine. The heterogeneous mixture was filtered through a Buchner 
funnel and dried under high vacuum to obtain the desired 5-bromo-substituted N-acetyl indoline 
14 (94% yield). 1H NMR (500 MHz CDCl3): δ 8.09 (d, 1 H), 7.30 (s, 1 H). 7.29 (d, 1 H), 4.07 (t, 
2 H), 3.19 (t, 2 H), 2.22 (s, 3 H). 
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1-Acetyl 5-bromoindoline -6-sulfonyl chloride (15): Chlorosulfonic acid (18.75 mL) was slowly 
added to dried round bottom flask with indoline 14 (2.50 g, 10.41 mmol) drop wise by addition 
funnel. The neat reaction was stirred and heated between 60o-70oC for 3hr. The black solution 
was cooled to room temperature and then quenched by pouring slowly over ice with stirring. An 
off-white precipitate was isolated via vacuum filtration, washed with deionized water and dried 
in vacuo to produce 15 (52% yield). 1H NMR (500 MHz CDCl3): δ 9.00 (s, 1 H), 7.60 (s, 1 H), 
4.18 (t, 2 H), 3.31 (t, 2 H), 1.60 ( s, 3 H). 
 
General procedure for the synthesis of N-acetyl 5-bromo-6-sulfonamide indolines (16). 
 
To a solution of sulfonyl chloride 15 (1eq, 0.148 mmol) and triethylamine (1.25 eq, 31.0 
uL) in dichloromethane was added the desired amine (1.25 eq, 0.185 mmol) and the reaction 
stirred at room temperature until complete as determined by TLC. Upon completion the reaction 
was diluted with dichloromethane, washed once with water, twice with 1M HCl and once with 
brine. The reaction was then dried over Na2SO4, filtered and concentrated on the rotovap to 
obtain indoline derivatives 16. Secondary amines and nitrogen heterocycles were reacted with 
the addition of DMAP as a catalyst (10 mol%) and reaction times were longer that primary 
amine derivatives.  
 
 
 
1-Acetyl-5-bromo-N-isopentylindoline-6-sulfonamide (16a): The synthesis of 16a was achieved 
by following the general procedure for 16 using isopentyl amine to produce a light yellow solid 
(82%) mp: 184-186°C. 1H NMR (500 MHz, Chloroform-d) δ 8.90 (s, 1H), 7.48 (s, 1H), 4.98 (bs, 
1H), 4.14 (t, J = 8.7 Hz, 2H), 3.25 (t, J = 8.6 Hz, 2H), 3.14 (s, 1H), 2.92 (q, J = 6.9 Hz, 2H), 2.47 
(s, 1H), 1.67 – 1.56 (m, 2H), 1.37 (q, J = 7.2 Hz, 1H), 0.85 (dd, J = 6.7, 2.3 Hz, 6H). 
 
 
1-Acetyl-5-bromo-6-(piperidin-1-sulfonyl) indoline (16b): The synthesis of 16b was achieved by 
following the general procedure for 16 using piperidine to produce an off-white solid. (79 % 
yield) MP: 197-201°C. 1H NMR (500 MHz, Chloroform-d) δ 8.76 (s, J = 6.1 Hz, 1H), 7.49 (s, 
1H), 4.13 (t, J = 8.6 Hz, 2H), 3.30 (q, J = 4.9 Hz, 4H), 3.24 (t, J = 8.7 Hz, 2H), 2.23 (s, J = 2.7 
Hz, 3H), 1.67 – 1.60 (m, 2H), 1.56 (t, J = 7.3 Hz, 2H). 
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1-Acetyl-5-bromo-N,N- dipropylindoline-6-sulfonamide (16c): The synthesis of 16c was 
achieved by following the general procedure for 16 using dipropyl amine to produce a brown 
waxy substance (78%). 1H NMR (500 MHz, Chloroform-d) δ 8.73 (s, 1H), 7.51 (s, 1H), 4.15 (t, J 
= 8.6 Hz, 2H), 3.33 (s, 1H), 3.34 – 3.22 (m, 4H), 2.26 (s, 3H), 1.70 – 1.53 (m, 4H), 1.28 (s, 1H), 
0.88 (t, J = 7.4 Hz, 6H),  
 
 
 
1-Acetyl-5-bromo-6-(pyrrolidin-1-sulfonyl) indoline (16g): The synthesis of 16g was achieved 
by following the general procedure for 16 using pyrrolidine to produce an off-white solid (62%) 
mp: 190-198°C. 1H NMR (500 MHz, DMSO-d6) δ 8.58 (d, J = 3.3 Hz, 1H), 7.69 (s, 1H), 4.13 (q, 
J = 10.4, 9.7 Hz, 2H), 3.31 (d, J = 3.4 Hz, 4H), 3.20 (t, J = 8.8 Hz, 2H), 2.16 (s, 3H), 1.86 (q, J = 
4.8, 4.1 Hz, 4H) 
 
 
 
1-Acetyl-5-bromo-N-cyclohexylindoline-6-sulfonamide (16h): The synthesis of 16h was 
achieved by following the general procedure for 16 using cyclohexylamine (77% ) mp: 217-
221°C. 1H NMR (500 MHz, Chloroform-d) δ 8.93 (s, 1H), 7.48 (s, 1H), 5.01 (d, J = 7.6 Hz, 1H), 
4.14 (t, J = 8.6 Hz, 2H), 3.25 (t, J = 8.7 Hz, 3H), 2.48 (m, 1H), 2.24 (s, 3H), 1.81 – 1.75 (m, 2H), 
1.50 (d, J = 12.7 Hz, 3H), 1.27 – 1.19 (m, 5H), 1.14 (t, J = 12.3 Hz, 1H) 
 
 
 
1-Acetyl-5-bromo-N-phenylindoline-6-sulfonamide (16i): The synthesis of 16i was achieved by 
following the general procedure for 16 using aniline to produce an off-white solid (82%). 1H 
NMR (500 MHz, DMSO-d6) δ 10.50 (s, 1H), 8.76 (s, 1H), 7.61 (s, 1H), 7.20 (t, J = 7.9 Hz, 2H), 
7.08 (d, J = 8.0 Hz, 2H), 6.97 (t, J = 7.7 Hz, 1H), 4.10 (t, J = 8.0, 7.3 Hz, 2H), 3.19 – 3.06 (t, 
2H), 2.14 (s, 3H). 
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1-Acetyl-5-bromo-6-(indolin-1-sulfonyl) indoline (16j): The synthesis of 16j was achieved by 
following the general procedure for 16 using indoline to give a dark brown solid (83.4% yield) 
MP: 211-218°C. 1H NMR (500 MHz CDCl3) δ 8.864 (s, 1 H), 7.47 (s, 1 H), 7.31 (d, 1 H), 7.10 
(d, 1 H), 7.07 (t, 1 H), 6.95 (t, 1 H), 4.26 (t, 2 H), 4.10 (t, 2 H), 3.19 (m, 4 H), 1.25 (s, 3 H). 13C 
NMR (126 MHz, DMSO-d6) δ 169.1, 138.5, 131.6, 127.6, 125.5, 123.4, 118.9, 113.9, 113.6, 
50.9, 49.3, 29.9, 28.1, 27.9, 24.4. 
 
 
1-Acetyl-N-benzyl-5-bromoindoline-6-sulfonamide (16k): The synthesis of 16k was achieved by 
following the general procedure for 16 using benzylamine to produce a yellow solid (81%) mp: 
202-208°C. 1H NMR (500 MHz, Chloroform-d) δ 8.96 (s, 1H), 7.50 (s, 1H), 7.31 – 7.22 (m, 5H), 
5.34 (s, 2H), 4.21 – 4.10 (m, 4H), 3.28 (t, J = 8.7 Hz, 2H), 2.27 (s, 3H).  
 
 
Methyl 3-((1-acetyl-5-bromoindoline)-6-sulfonamido)propanoate (16l): The synthesis of 16l was 
achieved by following the general procedure for 16 using β-alanine methyl ester to give a light 
brown solid (60%) mp: 180-184°C. 1H NMR (500 MHz, Chloroform-d) δ 8.91 (s, 1H), 7.50 (s, 
1H), 5.78 (s, 1H), 4.14 (t, J = 8.6 Hz, 2H), 3.70 (s, 2H), 3.69 (s, 1H), 3.26 (t, J = 8.7 Hz, 2H), 
3.24 – 3.16 (m, 2H), 2.53 (t, J = 6.0 Hz, 2H), 2.24 (s, 3H), 1.26 (s, 3H). 13C NMR (500 DMSO- 
d6) δ 171.6, 169.9, 143.3, 139.3, 138.4, 131.8, 117.7, 112.8, 52.17, 49.4, 46.6, 39.2, 34.7, 27.8, 
24.7.  
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1-Acetyl-5-bromoindolin-6-(sulfonyl glycine methyl ester) (16m): The synthesis of 16m was 
achieved by following the general procedure for 16 using glycine methyl ester to produce a light 
yellow solid (72.5%) mp: 163-167°C. 1H NMR (500 MHz, Chloroform-d) δ 8.87 (s, 1H), 7.50 (s, 
1H), 5.69 (s, 2H), 4.13 (t, J = 8.6 Hz, 2H), 3.82 (d, J = 5.4 Hz, 2H), 3.68 (s, 3H), 3.15 – 3.06 (m, 
2H), 2.24 (s, 3H) 
 
 
Methyl ((1-acetyl-5-bromoindolin-6-yl)sulfonyl)valinate (16n): The synthesis of 16n was 
achieved by following the general procedure for 16 using valine methyl ester to produce an off 
white solid (55%) mp: 165-176°C. 1H NMR (500 MHz, Chloroform-d) δ 8.85 (s, 1H), 7.48 (s, 
1H), 5.68 (d, J = 9.4 Hz, 1H), 4.13 (t, J = 8.5 Hz, 2H), 3.85 (d, J = 8.0 Hz, 1H), 3.54 (d, J = 1.8 
Hz, 3H), 3.24 (s, 2H), 3.11 (s, 3H), 2.23 (s, 3H), 2.12 – 2.04 (m, 1H), 0.97 – 0.88 (m, 6H). 13C 
NMR (126 MHz, DMSO-d6) δ 171.6, 169.9, 143.3, 139.3, 138.4, 131.8, 117.7, 112.8, 52.2, 49.4, 
46.6, 39.2, 34.7, 27.9, 24.7. 
 
 
Methyl 6-((1-acetyl-5-bromoindoline)-6-sulfonamido)6-hexanoate (16o): The synthesis of 16o 
was achieved by following the general procedure for 16 using amino valeric acid methyl ester to 
produce an off white solid (65.1% yield) MP: 119-123°C. 1H NMR (500 MHz Chloroform-d) δ 
8.90 (s, 1H), 7.49 (s, 1 H), 5.10 (bs, 1 H), 4.17 (t, 2 H), 3.67 (s, 3 H), 3.27 (t, 2 H), 2.94 (t, 2 H), 
2.27 (t, 2 H), 2.25 (s, 3 H), 1.56 (m 2 H), 1.48 (m, 2 H), 1.32 (m, 2 H). 13C NMR (126 MHz, 
Chloroform-d) δ 138.3, 130.8, 119., 113.1, 51.8, 49.2, 46.2, 43.5, 34.1, 30.0, 29.6, 27.9, 26.4, 
24.6, 24.4. 
 
1-Acetyl-5-bromo-N-(5-methylpyridin-2-yl)indoline-6-sulfonamide (16p): The synthesis of 16p 
was achieved by following the general procedure for 16 using 2amino-5-methyl pyridine, 1H 
NMR (500 MHz, DMSO-d6) δ 8.73 (s, 1H), 7.69 (s, 1H), 7.41 (s, 1H), 7.20 (s, 1H), 6.67 (d, J = 
8.8 Hz, 1H), 4.09 (t, J = 8.7 Hz, 2H), 3.11 (t, J = 8.4 Hz, 2H), 2.14 (s, 3H), 2.04 (s, 3H).  
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1-Acetyl-5-bromo-N-(pyridin-2-yl)indoline-6-sulfonamide (16q): The synthesis of 16q was 
achieved by following the general procedure for 16 using 2-aminopyridine to produce a brown 
solid (60%). mp: 197-200°C. 
 
 
1-Acetyl-5-bromo-N-(pyrimidin-2-yl)indoline-6-sulfonamide (16r): The synthesis of 16r was 
achieved by following the general procedure for 16 using 2-aminopyrimidine to yield a brown 
sticky solid (19%). 
 
1-Acetyl-5-bromo-N-(pyrazin-2-yl)indoline-6-sulfonamide (16s): The synthesis of 16s was 
achieved by following the general procedure for 16 using 2-amino pyrazine (22%). 
 
 
1-Acetyl-5-chloroindoline (21a): The 5-chloro indoline compound 21 was synthesized by adding 
NCS (1.74 g, 13.03 mmol) to a solution of 13 (2.00 g, 12.4 mmol) and NH4OAc (96.1 mg, 10 
mol%) in acetonitrile (65.1 mL) slowly and stirred at room temperature under air and monitored 
by TLC.  NCS was purified through recrystallization in glacial acetic acid (10.0 grams in 50.0 
mL), filtered and washed with hexane and then dried under vacuum. 1H NMR (500 MHz 
Chloroform-d) δ 8.16 (d, 1 H), 7.18 (m, 2 H), 4.09 (t, 2 H), 3.20 (t, 2 H), 2.79 (s, 1 H), 2.24 (s, 3 
H). 
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1-Acetyl-5-chloroindoline-6-sulfonyl chloride (21b): Chlorosulfonic acid (3.75 mL) was slowly 
added to chloroindoline 21 (500 mg), drop-wise by pressure equalizing funnel with stirring and 
heated between 60o-70oC for 3hr. The black solution was cooled to room temperature and 
quenched by pouring slowly over ice with stirring. A light yellow/gold precipitate was formed 
filtered via vacuum filtration. The precipitate was further washed with water and dried in vacuo 
to produce the desired product 21b (49%). 1H NMR (500 MHz CDCl3) δ 8.98 (s, 1 H), 7.42 (s, 1 
H), 4.20 (t, 2 H), 3.33 (t, 2 H), 2.28 (s, 3 H). 
 
General procedure for the synthesis of N-acetyl-5-chloroindoline-6-sulfonamides (22).  
 
The reaction of 21b (50 mg, 0.168 mmol) was added to a round bottom flask with the 
desired primary amine (0.211 mmol) and triethylamine (35.0 uL) in dichloromethane (2 mL) and 
allowed to stir until completion. The reaction was diluted with dichloromethane and the organic 
layer was washed one time with deionized water, twice with 1M HCl, once with 1M NaCl and 
dried over sodium sulfate, filtered and concentrated on the rotovap to produce analogs 
represented by 22. The secondary amines and nitrogen heterocycles followed the same synthesis 
with addition of 4-dimethylamino pyridine (DMAP) (10 mol %) catalyst. The 5-chloro indoline 
reaction times ran longer than their 5-bromo indoline counterparts.  
 
Methyl 3-((1-acetyl-5-chloroindoline)-6-sulfonamido)propanoate (22l): The synthesis of 22l was 
achieved by following the general procedure for 22 using β-alanine methyl ester to produce a waxy 
solid (48%). 1H NMR (500 MHz Chloroform-d) δ 8.89 (s, 1 H), 7.32 (s, 1 H), 4.42 (t, 2 H), 3.70 
(m, 3 H), 3.29 (t, 2 H), 2.54 (t, 2 H), 2.28 (d, 2 H), 1.45 (t, 2 H). 
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1-Acetyl-5-chloro-N-(5-methylpyridin-2-yl)indoline-6-sulfonamide (22p): The synthesis of 22p 
was achieved by following the general procedure for 22 using 2-amino-5-methyl pyridine to 
produce a brown solid (51%).  
 
1-Acetyl-5-chloro-N-(pyrimidin-2-yl)indoline-6-sulfonamide (22r): The synthesis of 22r was 
achieved by following the general procedure for 22 using 2-amino-pyrimidine to yield a brown 
waxy solid (34%).  
 
2-((1-Phenyl-1H-tetrazol-5-yl)thio)propanoic acid (32a) To a solution of phenyl-1H-tetrazole 
thiol 30 (1 eq) in anhydrous EtOH was added KOH (1.1 eq) and refluxed for one hour. The 
mixture was then allowed to cool to room temperature and 2-bromoproprionic acid (1.1 eq) was 
added and the reaction was refluxed for 20 hours and solvent was removed to produce a yellow 
oil. The reaction was diluted with water and extracted with diethyl ether and organic portion 
washed with brine and dried over Na2SO4 and solvent was removed to give 32a as a light-yellow 
oil. 69%. 1H NMR (500 MHz, Chloroform-d) δ 7.97 – 7.90 (m, 2H), 7.63 – 7.53 (m, 2H), 7.57 – 
7.50 (m, 1H), 4.44 (q, J = 6.9 Hz, 1H), 1.91 – 1.73 (d, 3H).  
 
 
 
2-((1-Phenyl-1H-tetrazol-5-yl)thio)-N-(thiazol-2-yl)propenamide (33a). To a solution of 
carboxylic acid 33a (1 eq) dissolved in DMF (0.4 M) was added CDI (1.16 eq) and stirred for 2.5 
hours at 80oC. The reaction was cooled and the amine (1.08 eq) was added and stirred for 4 hrs at 
80oC in a sealed vial and effervescence was observed upon addition. The reaction was 
determined complete via HPLC. The mixtures were poured into 3% aqueous NaHCO3 where a 
ppt formed. Aqueous portions were extracted with EA, dried over Na2SO4 and concentrated to 
give 33a as a light-yellow oil.  
 
 
122 
 
 
N-(2-Methoxyphenyl)-4-methylbenzenesulfonamide (41a): To a solution of p-toluene sulfonyl 
chloride (2.62 mmol) in DCM (0.524M) was added trimethylamine (1.2 eq). The vials were 
fitted with stir bars and the anisidine analogs (1.1 eq) were added in one portion, vials were 
sealed and purged with N2 and allowed to stir to completion. The reaction was quenched by 
addition of water and the organic portions were further diluted with DCM, washed with 1 M HCl 
and brine and dried over Na2SO4 and concentrated on rotovap. Reaction gave near quantitative 
yield for 41a o-anisidine analog 87% purity HPLC, Products were recrystallized in methanol and 
taken into next step. 1H NMR matched those found in the literature. 
 
 
N-(4-Methoxyphenyl)-4-methylbenzenesulfonamide (41b): Sulfonamide 41b was synthesized 
following the general procedure for 41a using p-anisidine. Reaction gave a light purple 
crystalline solid with near quantitative yield for 30b with 92% purity HPLC. 1H NMR matched 
those in literature. 
 
N-(Difluoromethyl)-N-(2-methoxyphenyl)-4-methylbenzenesulfonamide (42a): To a vial of 
sulfonamide 30 (1eq) and K2CO3 (3 eq) was added anhydrous acetonitrile (0.3M) and flushed 
with N2 and the slurry stirred for 10 minutes at rt and was then heated to 70 °C for 1 hour. The 
reaction was cooled to 0°C and sodium chlorodifluorocaetate (3 eq) was added slowly to the 
mixture. After complete addition the reaction was warmed to rt and then heated to 70°C until 
complete. The solvent was removed and the reaction was diluted with DCM, washed with water, 
and dried over MgSO4 and concentrated on rotovap. Product was isolated by trituration of 
residue. 93% purity.  
 
 
N-(2-Methoxyphenyl)-N,4-dimethylbenzenesulfonamide (43a): To a solution of sulfonamide 41a 
dissolved in anhydrous acetonitrile (0.3 M) was added K2CO3 (1.05 eq) and sealed under N2. 
After five minutes of stirring methyl iodide was added and heated to 70°C and allowed to stir 
until complete as determined by TLC. The solvent was removed on rotovap and organic residue 
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was dissolved in DCM and washed with 1M HCl and brine and dried over MgSO4 and 
concentrated. 43a was produced as a light brown solid (86%). 1H NMR (300 MHz, Chloroform-
d) δ 7.60 (d, J = 8.2 Hz, 2H), 7.35 – 7.23 (m, 4H), 7.01 – 6.89 (t, 1H), 6.87 – 6.77 (d, 1H), 3.45 
(s, 3H), 3.22 (s, J = 0.5 Hz, 3H), 2.44 (s, 3H). 
 
N-(4-Methoxyphenyl)-N,4-dimethylbenzenesulfonamide (43b): The methylated derivative 41b 
was synthesized following the same procedure for 43a to produce a light brown solid (82%). 1H 
NMR (300 MHz, Chloroform-d) δ 7.48 (d, J = 8.3 Hz, 2H), 7.29 (d, J = 2.1 Hz, 2H), 7.07 – 6.96 
(m, 2H), 6.88 – 6.79 (m, 2H), 3.83 (s, 3H), 3.16 (s, 3H), 2.46 (s, 3H). 
 
 
 
 
DapE Assay Protocol 
 
All reaction volumes are 200 μL with 10 nM HiDapE and 2 mM of N-methyl SDAP TFA 
unless otherwise stated. Enzyme assay absorbances were read on BioTek Syngen microplate 
reader.  
 
Ninhydrin-based enzymatic assay.  
To 50mM HEPES at pH 7.5 buffered solution with 8nM DapE at 30°C was added 2mM 
N-methyl SDAP (final volume 200 μL). The reaction proceeded for 10 minutes and quenched by 
heating at 100°C for 1 minute and subsequent cooling on ice for 1 minute. To the cooled reaction 
was added the 2% ninhydrin, the reaction vortexed and subsequently heated at 80 °C for 15 minutes 
for the ninhydrin reaction. This reaction was quenched by placing cooling on ice minutes and the 
absorbance of 80µL was read at 570nm.  
 
IC50 Determinations. 
 All inhibition assays were conducted with a reaction volume of 200 μL, 2 mM N-methyl 
SDAP and 8 nM DapE unless otherwise stated. Glutamic acid standards of 0 to 0.5 mM were used 
in every trial. All inhibitor stock solutions were made in 100% DMSO and serial dilutions to 
desired concentration with 50% DMSO. To a 50 mM HEPES pH 7.5 buffered solution was added 
desired inhibitor concentration at 0 ˚C followed by DapE and allowed to incubate for 5 min. The 
reactions were warmed to 30°C and N-methyl SDAP TFA was added and allowed to react for an 
additional 10 min. The enzymatic reaction was quenched by heating at 100 ˚C for 1 minute and 
cooled on ice to 30 ˚C. The 2% ninhydrin solution (100 μL) was added, the reaction vortexed and 
heated at 80 ˚C for 15 min. after which the reaction was quenched by cooling on ice to 30 ˚C and 
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the absorbance of 80 μL was examined at 570 nm via microplate reader. IC50 values were fitted to 
a curve through Excel. 
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APPENDIX E 
NMR SPECTRA FOR CHAPTER FOUR 
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1H NMR for 1-Acetyl-5-bromo-N-isopentylindoline-6-sulfonamide (16a)  
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13C NMR for 1-Acetyl-5-bromo-N-isopentylindoline-6-sulfonamide (16a)  
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1H NMR for 1-Acetyl-5-bromo-6-(piperidin-1-sulfonyl) indoline (16b) 
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1H NMR for 1-Acetyl-5-bromo-N,N- dipropylindoline-6-sulfonamide (16c) 
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1H NMR for 1-Acetyl-5-bromo-6-(pyrrolidin-1-sulfonyl) indoline (16g):  
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1H NMR for 1-Acetyl-5-bromo-N-cyclohexylindoline-6-sulfonamide (16h) 
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1H NMR for 1-Acetyl-5-bromo-N-phenylindoline-6-sulfonamide (16i) 
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1H NMR for 1-Acetyl-5-bromo-6-(indolin-1-sulfonyl) indoline (16j) 
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13C NMR for 1-Acetyl-5-bromo-6-(indolin-1-sulfonyl) indoline (16j) 
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1H NMR for 1-Acetyl-N-benzyl-5-bromoindoline-6-sulfonamide (16k) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
136 
 
136 
 
1H NMR for methyl 3-((1-acetyl-5-bromoindoline)-6-sulfonamido)propanoate (16l) 
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13C NMR for methyl 3-((1-acetyl-5-bromoindoline)-6-sulfonamido)propanoate (16l) 
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1H NMR for 1-Acetyl-5-bromoindolin-6-(sulfonyl glycine methyl ester) (16m) 
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1H NMR for methyl ((1-acetyl-5-bromoindolin-6-yl)sulfonyl)valinate (16n) 
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13C NMR for methyl ((1-acetyl-5-bromoindolin-6-yl)sulfonyl)valinate (16n) 
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13C NMR spectra of methyl 6-((1-acetyl-5-bromoindoline)-6-sulfonamido)6-hexanoate (16o)  
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1H NMR spectra of 1-Acetyl-5-bromo-N-(5-methylpyridin-2-yl)indoline-6-sulfonamide (16p)  
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1H NMR for 1-Acetyl-5-chloroindoline-6-sulfonyl chloride (21b)  
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144 
 
1-Acetyl-5-chloro-N-(5-methylpyridin-2-yl)indoline-6-sulfonamide 22p 
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1H NMR for 2-((1-phenyl-1H-tetrazol-5-yl)thio)propanoic acid (32a)  
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1H NMR for 2-((1-phenyl-1H-tetrazol-5-yl)thio)-N-(thiazol-2-yl)propenamide (33a) 
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1H NMR for N-(2-methoxyphenyl)-N,4-dimethylbenzenesulfonamide (43a) 
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1H NMR for N-(4-methoxyphenyl)-N,4-dimethylbenzenesulfonamide (43b) 
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APPENDIX F 
EXPERIMENTAL DATA FOR CHAPTER FIVE 
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1-Acetyl-5-bromo-N-isopentylindoline-7-sulfonamide (49a): To a solution of 5-bromo 7-
sulfonamide indolines 54a dissolved in dichloromethane was added triethylamine and the 
reaction was stirred at room temperature for 15 minutes. The mixture was cooled to 0oC via ice 
bath where acetyl chloride was added slowly drop wise making sure the temperature remained 
between 0-10oC. After complete addition the reaction was warmed to room temperature and 
stirred until complete as determined by TLC. The reaction was diluted with dichloromethane and 
washed one time with dilute HCl, one time with water and then once with brine and the organic 
layer was dried over Na2SO4 and concentrated in vacuum producing 49a. 
1H NMR (500 MHz, 
Chloroform-d) δ 7.68 (dd, J = 1.7, 0.9 Hz, 1H), 7.59 – 7.50 (m, 1H), 7.29 (d, J = 2.1 Hz, 1H), 
4.26 (td, J = 8.4, 4.6 Hz, 1H), 3.88 (s, 1H), 3.32 (t, J = 8.5 Hz, 1H), 2.17 (s, 7H), 1.67 – 1.61 (m, 
2H), 1.23 (s, 2H), 0.94 (p, J = 2.4 Hz, 3H). 
 
 
1-Acetyl-5-bromo-N-propylindoline-7-sulfonamide (49b): Indoline 49b was synthesized using 
the general procedure for 49a to produce a light brown solid. 1H NMR (500 MHz DMSO-D6) δ 
7.67 (s, 1 H), 7.52 (s, 1 H), 4.26 (t, 2 H, J= 4.8), 3.81 (t, 2 H, J=4.8), 3.31 (t, 2 H, J=4.8), 1.75 
(m, 2 H, J=4.5) 1.21 (s, 3 H), 0.92 (t, 3 H).   
 
1-Acetyl-5-bromo-N-benzylindoline-7-sulfonamide (49c): Indoline 49c was synthesized using the 
general procedure for 49a to produce a white solid. 1H NMR (300 MHz, DMSO D6) 7.70 (s, 1 
H), 7.58 (d, 2 H), 7.51 (s, 1 H), 7.46-7.40(dd, 1 H), 7.15 (t, 2 H), 5.01 (s, 2 H), 4.23 (t, 2 H), 3.29 
(t, 2 H), 1.21 (s, 2 H).  
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8-Bromo-2-isopentyl-5,6-dihydro-[1,2,4]thiadiazino[6,5,4-hi]indol-3(2H)-one 1,1-dioxide (53a): 
The alkylated cyclic sulfonyl urea indolines 57a was dissolved in a minimum amount of glacial 
acetic acid and stirred vigorously. This solution was cooled in an ice bath and Br2 was added 
slowly drop wise with stirring.  The reaction was warmed to room temperature and left to stir for 
75 minutes and then heated to 50 oC for 1 hour.  Reaction was quenched by pouring into ice 
water and isolating the white solid via vacuum filtration and dried via high vacuum to give 
produce a light brown solid. (75 % yield.) 1H NMR (300 MHz, DMSO D6) 
 
 
8-Bromo-2-propyl-5,6-dihydro-[1,2,4]thiadiazino[6,5,4-hi]indol-3(2H)-one 1,1-dioxide (53b): 
Indoline 53b was synthesized using the general procedure for 53a. (71%) 1H NMR (500 MHz 
DMSO D6) δ 7.91 (s, 1 H), 7.83 (s, 1 H), 4.20 (t, 2 H), 3.75 (t, 2 H), 3.31 (t, 2 H), 1.67 (m, 2 H), 
0.89 (t, 3 H). 
 
 
2-Benzyl-8-bromo-5,6-dihydro-[1,2,4]thiadiazino[6,5,4-hi]indol-3(2H)-one 1,1-dioxide (53c): 
Indoline 53c was synthesized using the general procedure for 53a to produce a light brown solid. 
(76.3 % yield.) 1H NMR (500 MHz, DMSO-D6) δ 7.96 (s, 1 H), 7.84 (s, 1 H), 7.38-7.25 (m, 5 
H), 4.99 (s, 2 H), 4.21 (t, 2 H), 3.34 (t, 2 H).  
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5-Bromo-N-isopentylindoline-7-sulfonamide (54a): A solution of the 5-bromo cyclic 
sulfonylurea 54a in 50 % sulfuric acid was heated to 135°C for two hours. The reaction was 
cooled to room temperature and then neutralized carefully with a 10 N NaOH solution while 
over ice. The aqueous layer was extracted with ethyl acetate three times and the organic fractions 
were combined and dried over magnesium sulfate and concentrated in vacuum yielding a light-
yellow solid (50%). 
 
5-Bromo-N-propylindoline-7-sulfonamide (54b): Indoline 54b was synthesized using the general 
procedure for 54a to produce a light brown solid. (50 % yield.)  1H NMR (500 MHz, DMSO-D6) 
δ 7.90 (s, 1 H), 7.82 (s, 1 H), 4.20 (t, 2 H, J=8), 3.75 (t, 2 H, J=8), 3.31 (t, 2 H), 1.67 (m , 2 H), 
0.89 (t, 3 H). 13C NMR (126 MHz, DMSO-d6) δ 148.7, 137.6, 136.3, 133.8, 133.2, 130.8, 124.7, 
121.54, 120.0, 119.4, 115.5, 115.5, 49.0, 48.6, 43.6, 43.3, 32.1, 31.9, 30.6, 30.1, 29.8, 29.5, 27.6, 
23.20, 23.2, 22.9, 14.8, 11.8, 11.7. 
 
 
5-Bromo-N-benzylindoline-7-sulfonamide (54c): Indoline 54c was synthesized using the general 
procedure for 54a to produce a light yellow solid. (50 %) 1H NMR (500 MHz, DMSO-d6) δ 7.95 
(d, J = 1.6 Hz, 1H), 7.84 (t, J = 1.5 Hz, 1H), 7.70 (dt, J = 8.0, 1.1 Hz, 1H), 7.40 – 7.23 (m, 5H), 
4.99 (s, 2H), 4.25 – 4.17 (t, 2H), 3.32 (d, J = 7.8 Hz, 3H). 
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5,6-Dihydro-[1,2,4]thiadiazino[6,5,4-hi]indol-3(2H)-one 1,1-dioxide (56): To a solution of 
chlorosulfonyl isocyanate (1.80 mL, 18.4 mmol) in nitroethane (32 mL) cooled to -42°C was 
added indoline 12 slowly drop wise with stirring. The intermediate precipitated and turned 
cloudy and white and the mixture was slowly warmed to room temperature over one hour with 
continued stirring.  Aluminum chloride (2.45 g, 18.4 mmol) was added in one portion and 
allowed to stir for 15 minutes at room temperature.  The solution went from cloudy and white to 
a clear, pale yellow solution to a light purple to a dark purple over time.  The reaction was then 
heated to 110°C for one hour. The mixture was cooled to room temperature and quenched by 
pouring into ice water slowly where a black precipitate formed. The solid was isolated by 
filtering via vacuum filtration.  A dark gray clay-like substance was obtained and dried overnight 
via vacuum yielding the cyclic sulfonyl urea indoline 56 (58-83%) as a dark gray solid 
compound.  The solid was not purified and taken into the next reaction.  1H NMR (300 MHz, 
DMSO D6) δ 7.55 (2H, t), 7.22 (1H, t), 4.18 (2H, t), 3.35 (2H, t).23 1H NMR (500 MHz, DMSO-
d6) δ 7.57 (ddq, J = 13.3, 7.4, 1.1 Hz, 2H), 7.21 (t, J = 7.7 Hz, 1H), 4.12 (dd, J = 9.1, 7.9 Hz, 
2H), 3.34 – 3.26 (m, 2H). 13C NMR (126 MHz, DMSO-d6) δ 148.9, 138.8, 133.0, 130.3, 124.5, 
120.6, 119.3, 47.6, 27.8. 
 
 
2-Isopentyl-5,6-dihydro-[1,2,4]thiadiazino[6,5,4-hi]indol-3(2H)-one 1,1-dioxide (57a): To a 
solution of cyclic sulfonyl urea indoline 56 (150 mg, 0.67 mmol) in DMF (2 mL) was added 
NaH in 60% mineral oil (30 mg) and allowed to stir under nitrogen. N-propyliodide (0.78 mmol) 
was added drop wise and left stirring until completion as determined by TLC. The reaction was 
diluted with ethyl acetate and washed with 0.1 M HCl followed by a wash with saturated 
NaHCO3 and then brine. The organic portion was concentrated in vacuum to yield the solid 
alkylation product (43%).  1H NMR (500 MHz, DMSO-D6) δ 7.67 (d, 1 H), 7.63 (d, 1 H), 7.26 (t, 
1 H), 4.21 (t, 2 H), 3.76 (t, 2 H), 3.29 (t, 2 H), 1.67 (m, 2 H), 0.97 (t, 3 H). 
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2-Propyl-5,6-dihydro-[1,2,4]thiadiazino[6,5,4-hi]indol-3(2H)-one 1,1-dioxide (57b): Indoline 
57b was synthesized using the general procedure for 57a using isoamyl bromide to produce 
brown solid. (45 % yield.) 1H NMR (500 MHz, CDCl3) δ 7.60 (d, 1 H), 7.44 ( d, 1 H), 7.18 (t, 1 
H), 4.29 (t , 2 H), 3.94 (t, 2 H), 3.34 (t, 2 H), 1.69 (m, 2 H), 0.99 (d, 6 H). 
 
 
 
2-Benzyl-5,6-dihydro-[1,2,4]thiadiazino[6,5,4-hi]indol-3(2H)-one 1,1-dioxide (57c): Indoline 
57c was synthesized using the general procedure for 57a using benzyl bromide to produce a x 
solid. (69 %) 1H NMR (500 MHz, DMSO-D6) δ 7.71 (d, 1 H), 7.65 (d, 1 H), 7.38 (d, 2 H), 7.34 
(t, 1 H) 7.31-7.25 (m, 3 H), 4.99 (s, 2 H), 4.22 (t, 2 H), 3.33 ( t, 2 H). 
 
 
Indoline-7-sulfonamide (58): Indoline 58 was synthesized by hydrolysis of cyclic indoline 56 
using the general procedure for 54. 1H NMR (500 MHz, DMSO-d6) δ 7.25 (d, J = 8.1 Hz, 1H), 
7.16 (d, J = 7.1 Hz, 1H), 7.11 (s, 2H), 6.55 (t, J = 8.0 Hz, 1H), 5.79 (s, 1H), 3.57 (t, J = 8.7 Hz, 
2H), 2.97 (t, J = 8.7 Hz, 2H). 13C NMR (126 MHz, DMSO-d6) δ 149.1, 149.1, 132.2, 132.2, 
132.1, 128.1, 128.1, 128.0, 125.6, 125.5, 125.5, 122.0, 116.3, 116.3, 116.3, 47.3, 47.3, 47.3, 29.0, 
28.9, 28.9. 
 
 
1-Acetylindoline-7-sulfonamide (59): 1H NMR (500 MHz, DMSO-d6) δ 7.66 (d, J = 8.0 Hz, 1H), 
7.50 (d, J = 7.3 Hz, 1H), 7.26 (t, J = 7.7 Hz, 1H), 7.05 (s, 2H), 4.12 (t, J = 7.6 Hz, 2H), 3.08 (t, J 
= 7.6 Hz, 2H), 2.24 (s, 3H). 13C NMR (126 MHz, DMSO-d6) δ 171.4, 138.9, 137.9, 133.8, 129.1, 
127.6, 51.8, 29.85, 24.39. 
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N-(Indolin-7-ylsulfonyl)acetamide (63): 1H NMR (500 MHz, DMSO-d6) δ 7.66 (d, J = 8.0 Hz, 
1H), 7.50 (d, J = 7.3 Hz, 1H), 7.26 (t, J = 7.7 Hz, 1H), 7.05 (s, 2H), 4.12 (t, J = 7.6 Hz, 2H), 3.08 
(t, J = 7.6 Hz, 2H), 2.24 (s, 3H).  
 
 
 
 
1-((Benzyloxy)carbonyl)indoline-7-sulfonamide (64): To a round-bottom flask was added 7-
sulfonamide indoline 58 (1 eq) in THF (0.17M) followed by NaHCO3 (11 eq) and water 
(1.76M). The round bottom flask was sealed and flushed with N2 gas. To this sealed mixture was 
added benzyl chloroformate (3.8 eq) slowly over a few minutes by syringe. After complete 
addition the reaction was allowed to stir at room temperature overnight.  The reaction was 
diluted with EA and filtered to remove undissolved excess NaHCO3. The organic portion was 
acidified with 6M HCl. The aqueous portions were further extracted with EA two times. The 
organic fractions were combined and washed with brine and dried over NaSO4 and concentrated 
giving a greasy off white solid. 4 mL of Et2O was added along with 2 mL of pet ether and the 
white solid was collected via vacuum filtration and further washed with pet ether and placed on 
high vac to fully dry. This reaction yields 62% white, light fluffy and pure white solid. 1H NMR 
(300 MHz, CDCl3) δ 7.87 (d, 1 H), 7.21 (t, 1 H), 7.44-7.29 (m, 6 H), 5.90 (bs, 2 H), 5.28 (s, 2 H), 
4.24 (t, 2 H), 3.02 (t, 2 H). 13C NMR (126 MHz, DMSO-d6) δ 155.5, 139.3, 137.3, 136.7, 133.1, 
129.1, 129.0, 128.7, 128.5, 127.8, 125.2, 68.0, 51.6, 29.4. 
 
 
Benzyl 5-bromo-7-sulfamoylindoline-1-carboxylate (64b):To a round bottom flask of 64 
dissolved in glacial AcOH was added Br2 dropwise with stirring. The reaction was allowed to 
stir until complete as determined by TLC and quenched by pouring in water. To the aqueous 
portion was added sodium thiosulfate and the precipitate was filtered by vacuum filtration.  1H 
NMR (500 MHz, DMSO-d6) δ 7.80 (d, J = 2.0 Hz, 1H), 7.69 (dd, J = 2.1, 1.1 Hz, 1H), 7.45 – 
7.38 (m, 2H), 7.41 – 7.30 (m, 3H), 7.34 – 7.24 (m, 1H), 7.21 (ddt, J = 6.0, 4.6, 3.2 Hz, 0H), 7.16 
(s, 2H), 5.20 (s, 2H), 4.48 (s, 0H), 4.10 (t, J = 7.9 Hz, 2H), 3.12 – 3.05 (m, 2H). 
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1-((Benzyloxy)carbonyl)indoline-7-sulfonic acid (67): N-Cbz-7-sulfonamide indoline 64 (0.3 
mmol) was added to a sealed test tube flushed with Argon. The sulfonamide was dissolved by 
the addition of anhydrous 1,4 dioxane (0.375 M). The reaction was heated to 65°C until most 
solid dissolved with stirring. Isoamyl nitrite was added to the test tube via syringe in two 
portions. After the first addition evolution of N2 was observed. After addition of the second 
portion the reaction was heated to 85°C to which the reaction turned a yellow-orange color. The 
reaction was heated at reflux for 2 hours and solvent was removed by rotary evaporation. The 
remaining sticky residue was chased with DCM, a brown liquid remained and reaction was 
triturated by addition of Et2O. The product filtered was removed and an off white solid remained 
giving. 47% yield with 98+% purity by HPLC. 1H NMR (300 MHz, CDCl3) δ7.96 (d, 1 H), 7.25 
(t, 1 H), 7.45-7.43 (m, 5 H), 7.50 (d, 1 H), 5.32 (s, 2 H), 4.29 (t, 2 H), 3.12 (t, 2 H).  
 
 
 
 
Benzyl 7-(N-acetylsulfamoyl)indoline-1-carboxylate (76a): A solution of acid chloride or 
anhydride (1.25 eq) and DMAP (10 mol %) in DCM was cooled to 0°C, a separate solution of N-
Cbz-7-sulfonamide indoline 58 and Et3N in DCM was placed on ice. The solution of acid 
chloride was slowly added to the solution of sulfonamide dropwise over ten minutes while 
maintaining a temperature close to 0°C. After complete addition, the reaction was warmed to rt 
with continued stirring. After completion of the reaction as determined by TLC the reaction was 
quenched by addition of water and the aqueous portion was extracted with DCM. The organic 
layers were combined and washed with 1 M HCl and brine and dried of Na2SO4 and solvent was 
removed via rotovap. The solid was purified via trituration by dissolving in EA, cooling on ice 
and crashing out with Et2O. 
1H NMR (300 MHz, DMSO D6) δ 11.65 (s, 1 H), 7.70 (d, 1 H), 7.53 
(d, 1 H), 7.24 (t, 2 H), 7.32 (d, 2 H), 7.37 (m, 5 H), 5.40 (s, 2 H), 4.13 (t, 2 H), 3.08 (t, 2 H), 1.93 
(s, 3 H). 13C NMR (126 MHz, Chloroform-d) δ 168.5, 155.5, 140.1, 136.7, 135.8, 130.4, 129.9, 
129.1, 128.8, 128.6, 128.2, 124.8, 68.8, 68.8, 51.4, 31.0, 29.4, 24.5. 
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Benzyl 7-(N-benzoylsulfamoyl)indoline-1-carboxylate (76b): Indoline 76b was synthesized using 
the general procedure for 76a using benzoic anhydride to produce an off white solid. 1H NMR 
(300 MHz, DMSO-D6) 
 
Benzyl 7-(N-(4-methoxybenzoyl)sulfamoyl)indoline-1-carboxylate (76c): Indoline 76c was 
synthesized using the general procedure for 76a using anisoyl chloride to produce an off white 
solid. 1H NMR (300 MHz, CDCl3) δ 8.19 (d, 1 H), 7.96 (d, 2 H), 7.42-7.30 (m, 6 H), 7.2 (t, 1 H), 
6.93 (d, 2 H), 5.32 (s, 2 H), 4.20 (t, 2 H), 3.87 (s, 3 H), 3.05 (t, 2 H). 
 
 
Benzyl 7-(N-(thiazole-5-carbonyl)sulfamoyl)indoline-1-carboxylate (76d): Indoline 76d was 
synthesized using the general procedure for 76a using thiazole-5-carbamoyl chloride to produce 
an off white solid. (49%). 1H NMR (500 MHz, DMSO-D6)  
 
 
Benzyl 7-(N-(isoxazole-5-carbonyl)sulfamoyl)indoline-1-carboxylate (76e): Indoline 76e was 
synthesized using the general procedure for 76a using isoxazole-5-carbamoyl chloride to 
produce an off white solid. (70%) 
 
 
 
Benzyl 7-(N-(3-methylbutanoyl)sulfamoyl)indoline-1-carboxylate (76f): Indoline 76f was 
synthesized using the general procedure for 76a using isovaleric acid to produce an off white 
solid. 
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Benzyl 7-(N-(morpholine-4-carbonyl)sulfamoyl)indoline-1-carboxylate (78a): To a solution of N-
Cbz-7-sulfonamide Indoline 64 (0.3 mmol) in anhydrous THF (0.2 M) was added carbonyl 
chloride (0.33 mmol) and reaction was allowed to stir at rt. NaH 60% dispersion in mineral oil 
(0.375 mmol) was added and effervescence was observed. The vails were then purged with N2 and 
allowed to stir at rt for 4 days. HPLC showed starting material still present to which 0.5 more 
equivalence of NaH was added. The reaction was quenched by addition of water, the aqueous layer 
was extracted with EA three times and the organic layers were washed with brine, dried over 
MgSO4 and concentrated. (94%) 
 
 
Benzyl 7-(N-(pyrrolidine-1-carbonyl)sulfamoyl)indoline-1-carboxylate (78b): Synthesized with 
the general procedure of 78a using pyrrolidine carbonyl chloride. (91%). 
 
 
Benzyl 7-(N-(4-methylpiperazine-1-carbonyl)sulfamoyl)indoline-1-carboxylate (78c): 
Synthesized with the general procedure of 78a using 4-methyl-1-piperidine carbonyl chloride ca. 
45% HPLC.  
 
 
N-((1-(Morpholine-4-carbonyl)indolin-7-yl)sulfonyl)acetamide (79d): Synthesized with the 
general procedure of 78a using N-morpholine-carbomoyl chloride. 
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N-((1-(Isoxazole-5-carbonyl)indolin-7-yl)sulfonyl)acetamide (79e):  Synthesized with the 
general procedure of 78a using isoxazole-5-carbonyl chloride. 
 
 
7-(N-Acetylsulfamoyl)-N,N-dimethylindoline-1-carboxamide (79f): Synthesized with the general 
procedure of 78a using N,N-dimethyl-carbonyl chloride. 
 
 
 
1-(Tert-butoxycarbonyl)indoline-7-sulfonic acid (83): To a three-neck round bottom flask fitted 
with a stir bar was added N-Boc indoline followed by degassing with N2. The indoline was 
dissolved in anhydrous THF and cooled to -78 °C. Next, the addition of TMEDA followed by 
addition n-BuLi slowly addition at -78 oC with continued stirring for one hour and slow warming 
to rt. Reaction was allowed to stir over night. To a second solution of sulfur trioxide trimethyl 
amine complex (STTAC) in THF under nitrogen at -78° C was added the first mixture slowly 
over time to which a yellow color appeared. This was allowed to stir for 2 hours at -78˚C and 
warmed to room temperature with continued stirring overnight. The thick white solution was 
concentrated to remove solvent and 4 equivalents of HCl was added and the organic portion was 
extracted with EA an concentrated in vacuo. 45% yield by HPLC. 
 
 
 
Inoldine-1-sulfonic acid (87): To a three-neck round bottom flask with a stir bar was added 
indoline dissolved in hexane. The flask was flushed with nitrogen and cooled to -78°C. Next, the 
addition of n-BuLi followed by warming to room temperature with continued stirring overnight. 
The reaction went from clear to gelatinous. The reaction was cooled back down to -78 °C, 
diluted with Et2O and CO2 was introduced through a drying tube by needle places directly under 
the surface of the solvent. Excess CO2 was allowed to escape and reaction was stirred at room 
temperature overnight. The reaction was then diluted with THF and cooled to -78 °C and 
TMEDA followed by n-BuLi was added and the reaction was allowed to stir. A second round- 
bottom flask with THF and STTAC at - 78°C was purged with Nitrogen and the addition of the 
first mixture was added via syringe and allowed to stir for 18 hrs. The reaction was then 
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concentrated, washed with water and brine, dried over MgSO4 and concentrated to produce a 
reddish-pink colored solid. 
 
 
N-Isopentylindoline-7-sulfonamide (93a): 1H NMR (500 MHz, Chloroform-d) δ 7.60 (dt, J = 8.0, 
1.0 Hz, 1H), 7.44 (dq, J = 7.4, 1.2 Hz, 1H), 7.17 (t, J = 7.7 Hz, 1H), 4.29 (dd, J = 9.1, 8.1 Hz, 
2H), 3.98 – 3.88 (m, 2H), 3.34 (ddt, J = 9.4, 8.1, 1.1 Hz, 2H), 1.75 – 1.64 (m, 3H), 1.26 (d, J = 
1.7 Hz, 1H), 1.01 – 0.93 (m, 6H), 
 
 
N-Propylindoline-7-sulfonamide(93b): 1H NMR (300 MHz, Acetone-d6) δ 7.60 (d, J = 7.6 Hz, 
3H), 7.27 (s, 1H), 4.29 (s, 2H), 3.82 (s, 2H), 3.41 (t, J = 8.2 Hz, 3H), 2.05 (s, 2H), 1.75 (s, 3H), 
1.74 (d, J = 7.5 Hz, 0H), 1.30 (s, 2H), 0.94 (t, J = 7.5 Hz, 1H). 
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N-Benzylindoline-7-sulfonamide  1H NMR (500 MHz, DMSO-d6) δ 7.70 (d, J = 8.0 Hz, 1H), 
7.64 (d, J = 7.4 Hz, 1H), 7.40 – 7.23 (m, 6H), 4.99 (s, 2H), 4.24 – 4.17 (m, 2H), 3.41 – 3.28 (m, 
1H). 
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1-Acetyl-5-bromo-N-isopentylindoline-7-sulfonamide (49a) 
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1-Acetyl-5-bromo-N-propylindoline-7-sulfonamide (49b) 
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1-Acetyl-5-bromo-N-benzylindoline-7-sulfonamide (49c) 
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8-Bromo-2-propyl-5,6-dihydro-[1,2,4]thiadiazino[6,5,4-hi]indol-3(2H)-one 1,1-dioxide (53b) 
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5-Bromo-N-propylindoline-7-sulfonamide (54b) 
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5-Bromo-N-propylindoline-7-sulfonamide (54b) 
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5-Bromo-N-benzylindoline-7-sulfonamide (54c) 
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5,6-Dihydro-[1,2,4]thiadiazino[6,5,4-hi]indol-3(2H)-one 1,1-dioxide (56) 
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5,6-Dihydro-[1,2,4]thiadiazino[6,5,4-hi]indol-3(2H)-one 1,1-dioxide (56) 
 
 
 
 
 
 
 
 
 
 
172 
 
 
2-Isopentyl-5,6-dihydro-[1,2,4]thiadiazino[6,5,4-hi]indol-3(2H)-one 1,1-dioxide (57a) 
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2-Propyl-5,6-dihydro-[1,2,4]thiadiazino[6,5,4-hi]indol-3(2H)-one 1,1-dioxide (57b) 
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2-Benzyl-5,6-dihydro-[1,2,4]thiadiazino[6,5,4-hi]indol-3(2H)-one 1,1-dioxide (57c) 
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Indoline-7-sulfonamide (58) 
 
 
 
 
 
 
 
 
 
 
176 
 
 
Indoline-7-sulfonamide (58) 
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1-Acetylindoline-7-sulfonamide (59) 
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1-Acetylindoline-7-sulfonamide (59) 
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N-(Indolin-7-ylsulfonyl)acetamide (63): 
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1-((Benzyloxy)carbonyl)indoline-7-sulfonamide (64) 
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Benzyl 5-bromo-7-sulfamoylindoline-1-carboxylate (64b): 
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1-((Benzyloxy)carbonyl)indoline-7-sulfonic acid (67) 
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Benzyl 7-(N-acetylsulfamoyl)indoline-1-carboxylate (76a) 
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Benzyl 7-(N-acetylsulfamoyl)indoline-1-carboxylate (76a) 
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Benzyl 7-(N-benzoylsulfamoyl)indoline-1-carboxylate (76b) 
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Benzyl 7-(N-(4-methoxybenzoyl)sulfamoyl)indoline-1-carboxylate (76c) 
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Benzyl 7-(N-(thiazole-5-carbonyl)sulfamoyl)indoline-1-carboxylate (76d) 
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Benzyl 7-(N-(isoxazole-5-carbonyl)sulfamoyl)indoline-1-carboxylate (76e): 
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Benzyl 7-(N-(3-methylbutanoyl)sulfamoyl)indoline-1-carboxylate (76f) 
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Benzyl 7-(N-(3-methylbutanoyl)sulfamoyl)indoline-1-carboxylate (76f) 
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Benzyl 7-(N-(morpholine-4-carbonyl)sulfamoyl)indoline-1-carboxylate (78a) 
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Benzyl 7-(N-(pyrrolidine-1-carbonyl)sulfamoyl)indoline-1-carboxylate (78b) 
 
 
 
 
 
 
 
 
 
 
193 
 
 
N-((1-(Morpholine-4-carbonyl)indolin-7-yl)sulfonyl)acetamide (79d) 
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N-((1-(Morpholine-4-carbonyl)indolin-7-yl)sulfonyl)acetamide (79d) 
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N-((1-(Isoxazole-5-carbonyl)indolin-7-yl)sulfonyl)acetamide (79e)  
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N-((1-(Isoxazole-5-carbonyl)indolin-7-yl)sulfonyl)acetamide (79e)  
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7-(N-acetylsulfamoyl)-N,N-dimethylindoline-1-carboxamide (79f) 
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7-(N-acetylsulfamoyl)-N,N-dimethylindoline-1-carboxamide (79f) 
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N-Isopentylindoline-7-sulfonamide 
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N-Propylindoline-7-sulfonamide 
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N-Benzylindoline-7-sulfonamide 
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